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Abstract 
Parkinson’s disease (PD) affects 1 in 500 of the UK population.  A critical step in 
disease aetiology is the formation of Lewy bodies (LBs), deposits of aggregated 
alpha-synuclein (αsyn) as amyloid inclusions, within surviving neurons.  It is well 
established that αsyn within LBs has undergone a variety of post-translational 
modifications, including S 129 phosphorylation, and LBs are known to be rich in 
metals such as copper.  It has however, yet to be established how 
phosphorylation of αsyn and metal ions influence in the pathology of PD, and if 
the formation of LBs can be prevented by the use of small molecule inhibitors.  
E lectrospray ionisation-ion mobility spectrometry- mass spectrometry (E S I-IMS -
MS ) was used to investigate the conformational changes to compact states of 
αsyn known to be linked to amyloid formation, for WT and two αsyn mutants 
mimicking phosphorylation at S 87 and S 129, in the presence of copper, and their 
aggregation was monitored by thioflavin-T assays.  R esults demonstrate that the 
conformational state of αsyn can be modulated by interactions with copper, 
causing an increase in the compact state, leading to an increased rate of 
aggregation.  S 129D αsyn showed the highest affinity for copper, and the fastest 
aggregation rates overall.  S H-S Y 5Y  cell culture models were used to investigate 
intracellular aggregation and phosphorylation state upon copper exposure.  
Increased copper concentration correlated with increased formation of 
unmodified and phosphorylated intracellular aggregates, an increase in 
apoptosis, and decreased cell viability.  E S I-IMS -MS  demonstrated curcumin and 
its derivatives were able to disrupt amyloid assembly, via prevention of 
autofragmentation and dissociation of low-order oligomers, thus preventing the 
aggregation of αsyn.  In S H-S Y 5Y  model used however, curcumins were unable 
to prevent the metal-induced intracellular aggregation of αsyn.  Together, results 
support the hypothesis that phosphorylation has a key role in PD progression, 
and demonstrated that modified curcumins may be a potential therapeutic for PD. 
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1. Introduction 
1.1  Protein Misfolding and Disease 
1.1.1  Protein S tructure and F unction 
Proteins are biological polymers which tend to adopt a unique three-dimensional 
(3D) structure under native physiological conditions, and this unique structure 
determines the protein’s native function (Wright and Dyson, 1999).  This 3D 
shape is determined by the protein’s primary amino acid (aa) sequence, as the 
different side chains of the amino acids interact with each other forming non-
covalent bonds such as hydrogen bonds and ionic bonds.  This coupled with Van 
der Waals forces and hydrophobic packaging determines the spatial arrangement 
of the individual amino acid residues and thus the protein’s final conformation.  
The protein will fold into its minimal-energy configuration, to minimise the amount 
of free energy around itself, for example by shielding electrostatically charged 
side chains internally within the structure and folding is related to the 
thermodynamics of the protein (E ichner and R adford, 2011). 
Failure of a protein to correctly form its native structure, if it has one, will render 
the protein unable to carry out its biological role, as it will no longer interact with 
its usual binding epitopes.  This misfolding can also lead to proteins becoming 
pathogenic, and has been associated with the formation of aggregated protein 
complexes in a number of diseases, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD) and diabetes (S weeney et al., 2017; Mukherjee et al., 
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2015).  Determining the structure and conformational arrangement of proteins 
and protein complexes therefore is essential to our understanding of both their 
biological function and roles within a range of diseases (Vendruscolo et al., 2011; 
Walzthoeni et al., 2013).   
 
1.1.2  Intrinsically Disordered Proteins  
Many proteins have no defined secondary structure, and these are universally 
termed intrinsically disordered proteins (IDPs).  IDPs include proteins such as α-
synuclein (αsyn), amyloid-β (Aβ) and p53, which are highly dynamic and have 
multiple conformational states to perform a variety of biological functions 
(Forman-Kay and Mittag, 2013).  This intrinsic disorder may apply to the whole 
protein, or regions within them, and around a third of all eukaryotic proteins have 
now been shown to contain intrinsically disordered regions of over thirty residues 
in length (Babu et al., 2011). 
 
1.1.3  Protein Misfolding 
Proteins are known to occasionally adopt partially unfolded, non-native 
conformations due to changes in their native environment or interactions with 
other molecules.  S uch interactions can lead to an accumulation of transient 
folding intermediates alongside the native protein.  Normally these intermediates 
will be acted on by cellular quality control machinery, such as molecular 
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chaperones, and directed towards degradation or refolding (Chaudhuri and Paul, 
2006; Gregersen et al., 2006).  Degradation and removal of these misfolded 
conformations must be tightly regulated, as incomplete or incorrect folding of 
some proteins can result in aggregation of these misfolded forms, leading to 
cellular toxicity and disease (E croyd and Carver, 2008).  In vivo factors such as 
ageing, stress, environmental alterations or genetic mutations may affect this 
cellular quality control, shifting the protein’s equilibrium towards the non-native, 
misfolded conformations, increasing a person’s risk of developing these protein 
misfolding diseases (Natalello et al., 2011). 
 
1.2  Protein Misfolding Diseases 
Over fifty diseases are known to result from the misfolding of proteins (Y oung et 
al., 2015), collectively referred to as amyloid diseases or amyloidosis, due to the 
formation of so called amyloid material or amyloid deposits.  Over thirty distinct 
proteins have been identified as amyloidogenic (Phillips et al., 2015), but only a 
small number of these are known to cause disease in humans, some of which 
are outlined in table 1.1 (Uversky., 2008; Knowles et al., 2014).  The aggregation 
of some amyloid proteins however has been identified as functional, for example 
aggregated forms of Pmel17 play a role in the biosynthesis of melanin in humans, 
though these functional amyloids are much more commonly found in bacteria and 
fungi (Fowler et al., 2007; Hammer et al., 2008).  Formation of amyloid material 
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may confer a cellular loss-of-function, a toxic gain-of-function, or in some cases 
a mixture of the two, dependent on the protein and disease (Winklhofer et al., 
2008; Vabulas and Hartl, 2011).  Amyloid material has been identified in a variety 
of organs and tissue types, and these inclusions and plaques act as a hallmark 
for their relative diseases.  Deposition can be widespread in the case of systemic 
amyloidoses such as primary systemic amyloidosis, or be confined to a specific 
location, such as the S ubstantia Nigra Pars Compacta (S NPC ) of the brain in PD.  
The location of the inclusions often determines the symptoms, and consequently 
the clinical manifestations of amyloidosis are wide ranging (Uversky, 2008).  
S ome amyloidogenic proteins can spread their toxic pathology from cell to cell, 
and therefore amyloid formation may be an acquired trait, such as in cases of the 
spongiform encephalopathies.  These disease states are caused by exposure to 
a proteinaceous infectious particle, referred to as a prion protein (PrP) (Prusiner, 
2012).  
 
 
 
 
 
 
5 
 
Amyloidogenic Protein Protein S tructure Disease(s) 
 
 
 
α-Synuclein 
 
 
 
Natively Unfolded/IDP 
PD, Diffuse Lewy Body 
Disease (DLBD), Multiple 
S ystem Atrophy (MS A), 
Dementia with Lewy Bodies 
(DLB), Hallervoden-S patz 
disease 
 
β2-Microglobulin β-sheet Dialysis-related amyloidosis 
 
 
Amyloid-β 
 
Natively Unfolded/IDP 
AD, C ardiovascular 
Amyloidosis, Congophillic 
Angiopathy 
 
Amylin/ Islet Amyloid 
Polypeptide (IAPP) 
 
Natively Unfolded/IDP Type II Diabetes 
Huntingtin 
 
Unfolded R egions 
 
Huntington’s Disease 
Lysozyme α-helical and β-sheet regions 
 
Lysozyme Amyloidosis 
 
 
 
Prion Protein 
 
 
α-helical C -terminus 
Creutzfelt-J acob disease, 
Gertsmann-S traussler-
S cheineker S yndrome, 
Bovine S pongiform 
E ncelopathy (BS E ), S crapie 
 
Transthyretin β-sheet Familial Amyloidotic 
Polyneuropathy 
Table 1.1: Amyloid Proteins and Their R elated Diseases. 
S election of the currently identified amyloid forming proteins and their related 
diseases.  Adapted from Uversky, 2008 and Knowles et al., 2014. 
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1.2.1  Amyloid Aggregation 
Assembly into amyloid fibrils is initiated when the native protein becomes 
destabilised and unfolds, or in the case of intrinsically disordered amyloid 
proteins, such as αsyn, naturally adopt a more partially folded, globule-like 
conformation, which, due to exposed hydrophobic patches, are highly prone to 
aggregation (J ahn and R adford, 2008).  S elf-assembly then begins, through a 
nucleation-dependent elongation mechanism, in a process referred to as 
aggregation, that eventually leads to the formation of mature fibrils.  These fibrils 
are insoluble, non-branching, highly ordered structures, many µm in length and 
typically 5-15 nm in diameter under electron microscopy (Toyama and Weissman, 
2011). They are defined by their distinct X -ray diffraction pattern, showing a 
characteristic cross-β structure, with β-sheets running perpendicular to the fibril 
axis (E anes and Glenner, 1968; E isenberg and J ucker, 2012).  The fibrils are also 
protease resistant, insoluble in ionic detergents and can be recognised by the 
diagnostic indicator dye Congo R ed (Wolfe and Cyr, 2011; E isenberg and J ucker, 
2012; Nilsson, 2004). 
All amyloid proteins aggregate along a common pathway, outlined in figure 1.1, 
despite their often vast native structural differences (Wolfe and Cyr, 2011).  In 
vitro, proteins may be directed onto the amyloid pathway by the presence of non-
physiological conditions such as pH extremes, high temperature or pressure or 
the presence of metal ions or organic co-solvents (R ambaran and S erpell, 2008).  
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F igure 1.1:  Amyloid Aggregation Pathway. 
In the lag phase, the protein unfolds (if necessary), misfolds and then begins 
assembly into dimers, trimers and other low order oligomers.  During the 
elongation phase, the oligomers form protofibrils, which mature into amyloid fibrils 
in the saturation stage. 
 
In the case of IDPs, some monomeric conformations existing within the normal 
equilibrium have a higher propensity for aggregation, and aggregation in this case 
is triggered when the equilibrium is shifted in favour of these forms.  Transition 
from these non-native partially folded structures to a pre-fibrillar conformation 
occurs via nucleated polymerisation, with the formation of oligomeric species 
during the lag phase of aggregation.  Increasing evidence suggests these 
amyloidogenic, early oligomeric protein forms to be the toxic species involved 
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with disease, as opposed to the mature fibrils themselves (Ingelsson, 2016).  
These oligomeric species then further aggregate into larger oligomeric species 
during the elongation phase, forming protofibrils rich in β-sheets (E isenberg and 
J ucker, 2012).  These protofibrils then further entwine into the mature amyloid 
fibrils, which have been found deposited as plaques and inclusions in the various 
diseases.  The number of protofibrils required to produce the mature fibrils varies 
between proteins and may also vary in number between fibres of the same 
protein (R ambaran and S erpell, 2008).  
 
1.3  α-S ynuclein and Parkinson’s Disease 
1.3.1  Parkinson’s Disease 
PD was first described in 1817 with the publication of J ames Parkinson’s essay 
entitled "An essay of the shaking palsy", where he discussed the clinical 
symptoms of six patients, and laid the groundwork for the diagnosis and 
terminology of the disease (Parkinson, 2002).  This disease is  the second most 
common neurodegenerative disorder after AD, and affects ~1% of the world’s 
population over the age of 65, with incident rates increasing to ~5% for individuals 
over the age of 85 (Marder et al., 1996; de Lau et al., 2006), making age the 
predominant risk factor for disease.  S poradic PD, which accounts for over 90% 
of patients, is the most prevalent form of the disease, however genetic factors 
have been identified in 5-10% of cases, which result in early-onset PD. 
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PD is an extremely debilitating disorder with clinical symptoms including, but not 
limited to, resting tremors on one or both sides of the body, muscle rigidity, 
slowness of movement referred to as bradykinesia, altered gait and balance and 
postural complications.  There are also non-motor symptoms of the disease which 
include cognitive dysfunction, depression and sleep disorders (J ankovic, 2008).  
Currently there is no cure or preventative measures to tackle the disease.  
Treatments such as Levodopa, a synthetic version of L-DOPA, the precursor to 
dopamine (DA), are currently utilised to manage the motor symptoms of the 
disease, but increasing our understanding of the causes and mechanisms of 
neuronal loss and amyloid fibre deposition is essential for future management 
and prevention of the disease.   
 
1.3.2  Cellular Pathology of Parkinson’s Disease 
The main pathological hallmarks of PD are the deposition of amyloid fibres, 
composed primarily of αsyn, in inclusions referred to as Lewy bodies (LB), and 
the gradual and selective degeneration of dopaminergic neurons in the S NPC  of 
the brain, as discussed later in this chapter.  The precise mechanisms behind 
neuronal cell death in PD are not however fully understood, as LBs are known to 
form within the surviving neurons as opposed to those which have lost their 
function (Natalello et al., 2011; Takahashi and Wakabayashi, 2001).  It is now 
believed that oligomeric species formed during the lag phase of amyloid 
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formation, rather than mature amyloid fibrils or LBs, are responsible for the 
observed cell death (Ingelsson, 2016).  Oligomeric species can create pores in 
the cell membrane, allowing for abnormal influx of ions such as calcium, leading 
to altered cellular homeostasis and apoptosis.  It has also been suggested these 
oligomeric species may be able to pass their pathology from cell to cell, in a prion-
like manner, leading to further disease progression (Ingelsson, 2016).  Abnormal 
αsyn deposits have also been observed within glial cells, such as 
oligodendrocytes and astrocytes, of PD patients.  These occur most frequently 
within the dorsomedial portion of the S NPC , and their numbers have been shown 
to increase with disease progression, as is seen with LBs (Takahashi and 
Wakabayashi, 2001).  The loss of neuronal function observed in PD, brought 
about by these abnormal deposits, leads to unregulated neurotransmitter release, 
resulting in the misfiring of neurons responsible for limb function and the motor 
symptoms of the disease. 
 
1.3.3  Oxidative S tress and Parkinson’s Disease 
PD is also known to be related to oxidative stress, caused by the excess 
production of reactive oxygen species (R OS ) in the brain (Blesa et al., 2015; 
Manoharan et al., 2016).  R OS  are continuously produced by all tissues in vivo, 
and have a variety of non-toxic functions such as cell signalling and homeostasis 
(S chieber and Chandel, 2014). However, when the balance between ROS  
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production and cellular antioxidant activity is uneven, and R OS  are accumulated, 
oxidative stress can occur.  In PD, oxidative stress is known to cause an 
imbalance in DA metabolism, further contributing to symptoms, and ROS  
mediated DNA damage is known to be a prominent feature in PD patients 
(Manoharan et al., 2016).  The primary causes of oxidative stress in PD include 
iron accumulation, enhanced DA metabolism, mitochondrial DNA mutations and 
the accumulation of hydroxyl radicals (Manoharan et al., 2016).   
 
1.3.4  α-S ynuclein and Parkinson’s Disease 
As mentioned in the previous section, one of the hallmarks of PD is the deposition 
of intracellular inclusions, LBs, within the dopaminergic neurons of the S NPC  in 
the brain (Natalello et al., 2011; Lee et al., 2014).  LBs were first described in 
1912 by Freidrich Henry Lewy as abnormal intracellular protein inclusions, which 
were later demonstrated to be composed of amyloid fibrils of αsyn, stacked in a 
highly ordered and highly heterogeneous fashion (S pillantini et al., 1997).  LB 
formation occurs alongside the selective loss of dopaminergic neurons within the 
affected brain region (Natalello et al., 2011; Lee et al., 2014; Illes-Toth et al., 
2015) and both increase as disease progresses. 
With the advancement in scientific technology, several other factors have since 
pointed to αsyns association with PD, such as the point mutations A53T, A53E , 
A30P, H50Q, E 46K and G15D in the S NCA gene encoding the protein being 
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identified as a cause of hereditary forms of the disease (Vargas et al., 2017; 
Mason et al., 2016).  A number of these mutated forms of αsyn have also been 
shown to have a higher propensity for aggregation than wild-type (WT) αsyn in 
vitro (Uversky and E liezer, 2009).  Duplication and triplication of the S NCA gene 
have also been shown to result in early-onset PD and variations within the genes 
promotor region have been shown to cause an increase in susceptibility for 
disease development within some families (Lill, 2016; Konno et al., 2016; 
Pankratz et al., 2007; Vargas et al., 2017).  
PD may also be caused in a synergistic manner by genetic mutations in other 
genes, such as LR R K2, encoding the dardarin protein, PR KN , encoding parkin 
and PINK1, encoding PTE N Induced Putative Kinase 1, where point mutations, 
frameshift mutations, truncating mutations, exon rearrangements, deletions and 
duplications of the genes have all been observed to result in hereditary PD 
(Pankratz et al., 2007; Lill, 2016). 
 
1.3.5  Other S ynucleinopathies 
αS yn’s disease causing properties are not limited to PD, and abnormal 
accumulation of αsyn aggregates can also result in Dementia with Lewy Bodies 
(DLB) or Multiple S ystem Atrophy (MS A) and all three are collectively termed 
synucleinopathies (S pillantini and Godert, 2000).  Due to the involvement of 
different cell types and brain regions between the three diseases, whilst there are 
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some similar symptoms, the clinical manifestation of the three diseases is varied 
(Y ang and Y u, 2017).  All three synucleinopathies manifest within the brain, but 
affect different cells and regions (S pillantini and Goedert, 2000).  
PD symptoms are concurrent with the formation of αsyn inclusions within 
dopaminergic neurons of the S NPC .  MS A however, results when αsyn 
accumulates within the glial cells, in particular the oligodendroglia, the cells 
responsible for making the myelin sheaths surrounding neurons (Laurens et al., 
2017).  S poradic disease is the most common form, as with PD, but hereditary 
forms associated with point mutations in the S NCA gene, such as rs3775444, 
rs3822086, rs1193107 and rs3857059 have also been reported (Al-Chalabi et al., 
2009; S cholz et al., 2009). 
DLB, like PD, results when αsyn accumulates into LBs within the S NPC .  DLB 
patients however show fewer PD-like motor symptoms, and demonstrate 
increased cognitive decline in comparison to their PD patient counterparts (E lahi 
and Miller, 2017).  S poradic onset DLB is again the most common, however 
genetic factors have also been identified, such as variants in the GBA and APOE  
genes, encoding the proteins beta-glucocerebrosidase and apolipoprotein E , 
respectively (Vergouw et al., 2017). 
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1.4  α-S ynuclein S tructure and Function 
1.4.1 S tructure of α-S ynuclein 
αS yn is an intrinsically disordered 14 kDa, 140 amino acid protein, predominantly 
found within the S NPC  of the brain.  It has no defined or permanent secondary 
structure, existing in an equilibrium of randomly disordered monomers of varying 
degrees of compactness and relative concentration.  As shown in figure 1.2, the 
protein has three main domains; the N-terminal region (aa1-60) (S tefanis, 2012) 
consisting of imperfect, repetitive tandem motifs, which has been demonstrated 
to adopt amphipathic, α-helical structures upon membrane binding (Uversky and 
E liezer, 2009; R ecchia et al., 2004).  The central hydrophobic domain (aa61-95) 
referred to as non-amyloid β-component (NAC) (S tefanis, 2012), which has been 
associated with pathological brain lesions, inducing apoptotic cell death in culture 
(Lashuel et al., 2013; E l-Agnaf et al., 1998) and has a natural tendency to form 
β-structures.  This region has also been demonstrated to be essential for the 
proteins aggregation (Lashuel et al., 2013; Giasson et al., 2001).  The C -terminal 
region (aa96-140) is highly acidic, proline rich and prone to disorder  (Meuvis et 
al., 2010; S tefanis, 2012), and exists in a disordered conformation in monomeric, 
fibrillary and membrane-bound forms of the protein (Oueslati, 2016; Del Mar et 
al., 2005).  This region is known to be important for a variety of αsyn's functions, 
including interaction with metal ions (Oueslati, 2016; Brown, 2007; Paik et al., 
1999), DA (Oueslati, 2016), and other proteins such as Tau (J ensen et al., 1999). 
1
5
 
 
 
F igure 1.2:  S implified S tructure and Amino Acid S equence of αS yn. 
S implified structure and amino acid sequence of αsyn, showing the NAC region highlighted in bold italic text, familial mutations 
with red lines and letters, phosphorylation sites with purple lines and letters and metal binding domains indicated on the sequence. 
16 
 
 αS yn is known to exist in a range of conformations at any one time, due to its 
intrinsic disorder, and the conformational equilibrium of these conformations can 
be altered depending upon the environment (Illes-Toth et al., 2015; Illes-Toth et 
al., 2013).  E xtended conformations, consistent with an unfolded structure, are 
dominant under physiological conditions, whereas co-populated more compact 
structures, associated with increased aggregation and subsequent amyloid 
formation, are most prevalent under non-physiological conditions such as under 
extreme pH, or with the presence of co-factors such as metal ions, which will be 
discussed further in sections 1.6.1 and chapter 3. 
E xtended conformations of proteins have no secondary structure and exist as a 
worm-like chain of amino-acids, in a range of highly disordered, heterogeneous 
monomers.  Compact conformations however have been suggested to exhibit 
small amounts of secondary structure, and representations of both forms of the 
protein are shown in figure 1.3.  α-Helical structures are observed within the N-
terminal region when αsyn is bound to membranes, and this is also known to 
contain a kink or break in the structure at aa43-44, as determined by molecular 
dynamics simulations coupled with Proteins with Atomic details on Course-
grained E nvironment (PACE ) modelling.  These α-helices are also observed 
within the compact conformations of αsyn, along with β-hairpin folds in the region 
of aa36-56 (Y u et al., 2015).  These β-hairpin folds have been shown to be linked 
to the aggregation of the protein, as mutant forms of αsyn known to have a faster 
aggregation propensity, such as the A30P and A53T variants, form these β-
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hairpin structures more quickly than the WT protein.  The region containing the β
-hairpin has also been demonstrated to interact with the C-terminal region of the 
protein, leading to further compaction (Y u et al., 2015).   
 
F igure 1.3:  R epresentation of E xtended and Compact αS yn Conformations 
The N-terminal is highlighted in blue, the NAC region in pink and the C-terminal 
region in red.  Adapted with permission from Y u et al., 2015. 
 
1.4.2  Physiological R ole of αS yn 
Currently, the exact physiological role of αsyn is poorly understood, though 
evidence is mounting for its role in a number of cellular processes.  It has been 
suggested to have a role in DA synthesis, via binding and inhibiting tyrosine 
hydroxylase, which is a rate limiting iron-dependent enzyme essential for DA 
biosynthesis (Perez et al., 2002).  It is also thought to have role in iron 
homeostasis, as its 5’ promotor region is known to contain an iron response 
element (R ogers et al., 2011).  The protein itself is often found localised to 
membranes, suggesting there may be a role in endo and exocytosis of this 
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element (Baksi et al., 2016; S nead and E liezer, 2014).  αS yn is also known to 
have ferrireductase activity, and it has been demonstrated to bind to and utilise 
the redox cycling ability of copper ions to remove electrons from Fe(III), reducing 
it to Fe(II).  This ferrireductase activity does not occur in the absence of copper 
ions, and a build-up of Fe(III) has been noted in the brains of PD patients, where 
a reduction in copper ions has also been observed (Dexter et al., 1989; Davies 
et al., 2011).  Other suggested roles include modulation of synaptic vesicle size, 
and modulation of neurotransmitter storage and release (Nemani et al., 2010; 
Lundblad et al., 2012). It is also thought to act as a molecular chaperone for 
molecules such as the soluble N-ethylmaleimide-sensitive factor activating 
protein receptor (S NAR E ) proteins (Burré et al., 2010). 
Attempts to further elucidate the functions of αsyn through knockout animal 
models have been attempted.  However, knockout of the S NCA gene in mice 
models shows little physiological effect, with no alterations to synaptic plasticity, 
vesicle pools or DA uptake and release noted in any studies (E riksen et al., 2005; 
Chandra et al., 2004).   
 
1.5  Post-translational Modification of α-S ynuclein 
It has been well documented that αsyn found within the LBs of PD patients has 
undergone a variety of post-translational modifications (PTMs), which include 
phosphorylation of serine and tyrosine residues, acetylation of the N-terminus 
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and ubiquitination of lysine residues (Barrett and Greenamyre, 2015; Duce et al., 
2017; Oueslati., 2016; Fujiwara et al., 2002; Popova et al., 2015; S chmid et al., 
2013). The majority of PTM sites are also known to be located within the highly 
disordered C-terminal region of the protein.  There are currently five known 
phosphorylation sites on αsyn; two located at serine residues 87 and 129, and a 
further three located at tyrosines 125, 133 and 136 (Oueslati., 2016; Paleologou 
et al. 2010). 
Phosphorylation at tyrosine residues appears to be predominantly associated 
with membrane binding, with phosphorylation at Y 125 specifically playing an 
important role.  It is suggested that this modification is important for the normal 
biological functions of αsyn (S chreurs et al., 2014).   Data currently suggests that 
phosphorylation at S 87, S 129 or Y 39 prevents the binding of αsyn with biological 
membranes. It has also been suggested that phosphorylation at Y 125 has a 
neuroprotective role and prevents the formation of neurotoxic oligomeric species 
(Chen et al., 2009). 
Phosphorylation at serine residues, and in particular S 129, has been suggested 
to play a role in the pathogenicity of the protein, with 90% of αsyn within LBs 
found to be phosphorylated at this amino acid residue.  In its normal function, 
phosphorylation at S 129 has been suggested to have a role in autophagy 
(Tenreiro et al., 2014) and in cellular clearance of αsyn via proteolytic degradation 
(Chau et al., 2009; Machiya et al., 2010). 
20 
 
Currently it is unclear exactly what the role of αsyn phosphorylation is in the 
pathogenesis of disease, and studies have yielded wildly contradictory results, 
but it is clear that phosphorylation at S 129 plays an important role, due to its 
substantial increase within LBs isolated from PD patients. 
 
1.6  Promotion and Prevention of α-S ynuclein Aggregation via Ligand 
Binding 
In vitro, the rapid formation of soluble oligomers and amyloid fibrils can be 
initiated by PTMs, metal binding and alterations to the protein’s environment such 
as shifts in pH or temperature, incubation with denaturants such as sodium 
dodecyl sulphate (S DS ), and vigorous agitation in solution.  Increased 
aggregation propensity may also be induced via the introduction of destabilising 
mutations into the protein’s primary sequence, such as the familial mutations 
A53T, A30P and E 46K discussed earlier in the chapter (Wolfe and Cyr, 2011; 
J ahn and R adford, 2008; Uversky and E liezer, 2009). The protein's 
conformational distribution is significantly dependent on the pH of the 
environment with acidic conditions resulting in the formation of the more compact 
species, and an observed increased in aggregation kinetics (Beveridge et al., 
2015; Morris and F inke, 2009).  These compact conformations can also be 
induced by other external factors including temperature, organic solvents, salts, 
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pesticides, herbicides, heparin, polycations, methionine oxidation (Natalello et al., 
2011, Uversky and E liezer, 2009, Brown, 2010).   
The binding of ligands such as metal ions to αsyn has also been demonstrated 
to induce the formation of more compact conformations, and cause an increase 
in the aggregation rate of the protein (Mason et al, 2016; Uversky et al, 2001).  In 
contrast, other ligands have been demonstrated to reduce the aggregation of 
αsyn in vitro, such as the presence of the natural polyphenolic compounds 
curcumin and E pigallocatechingallate (E GCG), which has also been 
demonstrated to increase the presence of the extended conformations of αsyn 
(Pandey et al., 2008; Liu et al., 2011).  These aggregation promoting and 
preventing ligands will be discussed individually in this section.   
 
1.6.1  Promotors of Aggregation 
Ligands discussed within this section have been either shown to shift αsyn’s 
conformational equilibrium towards the more compact, aggregation prone 
conformations, or increase the aggregation kinetics of the protein in vitro. 
 
1.6.1.1  Metal Ions 
Metal ions were first identified as a potentially important factor in PD progression 
as far back as 1924, when deposits of iron were identified, co-localised with LBs 
in the brains of PD patients (Lhermitte et al., 1924).  The link between heavy 
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metals and PD was then further solidified in the 1980s, when two separate studies 
identified increased levels of iron and zinc in the brains of PD patients (Dexter et 
al., 1989; R iederer et al., 1989).  In contrast, copper levels in the S NPC   were 
found to be reduced in comparison to control brains (Dexter et al., 1989), however 
high levels of copper had also recently been identified in the cerebrospinal fluid 
of PD patients (Pall et al., 1987).  Increased levels of all three metals have since 
been found in the LBs of PD patients, and have also since been observed in and 
around amyloid plaques in AD patients (Lovell et al., 1998; Miller et al., 2006).  
S everal epidemiological studies also noted that individuals with chronic industrial 
exposure to heavy metals, including copper, iron, manganese, zinc and 
aluminium, had an increased incidence rate of PD compared to the general 
population (Gorell et al., 1999; Gorell et al., 2004; Coon et al., 2006), leading to 
increased interest in the role of metal homeostasis in the development and 
progression of PD and other neurodegenerative disorders.   
The ability of metal ions, particularly copper to promote oligomerisation and 
increase amyloid fibril formation of αsyn has been well established (Natalello et 
al., 2011; Uversky and E liezer, 2009; Brown, 2009; Uversky et al., 2001). 
Incubation with copper has also demonstrated an increased population of the 
more compact, aggregation prone states of αsyn, and this has been observed by 
a number of techniques, including nuclear magnetic resonance (NMR ) (Binolfi et 
al., 2008), circular dichroism (Binolfi et al., 2008), electrospray ionisation – ion 
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mobility spectrometry – mass spectrometry (E S I-IMS -MS ) (Natalello et al., 2011; 
Mason et al., 2016) and calorimetric titrations (Drew et al., 2008).   
αS yn has been shown to have a high affinity for copper binding, and is known to 
have at least three specific binding motifs for the metal ion, as shown in figure 
1.2 (Ahmad et al., 2012).  A high affinity binding site has been observed at the N-
terminus, where the free nitrogen on the amino terminal anchors the metal ion.  
A second, lower affinity site has been observed at H50, anchored by the 
imidazole ring of the amino acid, and a third low affinity site was found within the 
C-terminus involving the residues D121, N122 and E 123 (Binolfi et al., 2012; 
Mason et al., 2016; Binolfi et al., 2006).  The protein has been demonstrated to 
bind copper ions more readily than any other metal currently investigated (Binolfi 
et al., 2006).  E lectron paramagnetic resonance (E PR ) spectroscopy 
demonstrated the high affinity binding site, within the N-terminus, could bind the 
protein when present in the nanomole range (Ahmad et al., 2012).   
Iron has also been shown to increase the aggregation rate of αsyn in vitro (Binolfi 
et al., 2006; Uversky et al., 2001).  Divalent iron has also been found to bind to 
the C-terminus of αsyn via 2D-NMR studies, and this metal also appears to be 
utilising D121 as an anchoring residue (Binolfi et al., 2006; Peng et al., 2010).   
The interaction of αsyn with metal ions will be discussed further in chapter 3. 
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1.6.1.2  S permine 
Another extensively studied promotor of αsyn aggregation is spermine, a 
naturally present polyamine involved in both neuronal cell proliferation and 
differentiation, and in the modulation of ion channel receptors (Grabenauer et al., 
2008).  It has the ability to complex with αsyn under native physiological 
conditions resulting in enhanced rates of fibrillation.  Upon the binding of 
spermine, which is known to occur on the C -terminus of the protein, αsyn and its 
familial variants undergo a structural collapse, resulting in a reduction in cross 
sectional area (Grabenauer et al., 2008; Illes-Toth et al., 2013; Moree et al., 
2015).  
 
1.6.2  Prevention of Aggregation 
The prevention of oligomer and amyloid assembly through the use of small 
molecule inhibitors, that bind specifically to precursor protein conformations, is 
an important challenge.  S mall molecules can prevent fibril formation by binding 
to and stabilising non-amyloidogenic states.  One strategy towards preventing 
aggregation is therefore to shift the population back to non-amyloidogenic 
conformations through stabilisation of the unfolded state.  Identifying such 
inhibitors is problematic, due to the conformational heterogeneity of amyloid 
proteins, but several compounds have been demonstrated in vitro to reduce the 
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aggregation of αsyn, which will be discussed in the following sections, and these 
could provide novel drug candidates for treating PD. 
 
1.6.2.1 Polyphenolic Compounds 
Polyphenolic compounds have been proving good novel candidates for anti-
amyloid therapeutics for some time.  Natural curcumin is of particular interest, as 
it appears to have a variety of medicinal properties in vitro, and has been utilised 
as medicine in eastern cultures for thousands of years (Witkin and Li, 2013). 
In 2008, curcumin was demonstrated by both western blot and in an S H-S Y 5Y  
neuroblastoma cell model, to inhibit the aggregation of αsyn (Pandey et al., 2008).  
The molecule is also known to have antioxidant properties, which may be how it 
exerts its effects on amyloid aggregation.  Increased oxidative stress is known to 
be initiated by overexpression of αsyn, and is suggested to play a key role in PD 
development and progression, through the production of free radicals such as 
R OS  (J enner and Olanow, 1996; Dexter et al., 1989).  Phenolic antioxidants, 
including curcumin, act as hydrogen donors, inhibiting the propagation of free 
radical chain reactions (Venkateswarlu et al., 2005), thereby reducing the 
damaging effect of these species.  Inhibition of free-radical species may therefore 
be a possible mechanism for curcumin to prevent αsyn aggregation.   
Another natural polyphenol known to interact with amyloid proteins is E GCG; an 
antioxidant found in green tea, which has been demonstrated to prevent amyloid 
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formation in vitro via multiple techniques.  Incubation of A53T mutant αsyn with 
E GCG prevented its aggregation into amyloid fibrils, as determined via thioflavin-
t (ThT) assay, where aggregation was completely halted.  The same study also 
determined binding to E CGC prevented the conformational shift towards the 
compact states, normally observed with A53T αsyn, as determined by E S I-IMS -
MS  (Liu et al., 2011).   
The interaction of αsyn with curcumin will be discussed further in chapter 4. 
 
1.6.2.2  Dopamine 
One of αsyn’s natural and most important ligands, DA, has also been suggested 
to prevent the aggregation of αsyn upon binding to the protein.  In the presence 
of DA, αsyn yields a diverse range of S DS  resistant, non-amyloid oligomers 
(Leong et al., 2009).  It has been observed that the incremental uptake of DA 
pushes the equilibrium of αsyn towards the highly expanded states, which 
become fully populated upon the binding of three DA ligands to the protein, when 
compact states may no longer be observed.  DA binds uniquely to the most 
expanded conformations of αsyn, as determined by E S I-IMS -MS , indicating that 
the ligand binding site in this instance requires an extended conformation (Illes-
Toth et al., 2013).   
These observations demonstrate that modulation of amyloid assembly is possible, 
by either alteration to the co-populated precursor states, or by directly blocking 
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assembly via the use of inhibitors.  With successful identification of appropriate 
ligands, targeting aggregation of αsyn via either targeting of the monomeric 
protein, or oligomeric species produced along the aggregation pathway, may be 
a promising potential therapeutic method for PD alleviation, and this will be further 
investigated in chapter 4. 
 
1.7  E S I-IMS -MS  as a Tool for Understanding Protein Conformation 
Native mass spectrometry (E S I-MS ) allows for highly sensitive and extremely 
rapid identification of proteins and protein complexes by simultaneously 
analysing all species present within a sample, through determination of their 
mass to charge ratio, or m/z.  It can provide information on the aggregation 
properties of amyloid proteins by identification of all species within a sample, 
including monomeric proteins, oligomeric species, protofibrils and protein 
fragments, whilst also determining their relative intensities.     
Further structural information on the conformation of monomeric and oligomeric 
species within a sample can be determined using ion mobility spectrometry, to 
separate co-populated conformations with the same m/z, appearing within the 
same spectral peak, which would not be distinguishable from one another with 
native E S I-MS .  By calculation of the collisional cross sectional area (CCS  or Ω ) 
of each ion, overlapping species within the spectra, with the same CS I but 
different conformational properties, can be determined from one another and 
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therefore, information on the conformation of each protein species can be 
determined (S mith et al., 2009; Ruotolo et al., 2008). 
 
1.7.1  E S I-IMS -MS  and the Advantages of Ion Mobility 
The addition of ion mobility drift cells to native mass spectrometry instrumentation 
has allowed for the characterisation of monomeric and oligomeric protein 
conformations, through determination of their CCS .  During an ion mobility 
experiment, the time taken for an analyte of interest to travel through an ion 
mobility cell or drift tube containing a neutral gas, whilst under the influence of a 
weak electric field, is measured.  As will be further discussed throughout this 
section, the mobility of an analyte through the drift cell is determined by its mass, 
conformation, and charge obtained during ionisation, with a physically larger 
analyte taking longer to transverse the drift cell, and an analyte with a smaller 
conformation travelling faster (Mason et al., 2016; S mith et al., 2009). 
 
1.7.1.1  E S I-IMS -MS  Instrumentation 
An E S I-IMS -MS  instrument, such as the S ynapt G2 (Waters, Manchester) utilised 
in this project, consists of a nano-electrospray source, which may be an 
automated sampler such as the NanoMate (Advion, UK), externally mounted to 
the instrument to conduct ambient ionisation at atmospheric pressure.  As shown 
in figure 1.4, this source is mounted near a sampling cone, which draws a 
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continuous beam of ions into the internal compartments of the instrument, which 
are kept under vacuum.  Ions then travel through an ion guide towards and 
through the quadrupole mass analyser to the ion mobility chamber.  Ions are then 
trapped, before being pulsed into the N2 cell for mobility separation, before being 
halted again in the transfer.  Ions then enter the vacuum of the time-of-flight (TOF ) 
mass analyser, which determines their m/z, before arrival time distributions (ATD) 
are determined by the ion detection system  
3
0
 
 
 
F igure 1.4:  S chematic representation of the S ynapt G2 E S I-IMS  Mass S pectrometer. 
Diagram shows regions of ionisation, mass selection (not used), IMS  and m/z determination. 
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1.7.1.2  Principles of E lectrospray Ionisation 
At the beginning of an ion mobility experiment, ions are produced when an 
electrical current is applied to either a gold-coated borosilicate needle or auto-
sampler tip, if using an automated source such as a NanoMate, which contains 
the analyte of interest.  This produces a Taylor cone, as shown in figure 1.5.  A 
fine mist of multiply charged solvent droplets containing the analyte are excluded 
from the Taylor cone, and machine parameters such as cone voltage, cone 
temperature, and distance from the source must all be optimised to ensure a 
stable electrospray for optimal analysis (Wilm, 2011).  Volatile solvents must be 
utilised, and with a small sample volume of around 2-10µl, to ensure production 
of very small and highly charged droplets. 
 
 
F igure 1.5: Mechanism of E lectrospray Ionisation. 
Diagram outlining the mechanism of electrospray ionisation, showing the 
production of a Taylor cone, solvent evaporation, and coulombic explosion, 
leading to the production of multiply charged analyte ions. 
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When coulombic repulsion of the charges on the surface of these solvent droplets 
overcomes the surface tension of the droplet, fission occurs and the droplet forms 
smaller, progeny droplets, and some of the solvent is removed through 
evaporation.  This point of fission and evaporation is referred to as the R aleigh 
limit, as highlighted in figure 1.5.  These smaller, progeny droplets then undergo 
further fission and evaporation, until all the solvent is removed and only gaseous, 
charged ions remain (Ho et al., 2003; Wilm, 2011).  The number of charges on 
the ions depends on the structure of the molecule or protein of interest, and this 
is determined by the accessible surface area and presence of ionisable functional 
groups on the molecule, and will be discussed further later.   
E S I is referred to as a ‘soft-ionisation’ technique, which allows for molecules with 
high molecular weights to be observed easily, and also preserves the 
conformation and any non-covalent interactions of proteins and protein-
complexes (Beveridge et al., 2013).  Three models exist to describe the ionisation 
in an electrospray source; the ion evaporation model, the charge residue model, 
and the chain ejection model.   
The ion evaporation model is usually used to describe ionisation of smaller ions, 
where shrinkage of the droplets occurs via evaporation, until the field strength on 
the surface is so large that ions are expelled from the droplet.  This type of 
ionisation is heavily influenced by the chemical properties of the ion, and usually 
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occurs when the droplet size reaches around 20nm in diameter (Konermann et 
al., 2013; Wilm, 2011).    
The charge residue model is associated with larger ions such as proteins and 
usually occurs when each droplet only contains one ion.  Ions become completely 
desolvated before gaining charges, which can be positive or negative dependent 
on the mode of acquisition (Konermann et al., 2013; Wilm, 2011).  This model of 
ionisation preserves non-covalent complexes, as it requires less energy, as the 
ions are not expelled from within the droplet, but the droplet is removed from 
around them, and is therefore less damaging.  It is generally accepted that 
compact proteins are ionised via the charge residue model (Donor et al., 2017). 
The chain ejection model describes the ionisation method for extended 
biopolymers such as the extended conformations of αsyn.  The unfolded protein 
chain is partially ejected from the solvent droplet, leading protons to attach to the 
exposed portion of the ion.  The ion is then further extruded from the droplet, 
gaining more charges, until it is fully ejected from the solvent (Konermann et al., 
2013; Donor et al., 2017). 
The number of charges a protein will acquire upon ionisation, also known as its 
charge state (CS ) is dictated by the number of basic amino acid residues 
available on its surface for ionisation (Coveyr et al., 1988; Loo et al., 1988) which 
is itself dictated by the electrostatic repulsions between protonated basic residues 
thus forming its tertiary structure (S chnier et al., 1995).  Ionisation may be 
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performed in either positive or negative mode, supplying the protein with either 
positive or negative charges, by addition or removal of electrons.  When a protein 
is ionised, it may then be referred to as a charge state ion (CS I), for example a 
conformation of said protein bound to 14 positive charges may then be referred 
to as the +14 CS I.     
Folded proteins with a compact CCS  generally only acquire 2 to 8 bound charges, 
so have CS Is of +2 to +8 for example, due to the limited number of basic residues 
on the surface of the protein.  Unfolded proteins pick up a higher number of 
charges on ionisation, as they have a more extended structure, and a higher 
number of ionisation sites are available.   Higher CS Is representing extended 
protein conformations are present within the lower m/z range, whilst smaller, 
more globular proteins pick up fewer charges and are found within the higher m/z 
range, therefore an increase in charge state often corresponds with an increase 
in CCS  (Vargas et al., 2017).  
During acquisition of a protein, particularly with IDPs such as αsyn, multiple 
charge states will be observed, due to the conformational flexibility of proteins, 
as some will have more exposed ionisable sites available than others.  The range 
of these charges is referred to as the charge state distribution (CS D).  Folded 
proteins will display a narrower CS D due to the limited number of basic residues 
on the surface of the protein, and limited flexibility, and tend to display a small 
CS D of around 2 to 6 different species within the mass spectra.  Unfolded proteins 
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however display a wider CS D due to their increased flexibility, and increased 
exposed basic residues, and will display a wider range of peaks on the mass 
spectra. 
A protein's CS D can be significantly altered by solution conditions, therefore care 
must be taken to ensure sampling is performed in a manner that retains the 
protein in its native state.  This is a particular problem with IDPs such as αsyn.  
Non-physiological solvent conditions such as low pH or the presence of alcohols 
can significantly alter the CS D of a protein (Beveridge et al., 2015; Duce et al., 
2017) so care must be taken to keep solution conditions as physiologically 
relevant as possible.   
 
1.7.1.3  Ion Mobility S eparation 
After ionisation and injection into the sampling cone, ions travel through the 
stacked ring ion guide and quadrupole mass filter, before being pulsed into a drift 
tube filled with an inert buffer gas, in the case of the S ynapt G2, N2. 
 
1.7.1.3.1  Drift Time IMS  
 In drift time ion mobility separation, a weak direct current (DC ) electric field is 
applied to the drift cell, and ions are drawn through via their interaction with the 
electric field, colliding with the buffer gas as they travel.  In this case, a molecule's 
transit time through the drift cell is determined by both its charge; with a higher 
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number of charges gained during ionisation resulting in a quicker transition, and 
its conformation; with the more collisions encountered with the gas causing the 
molecules speed of transition to slow.   
 
1.7.1.3.2  Travelling Wave IMS  
In a travelling wave experiment, the DC current applied over the drift cell is not 
linear, but in a transient wave form.  The drift tube consists of 168 x 0.5mm 
electrode plates, 1mm apart, in which a radio-frequency (R F ) is applied to guide 
the ions transit.  A continuous series of DC voltage pulses are applied to the ion 
guide, moving the ions through the drift cell.   
Following a gated release from the trap ion guide region, a pocket of ions is 
released into the drift cell and 200 mass spectra are acquired, before another 
packet of ions are pulsed into the drift tube and a further 200 spectra are acquired. 
Other settings must be adequately tuned to ensure adequate separation of ions, 
including wave heights, amplitudes, and wave velocities, as well as the type and 
pressure of the buffer gas (Thalassinos and S crivens, 2009; S hvartsburg and 
S mith, 2008). 
An ion's speed through the drift cell again is related to the ion's size, charge, 
gross morphology and its interaction with the buffer gas.  High mobility ions, such 
as those with a small CCS , travel with the wave and pass through the ion guide 
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faster.  Lower mobility ions with an extended structure and smaller CCS , will roll 
over the top of the waves and are ejected from the drift cell slower.   
Due to the stacked ring ion guides within the S ynapt G2, ions may also be 
fragmented during ion mobility separation, either in the trap or transfer region, or 
both if required.  The high sensitivity of the travelling wave allows isobaric species, 
stereoisomers and conformational isomers to be resolved with great accuracy. 
 
1.7.1.3.3  Time-Of-F light Mass Analysis 
F inally, mass data is acquired by use of time-of-flight (TOF) mass analysis 
allowing m/z’s to be determined, by examining the flight time of the ions through 
the TOF component of the mass spectrometer.  TOF mass analysers separate 
ions according to their velocities, which is dependent on the mass of the ion, with 
lighter ions having shorter flight times than heavier ions.   
An ion is accelerated into the TOF analyser via an electrical field of known 
strength, this means ions with the same charge will have the same kinetic energy.  
The velocity of the ion will depend on its mass, with heavier ions of the same 
charge having a longer flight time.  The  reflectron TOF component of the S ynapt 
G2, utilised for experiments presented in this thesis, has improved mass 
resolution than a standard, linear TOF detector, as the detector contains ion 
mirrors, or reflectrons; a stacked series of ring shaped electrodes that create an 
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electric field by way of a linear voltage gradient, off of which the ions are ‘bounced’ 
before detection (Mamyrin et al., 1973; Boesl, 2017).   
The principle behind reflectron mode TOF  is that ions with higher kinetic energy 
will penetrate further into the stacked electrodes than those with a lower kinetic 
energy, allowing ions of the same m/z but different kinetics to arrive at the 
detector at the same time (Boesl, 2017).    
 
1.7.1.3.4  Calculation of CCS  from Ion Mobility Data 
Once the drift time of an ion has been obtained the CCS  can be calculated, with 
comparison to proteins of known mass and structure.  Due to the non-linear 
electric field within a travelling wave experiment, wave heights, velocities and gas 
pressures can all affect the recorded drift time of ions.  It is therefore, important 
to account for these differences when calculating the CCS .  E xperimentally 
recorded values can be corrected using the following equations, alongside data 
from calibrant proteins of known CCS . 
CCS  can be determined from a linear IMS  device using equation 1 below: 
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E quation 1:  Calculation of CCS  on a Linear IMS  Instrument. 
Calculation of CCS  (Ω ), where z is the number of charges on the ion, e is the charge 
on the electron (1.6022 x 10-19C), kb is the Boltzmann constant, T  is temperature of 
the buffer gas, µ is the reduced mass, P  is the buffer gas pressure, N is the density 
of the buffer gas, E  is the electric field, and L is the length of the drift tube.   
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Correction factors can now be incorporated into the equation, to compensate for 
the non-linear effects of the triwave, which result in uneven electric fields and 
uneven temperatures and pressure within the system.  Correction parameters 
can be incorporated into equation 1, to give equation 2, where A is a correction 
factor for the electric field parameters, and B is a compensation factor for the non-
linear effects of the triwave instrument: 
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E quation 2:  Calculation of CCS (Ω ) with Incorporation of Correction Factors for 
Triwave IMS . 
Calculation of CCS  including correction factors for the non-linear effects of the 
triwave. A corrects for the electric field, and B corrects for the non-linear effects. 
 
R educed CCS , or Ω ’ can then be calculated, which is a charge and mass 
independent measurement, using equation 3: 
Ω′=
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E quation 3:  Calculation of reduced CCS  (Ω ’). 
Drift time data is obtained from standards with known CCS  and a calibration curve 
created, by plotting reduced CCS  against drift time, and fitting to determine the A 
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and B compensation values required for equations 2 and 3, which can then be 
utilised to determine the CCS  of the protein of interest. 
 
1.7.2  E S I-IMS -MS  as a Tool for S tudying Amyloid Protein Conformation 
Ion mobility mass spectrometry has proven unprecedented in its ability to provide 
information about the structural alterations and misfolding events occurring in a 
number of amyloid disease related proteins.  This has allowed the determination 
of fundamental, mechanistic details relating to amyloid protein aggregation, 
including structural changes, kinetics, dynamics, binding interactions, and 
degrees of heterogeneity in populations from a variety of disease causing 
proteins, including αsyn (Bernstein et al., 2004; Illes-Toth et al., 2015; Illes-Toth 
et al., 2013; Mason et al., 2016) and amyloid-β (Alzheimer's disease) (Y oung et 
al., 2015)  
These proteins have previously been investigated by a range of classical 
biophysical methods, such as FTIR , CD and NMR  spectroscopy, however 
extracting information pertaining to the aggregation kinetics using these methods 
is hindered by the transient nature of oligomers species, their low concentrations 
and the co-population of a range of different oligomeric species of the same mass 
which cannot be distinguished from each other by any of these methods. 
E S I-IMS -MS  by contrast has a unique advantage to aid in determining amyloid 
kinetics and conformational dynamics due to its sensitivity, speed of analysis and 
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ability to resolve heterogeneous populations (S mith et al., 2009; Y oung et al., 
2015; Beveridge et al., 2013). 
 
1.7.3  Potential Limitations of E S I-IMS -MS  
Because of their intrinsic disorder, IDPs display structural heterogeneity within 
the gas-phase, that is not observed with folded, globular proteins.  Initial 
investigations into IMS  suggested that IDPs were retaining memory of their 
structural flexibility in the absence of solvents, and all solution structures were 
surviving and being recorded in E S I-IMS -MS  experiments (S helimov and J arrold, 
1997).  Other fundamental studies however, indicated that whilst folded proteins 
retain their native-like states in the gas-phase, and experimentally derived CCS s 
have been shown to be consistent with theoretical values (R uotolo et al., 2015; 
S carff  et al., 2008; S aikusa et al., 2013), those with less secondary structure may 
undergo unfolding during transfer from the solvent to gas-phase (Bohrer et al., 
2008; Zilch et al., 2007), and the unfolding of subunits of globular proteins during 
E S I-IMS -MS  has also been reported (R uotolo et al., 2005).   
More recently however, it has been suggested that these disordered structures 
may undergo collapse in the absence of solvent.  Advances in the understanding 
of how proteins escape electrospray droplets and form gaseous ions, as 
described earlier, have also added to concerns of the true relationship between 
solution and gas-phase conformations of proteins, in particular IDPs (Borysik et 
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al., 2015).  Transient elements of secondary structure displayed by IDPs can 
reduce the hydrodynamic radius of the protein structure, giving rise to 
conformations of varying compactness during E S I-IMS -MS  experiments 
(Beveridge et al., 2015).  It is now understood that IDP domains could remain 
elongated in the gas-phase, much like the true extended conformations of some 
proteins, or they may undergo structural collapse in the absence of solvent, 
leading to more compact, folded structures (Pagel et al., 2013), and therefore 
care must be taken when interpreting E S I-IMS -MS  data. 
Combining E S I-IMS -MS  experiments with methods such as small-angle X -ray 
scattering (S AX S ), or by comparison of experimentally derived CCS s obtained by 
E S I-IMS -MS  with those determined via molecular dynamics simulations, has 
allowed gas-phase derived structures and those present in solution to be truly 
compared, and these have yielded some concerning results.  S AX S , in 
combination with genetic algorithm judging optimisation of ensembles (GAJ OE ) 
for validation, confirmed there was an absence of gas-phase determined 
structures, for a range of IDPs, in solution.  IDPs were found to sample a 3- to 5-
fold broader conformational space in the gas-phase compared to solution.  A 
unimodal distribution of conformations was observed using S AX S , whereas three 
subpopulations of extended, intermediate and compact conformations were 
observed by E S I-IMS -MS  (Borysik et al., 2015).  This suggests that the E S I 
process is generating additional subpopulations, and conformations, with the 
proteins observed to become more compact in the absence of solvent (Borysik 
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et al., 2015).  S AXS  also demonstrated compaction of the sw15-sfr1 protein, 
which has a role in homologous recombination, in the gas-phase, where 
structures were observed to be 56% more compact upon E S I-IMS -MS  (S aikusa 
et al., 2013).  Molecular dynamics simulations conducted alongside E S I-IMS -MS  
of the p53 protein also determined regions of the protein complex to have 50-
60% more compact conformations than those predicted under solution conditions 
(Pagel et al., 2013).    
Authors of these studies therefore suggest that extended IDPs can become 
trapped in E S I droplets during the electrospray process and become ionised more 
akin to globular proteins, undergoing structural collapse during solvent 
evaporation.  The subpopulations observed via E S I-IMS -MS  therefore may 
represent an array of ionisation techniques, as opposed to pre-formed states 
present in solution (Borysik et al., 2015; S aikusa et al., 2013; Pagel et al., 2013).  
Care must therefore be taken when interpreting E S I-IMS -MS  data, as the CCS  
determined experimentally may not necessarily represent the true CCS s 
observed in solution. 
 
1.8  E S I-IMS -MS  of α-S ynuclein 
1.8.1  E S I-IMS -MS  of WT α-S ynuclein 
Due to its intrinsic disorder, E S I-IMS -MS  acquisitions of WT αsyn yield results 
with altered CS D’s and conformational dynamics dependent on the acquisition 
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parameters, and the composition of the buffers, therefore there is are a variety of 
different reports.  In positive ion mode, a variety of CS D’s have been reported in 
the literature for the monomeric protein, when acquired in similar, near 
physiological solution conditions.  S everal of these reports also note the presence 
of dimeric species with varying CS Ds, and all have been summarised in table 1.2.  
The conformational dynamics are slightly different between reports.  One study 
reports four distinct conformations, spanning CS I’s +24 to +14, +17 to +10, +13 
to +7 and +10 to +5 (Beveridge et al., 2013), whereas another reports detection 
of three distinct conformations, with average CCS ’s of 1200Å 2, 1500Å2 and 
2530Å2 detected (Illes-Toth et al., 2013), and another just two conformational 
families with average CCS  of 1043Å 2 and 2742Å2 was reported (Beveridge et al., 
2015).  More recently, as many as eight distinct conformations have been 
identified by the use of Gaussian fitting to resolve conformational families, and 
these show a distinct pattern of extended conformations reducing in intensity 
before disappearing in favour of more compact species (Mason et al., 2016). 
The CS D and conformational distribution of WT αsyn is altered by solution 
conditions such as altered pH.  A number of studies utilising buffers with a lower 
pH yielded a range of results, including +12 to +3 at pH 2.5 (Beveridge et al., 
2015) and +12 to +3, with dimers of +13 to +7 (Beveridge et al., 2015), showing 
a narrowed CS D and increased population of more compact conformational 
species. 
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Monomer CS D Dimer CS D pH Reference 
+24 to +5  - 6.8 Beveridge et al., 2013 
+20 to +5 - 6.8 Beveridge et al., 2015 
+20 to +5 +23 to +10 6.8 Phillips et al., 2015 
+20 to +6 - 7.0 Illes-Toth et al., 2015 
+19 to +5 - 6.8 Beveridge et al., 2013 
+18 to +6 +21 to +13 6.8 Illes-Toth et al., 2013 
+15 to +5 - 6.8 Mason et al., 2016 
+13 to +4 +15 to +7 7.4 Kang et al., 2012 
 Table 1.2:  Comparison of WT αS yn Charge S tate Distributions 
Comparison of previously reported monomeric and dimeric WT αsyn CS Ds, 
acquired using positive ion mode E S I-IMS -MS . 
 
Negative ion mode E S I has also been utilised to investigate WT αsyn.  CS D’s of 
-16 to -6, with dimers of -21 to -17 when analysed at pH 7 was reported (Bernstein 
et al., 2004), with an average Ω of 2530 Å2. 
Decreased CS D’s favouring more compact conformations at altered pH 
conditions have also been observed in negative ion mode, with a CS D of -11 to -
6, centred at the -8 ion reported at pH 2.5, and the average CCS  was also 
demonstrated to decrease to 1690Å2 (Bernstein et al., 2004).  It appears therefore 
that there is a large degree of heterogeneity in the observed data sets and the 
mode of acquisition is critical in determining the observed CS D. Nevertheless, all 
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studies observed populations of extended and compact states when analysed by 
MS .  
 
1.8.2  E S I-IMS -MS  of αS yn Ligand Binding 
E S I-IMS -MS  is proving a useful tool to analyse the interactions of IDPs such as 
αsyn with a variety of ligands such as metal ions, to determine their effects on the 
conformational dynamics of the proteins. 
Investigations utilising E S I-IMS -MS  with 10mM ammonium acetate buffer, 
deduced that the dominant CS I of αsyn shifted from +14 to +8 upon addition of 
copper.  This also coincided with an increase in the more compact conformations 
at the majority of CS Is, for example at the -8 CS I, unbound protein was present 
in 3 conformations, with of the protein present in the most compact of these 
conformations.  Upon binding of copper however, this increased to 30% of the 
total protein at this CS I (Natalello et al., 2011).  More recently another study 
utilising E S I-IMS -MS  to investigate copper binding also demonstrated an 
increased CS D, from +15 to +5 to +16 to +5, and an increase in the more compact 
conformations within C S Is, upon the binding of one or more copper ions (Mason 
et al., 2016). 
These observed increases in the compact state correlate with an increase in 
aggregation rates and demonstrate the importance of the compact state in 
aggregation 
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E S I-IMS -MS  has proven itself unprecedented in its ability to categorise the 
conformational dynamics of IDPs such as αsyn, and is an incredibly useful tool 
for investigating disease-relevant proteins and potential drug candidates or 
targets. 
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1.9  Aims and Objectives 
The overall hypothesis of the work is that αsyn aggregation can be modulated by 
altering the population of the compact aggregation-prone state by post 
translational modifications and ligand binding.  Here E S I-IMS -MS  and a range of 
spectroscopy techniques were used to investigate the conformational changes 
and aggregation of αsyn in vitro.  C ell culture models were used to investigate 
intracellular aggregation.  
 
To achieve these aims, the following objectives were identified: 
 To determine the effect of post translational modifications in the form of 
phosphorylation mimics on the metal binding characteristics of αsyn: the 
subsequent effects on the conformation of the monomeric state will be 
determined by E S I-IMS -MS  and resulting aggregation properties 
investigated.   
 To determine if aggregation of αsyn can be inhibited by the presence of 
small molecule inhibitors.  To this end alterations of the compact state of 
the protein and the model of ligand interaction will be investigated by E S I-
IMS -MS  in the presence of curcumin derivatives.  
 To determine how the phosphorylation state of αsyn in cell culture affects 
copper-induced intracellular aggregation and determine if copper-induced 
aggregation can be inhibited using curcumin derivatives. 
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Chapter 2 - Materials and Methods 
2.1  Materials 
2.1.1  Buffers and S olutions  
Buffer solutions are shown in table 2.1.1. 
Buffer Composition 
TBS  50mM Tris (F isher S cientific C77-86-1), 150mM NaCl 
(F isher C10428420) (pH 7.6) 
TBS -T 50mM Tris, 150mM NaCl, 0.05% Tween20 (F isher 
C9005-64-5) (pH 7.6) 
Anion E xchange Buffer A 25mM Tris, 10mM NaCl (pH 8.0) 
Anion E xchange Buffer B 25mM Tris, 1M NaCl (pH 8.0) 
Blocking Buffer 1 TBS , 5% dried milk (Marvel), 0.05% Tween20 
Blocking buffer 2 TBS , 0.5% dried milk (Marvel) 
Complete Media DME M (Thermo F isher C42430-025), 50,000 units 
penicillin/0.1mg/ml streptomycin (Thermo C15140-122), 
10% FCS  (Thermo C10270-106) 
E . coli Cell Lysis Buffer 10mM Tris, 100µg/ml Lysozyme (S igma Aldrich CL6876), 
20µg/ml DNase (S igma CDN25), 20µg/ml RNase (S igma 
CR N6513), Protease Inhibitor Cocktail (S igma 
CS RE 0055), PMS F (Thermo C36978) (pH 8.0) 
Gel R unning Buffer 25mM Tris, 192mM glycine (F isher C56-40-6), 0.1% S DS  
at pH 8.5 
Lysogeny Broth (LyB) 10g Tryptone (S igma CT7293), 5g Y east E xtract (Oxoid 
CLP0021), 10g NaCl 
S ize E xclusion (S E ) Buffer 25mM Tris, 10mM NaCl at pH 8.0 
  
Table 2.1:  Buffer solutions. 
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2.2 Methods 
2.2.1 Protein Preparation 
2.2.1.1 Protein Production 
A pE T23a plasmid containing the appropriate αsyn insertion (WT or the mutants 
S 87D or S 129D) was combined with BL21-Gold DE 3 competent E scherichia coli 
(E . coli) cells (Agilent Technologies, C200121) in a culture tube at a ratio of 1:50, 
v/v, alongside a control tube containing no plasmid.  Tubes were kept on ice for 
30mins with occasional mixing, followed by heat-shock in a water bath at 42ºC 
for 45s, followed by a further 2mins on ice.  S terile LyB was added, followed by 
incubation with shaking at 37ºC for 35mins.  The starter cultures were centrifuged 
at 3,000 rpm for 5mins, in a Thermo F isher Fresco 21 centrifuge, 80% of the 
supernatant was discarded, and cells were resuspended in the remaining 20%.  
Petri dishes were prepared with LyB containing agar and 1% ampicillin (F isher 
S cientific, CF L-04-0406).  90% of the resuspension containing the plasmid was 
added, before incubation overnight at 37ºC.  Following incubation, one colony 
was selected from the plate and added to LB-broth containing 100mg/ml 
ampicillin, before incubation overnight at 37ºC with shaking at 250rpm on an 
orbital shaker.  F ive 2L conical flasks containing 1L auto-induction media without 
trace metals (Thermo CK6803) were warmed in an incubator at 37ºC overnight.  
The following day, 15ml of incubated culture was added to each conical flask, 
which were then further incubated with at 37ºC with agitation at 250rpm for 24hrs.  
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Cell pellets were collected by centrifugation at 8,000 rpm, in a S orval R C6+ 
centrifuge using a F10x 6x500Y  rotor, for 20 minutes, and the supernatant 
discarded.  If purification was not to be performed immediately, pellets were 
frozen and stored at -20ºC. 
 
2.2.1.2 Protein Purification 
2.2.1.2.1 C rude Purification 
Cell pellets were thawed at room temperature for 30mins if required, before 
resuspension in 50ml E . coli cell lysis buffer (table 2.1.1) and incubation at room 
temperature for 30mins.  The cell lysate was put on ice before further lysis via 
sonication at 45% for 1 minute, in pulses of 10s on, followed by 10s off.  Insoluble 
material was removed by centrifugation at 10,000 rpm, in an E ppendorf 5804 R  
centrifuge, for 40mins before acidification to pH 4.5 by the addition of HCl (F isher 
CA508).  The lysate was centrifuged at 10,000 rpm for a further 30mins, in the 
same centrifuge, to remove any remaining insoluble material, before 
neutralisation to pH 8.0 with addition NaOH (F isher C1310-73-2). 
 
2.2.1.2.2 Anion E xchange Chromatography 
Anion exchange chromatography was performed on an AKTA Prime (GE  
Healthcare, UK) liquid chromatography machine using a 50ml column loaded with 
Q-sepharose resin (S igma-Aldrich, CGE 17-0510-01), equilibrated with three 
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column volumes of buffer A (table 2.1.1) at 4 ºC.  The protein was loaded onto 
the column at 3ml/min in buffer A and eluted using buffer B (table 2.1.1) via a 
gradient protocol of 20ml 0-20%, 100ml 20-80% and 20ml 80-100%.  F ractions 
containing the highest concentration of protein were selected from the 
chromatogram, as shown in appendix 2A, and the presence of protein confirmed 
by S DS -PAGE  electrophoresis.  F ractions containing the highest concentration 
of protein were selected for buffer exchange using S nakeS kin dialysis tubing 
(Thermo S cientific, C68035) floated in ultrapure distilled water (ddH2O) with 
stirring at 4ºC.  Water was replaced 6 times over 24hrs, before the fractions were 
removed, snap-frozen in liquid nitrogen, then freeze-dried to remove the water 
and lyophilise the protein. 
 
2.2.1.2.3 S DS -PAGE  
Plates were set up as per manufacturer’s instructions (BioRad) with a 1.5mm gap 
between the two, and gels cast as per table 2.1 on the following page, with 15 
well combs inserted whilst setting to create sample wells.  
S amples were mixed 1:1 with tris-glycine loading buffer before loading into wells, 
alongside a pre-stained, broad range protein ladder (NE B, CP7706S ).  
E lectrophoresis was performed, utilising the previously described gel running 
buffer (Table 2.1.1) at 150V for 1hr before staining with Instant Blue (E xpedeon, 
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CIS B1L) for 20 minutes.  Gels were imaged on a LiCor scanner utilising the Image 
S tudio software with the 700 channel selected. 
  
R eagent R esolving Gel 
Volume (mL) 
(10%) 
S tacking Gel 
Volume (mL) 
3% 
MilliQ ddH2O 9     3.6 
2M TrisHCl pH 8.8 4.5     - 
0.5M TrisHCl pH 6.8 -      0.7 
10% (w/w) S DS  0.225     0.050 
40% 29:1 
acrylamide:bisacrylamide 
9      0.6 
10% (w/w) APS  (S igma CA3678) 0.1125     0.025 
TE ME D (S igma C9281) 0.03     0.01 
 
Table 2.2:  S DS -PAGE  Gel Components. 
Components of an S DS -PAGE  gel.  Reagents were added in the order shown 
above. 
 
2.2.1.2.4 S ize E xclusion Chromatography 
Previously freeze-dried protein was resuspended in size S E  buffer (table 2.1) 
before loading into a 5ml injection loop using a sterile syringe filter.  S ize 
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exclusion was performed using a HiLoad 26/600 S uperdex 200 pg column (GE  
Healthcare, UK), on an AKTA prime machine, equilibrated with 900mls S E  buffer.  
Protein was eluted at a flow rate of 1ml/minute at a temperature of 4ºC .  Fractions 
containing the highest protein concentrations were identified from the 
chromatogram, as shown in appendix 2B, and subjected to S DS -PAGE  
electrophoresis as described in section 2.2.1.2.1.  F ractions containing the 
highest and purest protein, based on S DS -PAGE  results, were selected for 
dialysis in S nakeS kin dialysis tubing (S igma C86035), and buffer exchange was 
performed utilising the same method as following anion exchange.  F ractions 
were snap frozen in liquid nitrogen, freeze dried and stored at -20ºC until required.   
 
2.2.1.2.5 Determination of Protein C oncentration  
A small amount of protein was dissolved in the appropriate buffer, depending on 
the experiment performed, and its absorbance acquired at 280nm, on either a 
UV/Vis spectrophotometer (J enway) or a NanoDrop spectrophotometer.  
Absorbance readings and the extinction coefficient of αsyn, 5960 M-1cm-1, were 
used to determine the molar concentration.  
 
2.2.2 Dot Blotting 
WT αsyn and potentially phosphorylated αsyn was spotted onto nitrocellulose 
membrane with a 0.45mm pore size (S igma CGE 10600002) before blocking with 
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blocking buffer 1 (table 2.1) for 1hr with rocking at room temperature.  Membranes 
were washed with TBS -T (table 2.1) three times for 3mins. The primary polyclonal 
rabbit antibody, anti phospho-synuclein pS er129 (S igma CS AB4503996), or 
monoclonal mouse anti-αsyn, syn211 (S igma CS 5566) diluted at 1:2000 in TBS -
T with 5% milk, was added to the membranes for 1hr at room temperature with 
rocking.  The membranes were washed with 1xTBS -T an additional three times, 
before addition of the secondary antibody, IR  Dye 680R D goat anti-rabbit 
immunoglobulin (Ig) (Thermo C31105), at 1:15,000 in TBS -T with 5% milk for 1hr 
at room temperature with rocking.  The membranes were washed a final three 
times with 1xTBS -T before imaging using a LiCor scanner utilising the Image 
S tudio software with the 700 nm channel. 
 
2.2.3 E S I-IMS -MS  
All mass spectra and ion mobility information were acquired using electrospray 
ionisation travelling wave ion mobility mass spectrometry, performed on a 
S ynapt-G2 tri-wave E S I-IMS -MS  (Waters, Manchester, UK) in positive ion mode 
utilising helium (He) and nitrogen (N2) gases.  Mass spectrometry settings for 
cone voltage, source temperature, trap and transfer collision energies, trap bias, 
IMS  wave settings, backing pressures and helium cell pressures were optimised 
for each set of mass spectrometry experiments.  These will be specified within 
the appropriate chapters.  The S ynapt was attached to an Advion Triversa 
56 
 
NanoMate autosampler, operated with gas pressure at 0.7 psi and tip voltage of 
1.7kV. 
 
2.2.3.1 Calculation of Calibrant Protein CCS   
The S ynapt was calibrated internally to within a 95% confidence window, using 
sodium iodide (NaI) (Waters C700001593).   Proteins with known masses and 
CCS , ubiquitin from bovine erythrocytes, cytochrome c from equine heart, and 
myoglobin from equine heart, were dissolved in 50% acetonitrile, 10% 
trifluoroacetic acid and 40% ddH2O (v/v/v) to a final protein concentration of 10 
µM and data acquired under the appropriate mass spectrometry settings, 
dependent on the experiment being performed.  Mass spectra were examined 
using the MassLynx 4.1 software (Waters, Manchester), and ATDs of the different 
CS Is of the calibrant proteins were extracted. 
The peak arrival time, or drift time, (tD) was determined from the raw data, and 
converted to corrected drift times (tD') using equation 4 below: 
t′
ୈ
=t
ୈ
−(� ඥ�/�)/1000 
E quation 4: Calculation of Corrected Drift Times at a S ingle Wave Height.  
Calculation of corrected drift times, where t’D is corrected drift time, tD is  
measured drift time.  The C constant is derived from within the mass spectrometry  
software, as the ‘enhanced duty cycle delay coefficient’, and usually ranges from  
1.4-1.6 dependent on the machine used. 
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R educed CCS s (Ω’) of each CS I for the calibrant proteins were also determined 
using equation 5 below: 
Ω′=Ω (1.602
ଵି
.�)�⁄⁄  
E quation 5: Calculation of calibrant reduced CCS , where z is the charge state of 
the ion and r is the reduced mass. 
 
Corrected tD' were then plotted against Ω’ and a line of best fit determined, as 
shown in figure 2.1, to determine the A' and B values required to determine the 
Ω of the protein conformation as per equation 3 in chapter 1.  
  
   
F igure 2.1: E xample Calibration Data S et. 
E xample calibration data set acquired utilising tD' and Ω' for cytochrome c, 
myoglobin and ubiquitin. R 2 value shows the regression analysis. 
tD' 
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2.2.3.2 Gaussian F itting for Determination of Conformational E quilibrium 
Gaussian models of probability were utilised to determine the relative proportions 
of the different conformations present within each CS I of the protein, using ATD 
data obtained from the chromatograms.  F itting was achieved using the least 
square regression method, to fit the minimum number of Gaussian distributions 
under the chromatogram, via multiples of equation 6: 
 
                                          
E quation 6: Gaussian equation utilised to determine conformational distributions 
at each CS I, where A is the total area under the curve, xo is the centre of the 
peak, and w is the width of the peak at half height. 
 
2.2.3.3 E S I-IMS -MS  for the S tudy of Monomeric Proteins Interaction with Metals 
Protein was resuspended in 50mM ammonium acetate (AA), and its 
concentration determined via NanoDrop, before dilution to 10µM final 
concentration.  Where appropriate, metal ions (CuC l2, F eC l2, ZnC l2, MgC l2, 
MgC l2, FeS , ZnS , MgS ) at 10, 20, 50 and 100µM diluted in the appropriate buffer 
were added, and 5µl of the sample was immediately injected into the mass 
spectrometer using the NanoMate autosampler, and mass spectra acquired in 
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the range 800-3000 m/z.  Instrument parameters utilised for each experiment are 
outlined in chapter 3 and 4. 
 
2.2.3.4  E S I-IMS -MS  for the S tudy of Monomeric αS yn and Oligomeric 
Complexes Interaction with Curcumins 
70µM WT αsyn was diluted in 50mM AA and, where appropriate, natural curcumin 
or the derivatives were added, to a final concentration of 10µM or 70µM, in a final 
DMS O concentration of 1% or ethanol concentration of 1% or 10% v/v.  The 
appropriate concentration of DMS O and ethanol was also added to curcumin free 
samples as a control.  5µl of each sample was then loaded onto the mass 
spectrometer using a NanoMate autosampler, with spectra acquired in the range 
500-3000 or 500-5000 m/z.  When appropriate, samples were then incubated at 
room temperature or 37° C , with or without agitation at 300rpm, for up to 48 hours 
for further analysis. 
Instrument parameters are specified in chapter 4. 
 
2.2.4  Thioflavin-T Assays for Aggregation S tudies 
2.2.4.1  Thioflavin-T to Assess Metal Induced αS yn Aggregation 
WT, S 87D and S 129D αsyn were added to 50mM AA, and the concentration 
determined as described previously.  100mM stocks of CuC l2, FeC l2, ZnS , MgCl2 
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and MnCl2 were prepared in 50mM AA, and diluted to a final concentration of 
1mM in the same buffer.  20mM ThT was prepared in 50mM AA, sterile filtered, 
and diluted to 100μM in the same buffer.  S amples were prepared in a black 96 
well plate (Thermo C 437111) to the following final concentrations; protein 70μM, 
thioflavin-T 10μM and metal 70μM, with the addition of glass beads to aid 
agitation.  Plates were analysed using a Clariostar plate reader (BMG Labtech) 
with readings taken hourly for 6 days, with excitation at wavelength 440nm and 
emission of 480nm. 
 
2.2.4.2.  Thioflavin-T to Assess the E ffect of Curcumins on α-S ynuclein 
Aggregation 
WT αsyn was dissolved in 50mM ammonium acetate and the concentration 
determined as described.  100mM stocks of natural Curcumin and one of 13 of 
its derivatives were prepared in 100% DMS O, and diluted to a final concentration 
of 7mM and 1% DMS O in the same buffer.  20mM ThT was dissolved 50mM 
ammonium acetate, sterile filtered and diluted to 100μM in the same buffer.  
S amples were prepared to the following final concentrations; protein 70μM, ThT 
10μM and curcumins 70μM.  S amples were shaken continuously at 300rpm at 
37ºC for 6 days, then transferred to a black 96 well plate with the addition of 10µM 
ThT and analysed using a C lariostar plate reader with excitation at wavelength 
440 and emission of 480nm. 
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2.2.4.3 Thioflavin-T to Assess the E ffect of C urcumins on Lysozyme Aggregation 
Lysozyme was prepared at a final concentration of 70µM in ddH2O at pH 2.5.  
70µM curcumin and 1% DMS O were added to the required samples, along with 
control samples containing 1% DMS O only.  S amples were shaken at 65ºC for 6 
days before being transferred to a black 96 well plate along with 10µM ThT diluted 
in ddH2O at pH 2.5 and analysed using a C lariostar plate reader with excitation 
at wavelength 440nm and emission of 480nm.5 
 
2.2.5  Cell Culture 
2.2.5.1  Maintenance of cell lines 
S HS Y 5Y  neuroblastoma cells of passage numbers 12-30 were maintained in T-
75 cell culture flasks (S igma CCLS 3290) incubated at 37° C with 5% CO2, grown 
in DME M media containing phenol red and glutamax, along with 10% Foetal Calf 
S erum (FCS ) and 1% Pen/S trep (Thermo C15070063), a solution of containing 
5000 units/ml of penicillin and 5000 µg/ml streptomycin.  When confluence of 
around 80% was reached, cells were washed with 1% phosphate buffered saline 
(PBS ) (Thermo C10010023) and unadhered using trypsin (Thermo C25300054).  
Following centrifugation at 10,000rpm in a S orval RT7 centrifuge, and 
resuspension in 10mls media, cells were either passaged at a 1:3 ratio, when 
they reached a confluence of 80%, or counted using Trypan Blue dye (Thermo 
C15250061) and a Countess cell counter ready for experimental use. 
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2.2.5.2  Immunocytochemistry 
Cells were plated in chamber slides at a confluence of 30,000 cells/well and left 
overnight to adhere before treatment with complete DME M media.  CuCl2 was 
added at concentrations of 100μM, 200μM, 300μM, 400μM and 500μM.  Cells 
were incubated for 48 hours before being rinsed with PBS  then fixed in ice-cold 
100% methanol at -20° C for 10mins. F ixed cells were then treated with S udan 
Black (S igma C380B) for 10 minutes before being washed in PBS  plus 0.05% 
tween20 three times for 3mins with agitation at 200rpm.  Cells were blocked in 
TBS  plus 5% powdered milk, and rocked for 1 hour at room temperature, before 
being washed with PBS  as previously described.  Primary antibodies, monoclonal 
mouse anti-αsyn (S igma CS 5566) or polyclonal rabbit anti phospho-synuclein 
pS er129 at 1:2000 were added in TBS -T plus 5% powdered milk and rocked for 
1hr at room temperature.  S lides were washed further with 1xPBS  before addition 
of the appropriate fluorescent secondary antibody Texas R ed, either anti-mouse 
(Thermo CT862) or anti-rabbit (Thermo CT6391) at 1:1000 in TBS -T plus 5% 
powdered milk and rocked at room temperature for 1 hour.  S lides were further 
washed with PBS  before mounting with Vectashield DAPI mounting medium 
(F isher CNC9029229) and cover slipping.  S lides were then imaged using a 
fluorescent microscope, with 40x and 100x objectives, utilising Image Capture 
Pro software to acquire images. 
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2.2.5.3 Antibody Validation 
To ensure the phos129 antibody was specific to phosphorylated forms of the 
protein, a simple dot blot control was performed, as described in section 2.2.2.  
As shown in figure 2.2 below, when the phos129 antibody was exposed to 
recombinant WT αsyn (A).  No binding was observed, suggesting this antibody is 
unable to bind to the unmodified form of the protein.  
 
 
F igure 2.2: Phos129 Antibody Validation Dot Blot. 
Dot blots of WT αsyn probed with primary antibodies A) phos129 for αsyn 
phosphorylated at serine-129, and B) S yn211 specific to unmodified WT αsyn, 
amino acids 121-125. 
 
To ensure the fluorescent secondary antibodies described previously were 
specific to the syn211 and phos129 antibodies, control wells were included in 
immunocytochemistry experiments; one well negative for primary antibody and 
A 
B 
A  
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positive for secondary antibody, and another well positive for primary antibody 
and negative for secondary antibody.  E xample images can be seen in figure 2.3. 
 
 
F igure 2.3:  S econdary Antibody for Immunocytochemistry Validation.   
Immunocytochemistry was performed on S HS Y 5Y  cells as described in section 
2.2.5.2. A) Untreated cells +syn211 and -Texas red, B) Untreated cells -syn211 
and +Texas red, C ) Untreated cells +phos129 and -Texas red, D) Untreated cells 
–phos129 and +Texas red. 
 
 
A B 
C D 
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2.2.5.4 Trypan Blue Viability Assay 
Cells were transferred into T-25 cell culture flasks (S igma CC LS 3815-24E A) at a 
confluence of 1,000,000 cells/flask and incubated overnight before treatment with 
complete DME M media with the addition of CuC l2 at concentrations of 100μM, 
200μM, 300μM, 400μM and 500µM, and an untreated flask containing complete 
DME M only.  After 48hrs cells were unadhered with trypsin, centrifuged at 
1000rpm for 5mins in a S orval RT7 centrifuge, to form a pellet before 
resuspension in complete DME M.  10µl of cells were added to an equal amount 
of Trypan Blue, and total cell viability was determined using a Countess cell 
counter. 
 
2.2.5.5  Analysis of C ell Images for Aggregates and Apoptosis 
Four Images were taken of each experimental condition, utilising the Image 
Capture Pro software, to ensure at least 200 cells were present within each the 
data set.  Data sets were then blinded by a second party through a random file 
naming system.  200 cells per data set were then counted for cells containing 
aggregates inclusions, or one of the signs of apoptosis, highlighted in chapter 5.    
Three repeat experiments were compared, and positive cell numbers were 
averaged to synthesise graphs, using the Prizm software (GraphPad, US A).   
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2.2.5.6  Analysis of C ell Images for F luorescence Intensity 
F luorescence intensity of cells stained for αsyn was analysed using the ImageJ  
software.  Ten cells per condition were selected using the software, along with a 
small section of the background image for each cell, extracting data for the area, 
integrated density, and mean grey value for each cell.  The corrected total cell 
fluorescence (CTCF ) of each selected cell was then calculated by multiplying the 
area of the cell by the mean fluorescence of the background readings (McCloy et 
al., 2014; Burgess et al., 2010).  Values from the 10 cells were then averaged, 
and three repeat experiments were compared to perform statistical analysis. 
 
2.2.6  S tatistical Analysis 
All statistical analysis for ThT assays and cell experiments was performed 
utilising the non-parametric, Kruskall-Wallis ANOVA test, on the S tats Direct 
software (S tats Direct Ltd, UK).  This was then paired with the C onover-Inman 
test, to compare significance between all conditions.  All graphs were created 
using the Prism software. 
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Chapter 3 – The E ffect of Phosphorylation Mimics and Metal 
Ions on α-S ynuclein Conformation and Aggregation 
3.1  Introduction 
It has been well documented that αsyn found in the LB of PD patients has 
undergone a variety of PTMs including phosphorylation, ubiquitination, nitration, 
acetylation and truncations (Barrett and Greenamyre, 2015; Duce et al., 2017; 
Oueslati, 2016; Fujiwara et al., 2002; Popova et al., 2015; S chmid et al., 2013).  
The majority of PTM sites are found within the highly disordered C -terminal region 
of the protein, including the phosphorylation sites Y 125, S 129, Y 133 and Y 136 
(Oueslati, 2016).  LBs are also known to be highly metal rich, and it has been well 
established that metal ions such as copper can accelerate the aggregation of 
αsyn in vitro (Uversky et al., 2001).  The metal binding domains are primarily 
located within the C-terminal region of the protein, in close proximity to and 
encompassing the phosphorylation sites as shown in figure 1.2 in chapter 1. 
The relationship between phosphorylation and metal-induced aggregation of 
αsyn and whether this has clinical relevance, have still to be fully determined, and 
investigations thus far have yielded conflicting results.  S tudies utilising C -
terminal fragments of αsyn, of residues 119-132 indicated there to be no effect of 
S 129 phosphorylation on the proteins interaction with metal ions (Liu and Franz, 
2007).  However, a later study utilising the fragment 107-140, encompassing the 
entire C -terminal region, suggested S 129 phosphorylation resulted in increased 
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binding affinities for the divalent metals Cu2+, Pb2+ and Fe2+ (Lu et al., 2011).  
There have however been no studies utilising the full protein, and therefore it is 
still to be fully determined what the relationship between phosphorylation and 
metal ion binding is in terms of PD pathology. 
  
3.1.1  Phosphorylation of αsyn 
αS yn has five known phosphorylation sites; two at serine residues 87 and 129, 
and another three located at tyrosines 125, 133 and 136 (Oueslati, 2016; 
Paleologou et al., 2010).  These phosphorylation sites appear to be conserved 
throughout all synuclein species in humans (Paleologou et al., 2010).  
Phosphorylation at tyrosine residues appears to be predominantly associated 
with membrane binding, with phosphorylation at Y 125 specifically playing an 
important role (S chreurs et al., 2014).  Data currently suggests that 
phosphorylation at S 87, S 129 and Y 39 all prevent the binding of αsyn with 
biological membranes.  It has also been suggested that phosphorylation at Y 125 
has a neuroprotective role and prevents the formation of neurotoxic oligomeric 
species (Chen et al., 2009).   
The role of phosphorylation at the serine residues is currently less clear, though 
phosphorylation at S 129 has been suggested to have a role in autophagy and 
cellular clearance of αsyn via proteolytic degradation (Chau et al., 2009; Machiya 
et al., 2010; Tenreiro et al., 2014).  Under normal physiological conditions, 
69 
 
approximately 4% of αsyn is phosphorylated at one or more of these sites 
(Tenreiro et al., 2014).  In LBs however, 90% of αsyn has been found to be 
phosphorylated at serine 129, suggesting a pathological role for this modification 
(Anderson et al., 2006).  The questions of how αsyn phosphorylation modulates 
αsyn normal function, and what role this phosphorylation has on the aggregation 
of the protein, whether it be suppressive or enhancing of aggregation, are still yet 
to be fully determined. 
 
3.1.1.1  Pathological R ole of αsyn Phosphorylation 
A variety of animal model studies have been conducted to investigate the role of 
S 129 phosphorylation on the pathogenesis of PD, however these studies have 
produced conflicting results.  S tudies conducted in Drosophila melanogaster and 
transgenic murine models both suggested a pathogenic role for the modification 
(Chen and Feany, 2005; Freichel et al., 2007), whereas a study utilising 
Caenorhabditis elegans nematode worms suggested a protective role for S 129 
phosphorylation, via a reduction in membrane binding (Kuwahara et al., 2012).  
In Drosophila, preventing phosphorylation via amino acid substitution from serine 
to alanine both increased aggregate formation rates and reduced dopaminergic 
loss, whilst mimicking phosphorylation with amino acid substitution to aspartic 
acid enhanced the toxicity of αsyn.  This suggests that increased aggregate load 
may be protective, whilst also suggesting a pathological role for phosphorylation 
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(Chen and Feany, 2005).  S imilarly in a transgenic mouse model where A30P 
αsyn was overexpressed, all pathologically relevant αsyn samples extracted from 
the mouse models were found to be phosphorylated at S 129, suggesting a 
pathologic role for the modification (F reichel et al., 2007).   
A more recent study utilizing budding yeast S accharomyces cerevisiae, found 
that blocking phosphorylation using an amino acid substitution of serine to 
alanine, resulted in a slower clearance of αsyn aggregates from an S H-S Y 5Y  
cellular model in relation to WT αsyn, which is in agreement with the findings from 
the Drosophila study and suggests it may have a role in autophagy (Tenreiro et 
al., 2014).  The same study concluded that phosphorylation reduced the toxic 
effects within the S H-S Y 5Y  cell model (Tenreiro et al., 2014).  Further studies in 
a rat models concluded there was no difference between phosphorylated and 
non-phosphorylated forms of the protein, and suggested modification at this site 
to be neither protective or pathogenic (da S ilveira et al., 2009; McFarland et al., 
2009).   
Currently it is unclear what role phosphorylation of αsyn has on the pathogenesis 
of PD.  It is difficult to come to a definitive conclusion from the highly contradictory, 
currently available data, but it is clear that phosphorylation at serine 129 plays an 
important role in the aggregation of αsyn.   
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3.1.1.2  Phosphomimetics of αsyn 
Phosphorylation at serine residues can be mimicked by substituting the native 
amino acid for aspartic acid, whereas glutamic acid can substituted to mimic 
phosphorylation at a tyrosine or threonine residue (Dephoure et al., 2013).   
Mimicking phosphorylation of a serine residue in this manner functions due to the 
carboxyl group on aspartic acid, which provides a similar negative charge (-1) to 
that of phosphoserine (-1.5), thus the conformational dynamics and any ligand 
interactions with the protein would be expected to behave in a similar manner.  
This process has been confirmed using the tau protein, where S DS -PAGE  and 
cellular studies confirmed that substituting serine for aspartic acid at residue 327 
resulted in the same conformational changes and microtubule assembly 
properties observed with phosphorylated tau (Leger et al., 1997).    
Phosphomimic mutants are now extensively used in research for a variety of 
applications (Dissmeyer and S chnittger, 2011;Fraser et al., 2014), including 
conformational studies(Hara et al., 2006), mass spectrometry (J ovcevski et al., 
2015) and studies into the effects of phosphorylation on αsyn aggregation (Chen 
and Feany, 2005; Chau et al., 2009; Oueslati et al., 2012; Paleologou et al., 
2008). 
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3.1.2  The R ole of Metal Ions in Parkinson’s Disease 
Increasing evidence is emerging for the role of dysfunctional metal homeostasis 
in the development and progression of a number of neurodegenerative diseases 
(Chen et al., 2016).  Concentrations of several transition metals, including copper 
and iron, are known to be increased in aging brains (Morita et al., 2001), and the 
levels of these metals, along with zinc, are also known to be elevated in the brains 
of patients with PD and AD, and are found in increased concentrations within the 
LBs of PD patients (Dexter et al., 1989;R iederer et al., 1989; Hirsch et al., 
1991;J enner and Olanow, 1996;Lovell et al., 1998).   
 
3.1.2.1  Homeostasis and the Physiological R ole of Metal Ions 
Metal ions play vital roles in a number of physiological processes including, but 
not limited to, cell structure maintenance, gene expression regulation, 
neurotransmission and antioxidant response (Chen et al., 2016).  
Oligodendrocyte development and neurotransmitter production are also 
processes which have also been shown to be dependent on metal ions (Todorich 
et al., 2009; F itzpatrick, 1989), therefore they are extremely important for a variety 
of normal processes occurring within the human brain. 
Transition metals, which include copper, iron, zinc, magnesium and manganese, 
are essential co-factors for almost half of all proteins (Waldron et al., 2009).  For 
example, tyrosine hydroxylase, which catalyses the conversion of tyrosine to 
73 
 
dopamine, requires ferrous iron to complete its function (F itzpatrick, 1989; Duce 
et al., 2017).  Correct brain development in infancy is also known to require 
optimum iron levels (Lozoff and Georgieff, 2006), and physiological iron is also 
important for the regulation of cellular development, mitochondrial respiration, 
and the production of myelin (Duce et al., 2017).  Iron response elements are 
also a known factor in post-transcriptional control of gene expression, and these 
are commonly found in proteins involved in iron homeostasis (Wang and 
Pantopoulos, 2011).  Iron is the most abundant trace element in the human body 
(Carboni and Lingor, 2015), and in the form of Fe(II) has been demonstrated to 
caused oxidative damage within cells via promoting the formation of reactive 
oxygen species (ROS ), leading to oxidative stress.  This includes the formation 
of hydroxyl free radicals via a Fenton reaction with hydrogen peroxide (H2O2) 
(S antner and Uversky, 2010).       
It has also previously been proposed that αsyn may possess some ferrireductase 
activity and can reduce Fe3+ to Fe2+ utilising copper bound to the protein to cycle 
between oxidized and reduced forms of the metal, and this may explain why the 
protein has the ability to bind these metals (Davies et al., 2011).  Copper is also 
a known cofactor for several cellular proteins, such as cytochrome c oxidase, 
which is involved in the mitochondrial production of ATP, and C u/Zn-superoxide 
dismutase (S OD1), which plays a role in R OS  detoxification.   
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3.1.2.2  Metals and Parkinson’s E pidemiology and Pathology 
Initial investigations into the role of metals in PD pathogenesis began over ninety 
years ago.  Despite this, there has been no progress in utilising metals as a 
therapeutic target thus far.  E levated levels of iron in the brains of Parkinson’s 
patients was first reported by Lhermitte and colleagues as far back as 1924, when 
deposits of the metal were observed to be co-localised to Lewy bodies using 
Pearl’s staining (Lhermitte et al., 1924).  The link between heavy metals and PD 
was further solidified in 1989, when two separate studies identified increased 
levels of iron and zinc in the brains of PD patients, upon post mortem examination 
(Dexter et al., 1989; R iederer et al., 1989).  S ome studies have also documented 
an increase in the Fe3+/Fe2+ ratios in the brains of PD patients (S ofic et al., 1988; 
R iederer et al., 1989).  In contrast, copper levels in the S NPC were found to be 
reduced in comparison to control brains (Dexter et al., 1989), however high levels 
of copper had also been identified in the cerebrospinal fluid of PD patients around 
that time (Pall et al., 1987).   
A number of epidemiological studies also noted that individuals with chronic 
industrial exposure to heavy metals, including copper, iron, manganese, zinc and 
aluminium amongst others, had an increased incidence rate of PD when 
compared with the general population (Gorell et al., 1999; Gorell et al., 2004; 
Coon et al., 2006).  This led to metal ions coming to the forefront of PD research, 
and metal homeostasis being identified as a potential therapeutic target in this 
area. 
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S ince these initial observations, increasing evidence has been gathered relating 
altered metal homeostasis to the progression of neurodegenerative diseases 
(Chen et al., 2016; Montes et al., 2014; Barnham et al., 2004; Zecca et al., 2004). 
In addition to concentrations of metals, such as iron and copper, being increased 
in normal aging brains (Morita et al., 1994), they are also increased in the brains 
of patients with neurodegenerative diseases.  High levels of copper, zinc, and 
iron are found in and around amyloid plaques in AD brains (Lovell et al.,1998).  
Increased levels of Fe(III) and reduced levels of the Fe(III)-binding protein ferritin 
were observed in the brains of PD patients (Dexter et al.,1991).  Increased iron 
deposits in the substantia nigra are associated with αsyn positive Lewy bodies in 
PD and neurodegeneration with brain iron accumulation (Hirsch et al., 1991; 
Tofaris et al., 2007).   
S imilar alterations in metal homeostasis were observed with toxin induced animal 
models of PD. An accumulation of iron was observed in the substantia nigra of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, which is likely 
a result of the observed up-regulation of transferrin receptor expression and iron 
uptake (Kalivendi et al., 2004; Mandel et al.,2004).  Although these observations 
may be consequences of the disease progression, experimental studies using 
FeC l3 injected directly into the substantia nigra of rats resulted in a 95% reduction 
in striatal dopamine and altered behaviour, supporting the idea that iron initiates 
dopaminergic neuron degeneration in PD (Y oudim et al., 1991).  
76 
 
3.1.2.3  Metals and α-S ynuclein  
A large body of research is available to date regarding the interaction of αsyn with 
polyvalent metal ions such as copper, iron, manganese, lead and zinc, and has 
been reviewed by S antner and Uversky (2010, and more recently by Carboni and 
Lingor, (2015).  It was concluded in these reviews that although it is known that 
some metals trigger the aggregation of αsyn and can exert cellular toxicity, not all 
mechanisms of metal-induced toxicity have been determined, and the interaction 
of αsyn with metal ions warrants further investigation in order to enable 
development of more specific and innovative drugs against PD. 
2D-NMR  spectroscopy is one method which has been utilized to investigate the 
binding of divalent metal ions to αsyn.  S tudies suggest these metal ions 
predominantly bind to the C -terminus of αsyn, at the DPDNE A motif (aa119-124), 
as shown in figure 1.2 in chapter 1, containing Asp-121, Asn-122 and Glu-123, 
which are believed to be the anchoring residues for Fe(II), Cu(II), Mn(II), Co(II) 
and Ni(II) (Binolfi et al., 2006).    
Copper is known to enhance the aggregation and fibrillation of αsyn in vitro, and 
an increased population of the more compact, aggregation prone states has been 
observed in the presence of this metal by NMR , circular dichroism studies, E S I-
IMS -MS  and calorimetric titrations (Natalello et al., 2011; Binolfi et al., 2008; 
Binolfi et al., 2010; Mason et al., 2016).  Binding of metal ions to the C-terminus 
of the protein has been suggested to alter the charge of the protein, leading to 
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structural collapse (Bernstein et al., 2004).  Quantum and molecular dynamics 
simulations also indicated the binding of copper to H50 causes the development 
of a β-hairpin within the protein, at aa36-56, thus accelerating its aggregation (Y u 
et al., 2015; R ose et al., 2011).  One example of this copper-induced 
conformational change can be seen in figure 3.1.      
 
 
 
F igure 3.1: E xample of a Copper-Induced Conformational Change to αS yn 
E xample of a Copper(II)-Induced Conformational Change to αS yn, as determined 
by molecular dynamics simulation. Top: Unbound αsyn highlighting the H50 
residue.  Bottom: Binding of Cu (II) to H50 results in a β-hairpin fold at this residue 
(Used with permission from R ose et al., 2011). 
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αS yn has been shown to have a high affinity for copper binding, and has been 
shown to bind the metal at three specific sites, though up to 16 potential binding 
sites have been proposed in the literature (Ahmad et al., 2012).  A high affinity 
binding site has been observed at the N-terminus, where the free nitrogen on the 
amino terminal anchors the metal ion.  A second, lower affinity site has been 
observed at histidine 50, anchored by the imidazole ring of the amino acid, and a 
third low affinity site at the C-terminus involving the previously mentioned Aspo-
121, Asn-122 and Glu-123 residues have also been identified (Binolfi et al., 2012; 
Mason et al., 2016; Binolfi et al., 2006).  The protein has been demonstrated to 
bind copper ions more readily than any other metal currently investigated (Binolfi 
et al., 2006).   
Iron has also been shown to increase the aggregation rate of αsyn in vitro,  
leading to faster accumulation of protein aggregates and amyloid fibrils (Binolfi et 
al., 2006; Uversky et al., 2001).  Divalent iron has also been demonstrated to bind 
to the C-terminus of αsyn via 2D-NMR studies, and this metal also appears to be 
utilizing Asp-121 as an anchoring residue (Binolfi et al., 2006; Peng et al., 2010). 
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3.2 Aims and Objectives 
In this chapter, E S I-IMS -MS  along with ThT assays will be utilised to investigate 
the binding of a variety of metal ions to recombinant WT αsyn, and two mutant 
forms of the protein, where amino acid substitution from serine to aspartic acid 
has been utilized to mimic phosphorylation at both serine residues individually 
within the protein.  The conformation of the protein upon metal binding was 
investigated to elucidate further data about the pathological relevance of both 
phosphorylation and metal binding in the progression of Parkinson’s disease and 
other synucleinopathies. 
The main aims of this chapter were to: 
 Determine the relationship between phosphorylation of αsyn at serine 
residues and the subsequent alterations to the aggregation and 
conformational dynamics of the protein in vitro 
 Determine the relationship between serine phosphorylation and the 
binding of metal ions, and the subsequent effects on the conformation and 
aggregation of αsyn in vitro 
 Determine the relative contributions of each conformational state at each 
CS I for the three protein variants, with and without exposure to metal ions  
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3.3  Results 
All mass spectrometry experiments in this chapter were performed under the 
following conditions, on a S ynapt G2 Q-TOF  mass spectrometer in positive ion 
mode; source temperature 60 C˚ , sampling cone 45V, trap collision energy 2.0V, 
transfer collision energy 4.0V, Trap DC  bias 45, IMS  wave velocity 800 m/s, IMS  
wave height 200V, backing pressure 2.93mbar and helium cell pressure 
1.42e3mbar.   
ATDs were analysed to determine both the CCS  of αsyn and its phosphomimic 
variants at each conformation, and the relative proportion of each of these 
conformations at each CS I, under the different conditions. 
 
3.3.1  αS yn has an Altered Charge S tate Distribution and Conformational 
E quilibrium Between E S I-IMS -MS  Acquisitions 
As previously discussed, αsyn is highly heterogeneous due to its intrinsic 
disorder, and therefore exists in a range of conformations at all times, dependent 
on its environment.  These conformations range from highly compact, 
aggregation prone globular-like conformations at CS Is +8 to +5, to flexible, more 
extended worm-like structures at CS Is +18 to +9, and these can be observed 
using E S I-IMS -MS , as shown in figure 3.2. 
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F igure 3.2  Typical E S I-MS  Mass S pectra of WT αS yn. 
Typical E S I-IMS -MS  mass spectra of WT αsyn, acquired in 50mM ammonium 
acetate in positive ion mode.  E xtended conformations are observed in the m/z 
range 800-1800m/z, and compact conformations are observed in the range 1800-
3000m/z. 
IDPs such as αsyn have a high degree of plasticity and are therefore highly prone 
to conformational changes depending on their solution conditions, mode of 
preparation, temperature and several other variables.  This can also lead to 
batch-to-batch and day-to-day variability in the data sets.  To demonstrate this, 
E S I-IMS -MS  data was collected during three different months, August 2016, 
February 2016 and November 2015, using two different batches of recombinant 
protein, one during November 2015 and F ebruary 2016, and another during 
August 2016.  ATDs were extracted from the individual spectra to investigate this 
batch-to-batch and experiment-to-experiment variability. 
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As demonstrated in figure 3.3, slight differences in drift times and conformational 
distributions are observed between experiments, when a different protein batch 
is compared or between different acquisition periods on the mass spectrometer.  
These differences result in a change in the relative proportion of populations 
between conformational states, at each CS I, of up to 8% when acquired at 
different times.  The +14 and +7 CS Is have been displayed here, as the +14 CS I 
is the most abundant extended ion in the majority of experiments, and the +7 CS I 
is the most abundant of the compact conformations. 
Proteins stored for extended periods, or proteins exposed to higher numbers of 
freeze-thaw cycles may also result in differences within the mass spectra.  For 
example, in figure 3.4, the same batch of recombinant αsyn was acquired in 
50mM ammonium acetate, under the same conditions, several months apart.  
There are clear differences between the two spectra, including the appearance 
of a third, intermediate conformational family group in the aged protein, whereas 
with the fresh protein only two families are seen.  Other data (not shown) using 
an older protein batch also resulted in a narrower CS D of + 16 to +5, with 
dominant ions of +11 and +7. To limit this variability, it was decided that protein 
preparations over 6-8 weeks old were no longer suitable for use in E S I-IMS -MS  
experiments.   This discrepancy is something that the ion mobility community 
must further address, and care must be taken when interpreting data.   
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F igure 3.3: Comparison of WT αS yn ATDs Acquired on Different Dates. 
ATDs of the +14 (A) and +7 (B) CS Is of 10mM αsyn acquired by E S I-IMS -MS  in 50mM ammonium acetate, at three different time 
points within a one-year time frame, using two batches of protein; one Nov 2015 and Feb 2016 and another in Aug 2016, with 
Gaussian distributions fitted to determine relative abundances of each population. 
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F igure 3.4: Comparison of WT αsyn spectra Acquired on Different Dates. 
Comparison of two WT αsyn spectra acquired in 50mM ammonium acetate several months apart, by E S I-IMS -MS  in positive ion 
mode. 
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R e-acquisition of samples within the same day however, show less variation.  
F igure 3.5 displays drift time chromatograms of two samples of 10μM αsyn in 
50mM ammonium acetate taken within 4 hours of each other. The percentage 
differences are much lower than the samples taken on different months, with 
variations of <5% in the conformational populations. 
Due to these discrepancies in the datasets acquired over different periods, it was 
decided to analyse and compare only data acquired at a single time period, using 
proteins produced within the same batch.  Because of the 8% difference observed 
between the three data sets presented in figure 3.3, for the remainder of this 
chapter, data with differences of 10% or less was not interpreted as a significant 
alteration to the conformational population. 
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F igure 3.5: Comparison of WT αS yn ATDs Acquired in a S hort Timeframe. 
WT αsyn in 50mM ammonium acetate acquired using E S I-IMS -MS  in positive ion mode. Two separate experiments conducted 
within a short time frame show little difference in arrival time distribution. 
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3.3.2  S 87D and S 129D Mutant αsyn occupy the same conformational families 
as WT αsyn  
ATDs were analysed to determine the CCS  of S 87D and S 129D αsyn, which were 
then plotted against the CS Is to determine the conformational arrangement of the 
protein. 
F igure 3.6 shows the ATD of all CS Is of WT αsyn, when acquired using E S I-IMS -
MS  in positive ion mode, in 50mM ammonium acetate buffer and with a protein 
concentration of 10µM.   Under these conditions, eight distinct conformations, 
ranging in size from 1303.7 Å2 to 3185.5 Å2, can be observed throughout the 
different CS Is.  Different conformational states are shared by multiple CS Is, and 
these can be observed to become more compact, as determined by their 
decreased CCS , at the lower CS Is.  The peak centre for each conformation has 
been plotted in figure 3.7 and the drift scope plot utilised to determine the 
conformational distribution can be observed in appendix 3.A.  For the remainder 
of the thesis, conformational states will be referred to by the lettering system 
outlined in table 3.1 on the following page. 
The relative population of more extended species can be observed to reduce in 
favour of an increase in the more compact conformations, as the charge on the 
ion decreases.  For example, within the higher charge states of +18 to +11, the 
most extended conformer, conformation A, can be seen to disappear as the more 
compact conformations B and C  increase in proportion, before they are too 
reduced, in favour of the more compact species in CS Is +11 to +5. 
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Conformational Family Chromatogram Colour CS I R ange 
A Purple +18 to +11 
B Green +18 to +10 
C  R ed +18 to +8 
D Light Blue +11 to +8 
E  Orange +11 to +7 
F  Dark Blue +10 to +5 
G Lilac +9 to +5 
H Fuscia +6 
 
Table 3.1:  Lettering S ystem for αS yn Conformational Families. 
Lettering system for conformational families observed during positive ion mode 
E S I-IMS -MS  of 10µM αsyn acquired in 50mM ammonium acetate. 
 
E S I-IMS -MS  demonstrated that both S 87D and S 129D αsyn mutants occupied 
the same eight conformational states as WT αsyn.  Drift scope mobilograms 
utilised to obtain conformational information of WT, S 87D and S 129D αsyn can 
be observed in appendices 3A to 3C  and the ATDs for both proteins can be 
viewed in appendices 3D and 3F , respectively.  Graphs plotting CS Is against 
CCS  for the two mutant proteins may be viewed in appendices 3E  and 3G. 
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F igure 3.6: WT αS yn ATDs. 
ATD of each CS I of WT αsyn acquired by E S I-IMS -MS  in 50mM ammonium 
acetate using E S I-IMS -MS  in positive ion mode.   
9
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F igure 3.7: WT αS yn Conformational Distribution. 
Conformational arrangement of WT αsyn acquired in 50mM ammonium acetate using E S I-IMS -MS  in positive ion mode.  WT αsyn 
occupies 8 distinct conformational families, represented by the different colours. 
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CCS s of the +7 and +14 CS Is are not altered significantly upon mimicking 
phosphorylation at these residues, as shown in table 3.2. Data suggests therefore 
that this modification does not provide enough of an altered charge to the protein 
to result in significant conformational changes.   
 
CS I A B C   
WT + 14 2817.6 2721.2 2605.0 
S 87D + 14 2807.8 2717.7 2607.8 
S 129D + 14 2794.2 2720.2 2639.5 
CS I E  F  G 
WT + 7 2014.8 1775.3 1530.1 
S 87D + 7 2021.4 1792.9 1550.7 
S 129D + 7 2008.2 1774.6 1530.9 
Table 3.2:  WT, S 87D and S 129D αS yn +14 and +7 CS S  Comparison. 
Comparison of the CCS , displayed in Å 2, of the +14 and +7 CS Is of the three 
protein variants, acquired in 50mM ammonium acetate by E S I-IMS -MS .   
 
The conformational distribution at each CS I was also examined, and overall no 
large scale alterations to the conformational equilibria were detected.  There were 
slight alterations at some CS Is however, which have been outlined in grey boxes 
on figures 3.8A-C .  Within the extended CS Is, slight alterations could be observed 
at CS Is +17, +14, +13 and +11.  At CS I +17, S 129D αsyn had an increased 
proportion of conformation B and decrease of conformation A in comparison with 
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both the WT and S 87D variants.  At the +13 CS I, S 87D was determined to have 
an increased proportion of conformation C  via a reduction in the more extended 
conformation B, compared to the WT and S 129D proteins, and this pattern was 
also observed with both S 87D and S 129D αsyn in comparison to the WT at CS I 
+14.  These alterations suggest the phosphomimic variants to have a slightly 
more compact structure overall, at these CS Is.  However, at the +11 CS I, both 
S 87D and S 129D αsyn demonstrated an increased proportion of the extended 
conformation B in comparison to the WT, suggesting a more extended structure. 
Within the more compact CS Is, observed alterations are again mixed.  At the +6 
CS I, Gaussian fitting determined S 129D αsyn to have a decreased proportion of 
conformation F , via a slight increase in the more compact conformations, F  and 
G, suggesting a more compact and amyloidogenic structure for this protein 
variant.  However, at the +5 CS I, S 87D demonstrated a decrease in compact 
conformation G via a slight increase in the more extended conformation F , 
suggesting a less amyloidogenic structure for this protein variant.  All changes 
observed again were small overall, and Gaussian fitting of this data therefore 
suggests that mimicking phosphorylation at either S 87 or S 129 has little effect on 
the overall conformational distribution or CCS  of αsyn, and this would suggest 
that these three protein variants should have the same aggregation propensity.  
S ome small alterations were observed however that may suggest some 
conformations of S 129D αsyn to be slightly more amyloidogenic than WT or S 87D 
αsyn. 
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F igure 3.8A: ATDS  and CCS  of WT, S 87D and S 129D αS yn. CS Is +18 to +14. 
A) ATDs and CCS s of 10µM WT, S 87D and S 129D αsyn in 50mM ammonium acetate from E S I-IMS -MS  experiments 
conducted in positive ion mode.  Percentages of each conformation at each CS I were calculated using Gaussian fitting. CS Is 
with conformational distributions displaying differences of over 10% between proteins are highlighted with grey boxes. 
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F igure 3.8B: ATDs and CCS s of WT, S 87D and S 129D αS yn.  CS Is +13 to +9. 
ATDs and CCS s of 10µM WT, S 87D and S 129D αsyn in 50mM ammonium acetate from E S I-IMS -MS  experiments conducted 
in positive ion mode.  Percentages of each conformation at each CS I were calculated using Gaussian fitting.  CS Is with 
conformational distributions displaying differences of over 10% between proteins are highlighted with grey boxes. 
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F igure 3.8C:  ATDs and CCS s of WT, S 87D and S 129D αS yn.  CS Is +8 to +5. 
ATDs and CCS s of 10µM WT, S 87D and S 129D αsyn in 50mM ammonium acetate from E S I-IMS -MS  experiments conducted 
in positive ion mode.  Percentages of each conformation at each CS I were calculated using Gaussian fitting.  CS Is with 
conformational distributions displaying differences of over 10% between proteins are highlighted in grey boxes. 
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3.3.3  Mimicking Phosphorylation at S erine 87 or S erine 129 Causes Little 
Alteration to the CS D of αSyn  
As demonstrated in figure 3.9, spectra C , WT αsyn has a CS D of +18 to +5.  Two 
distinct conformational family groups can be directly observed from the spectra 
as a whole; extended conformations ranging from CS I +18 to the +9, with the +14 
CS I being the most abundant, and more compact conformations at CS Is +8 to 
+5, with the +7 CS I in highest abundance. 
S 87D αsyn also demonstrated the same CS D as WT αsyn, when acquired under 
the same conditions, with two conformational families observed, ranging from 
CS Is +18 to +9 and +8 to +5, as shown in spectra B on figure 3.9.  This suggests 
both proteins to be occupying a similar range of conformations, with the same 
ionisation ability as the WT.  
S 129D αsyn, shown in spectra A, has a slightly narrower CS D of +17 to +5, which 
may be indicative of a more compact range of conformations overall, as the most 
highly charged of the CS Is on the WT and S 87D spectra, +18, cannot be 
observed above the signal to noise ratio.  The intensity of this CS I is however 
very low in the WT and S 87D spectra, at around just 5% relative intensity in 
comparison to the highest intensity peak, CS I +14.  Again, two conformational 
families can be clearly seen on the mass spectra; an extended family ranging 
from charge states +17 to + 9, and the more compact conformations at CS Is +8 
to +5.   
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A reduction in intensity of the extended +17 to +15 CS Is is also observed within 
the S 129D spectra in comparison to the S 87D and WT variants, as shown with 
grey lines on figure 3.9.  CS I +17 has a relative intensity of around 15% in the 
WT spectra, and around 20% in the S 87D spectra, whereas this is reduced to 
around 10% in the S 129D spectra.  The +16 CS I has a relative intensity of around 
45% in the WT spectra, 50% in the S 87D spectra, and just 35% in the S 129D 
spectra, and the +15 C S I has a relative intensity of around 75% in the WT spectra, 
80% in the S 87D spectra, and just 65% in the S 129D spectra.  This suggests that 
S 87D αsyn may have a higher proportion of more extended CS Is than WT αsyn, 
and S 129D may exist in an equilibrium containing proportionally less of these 
more extended conformations than both the WT and S 87D variants.  The 
dominant CS I for WT and S 87D αsyn is the +14 CS I, whereas for S 129D both 
the +14 and more compact +13 CS Is appear dominant in the spectra again 
indicating a shift to lower CS Is.  This loss of the +18 CS I and shift of the dominant 
ion to a slightly lower charge state would indicate a slight alteration in the overall 
conformation of the protein, towards more compact states, though this difference 
does not appear to be large overall. 
Dimeric species of αsyn can also be observed in all three spectra on figure 3.9.  
For WT and S 87D αsyn, dimers of CS Is +23 to +11 were observed, whereas 
more extended dimer CS Is of +25 to +11 were seen within the S 129D spectra, 
suggesting additional dimers and of greater conformational variety and increased 
physical size are being formed within the S 129D sample.   
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F igure 3.9: CS Ds of WT, S 87D and S 129D αS yn Acquired by ES I-IMS -MS . 
 CS Ds of A) S 129D, B) S 87D and C ) WT αsyn, acquired in 50mM ammonium acetate using E S I-IMS -MS  in positive ion mode 
(Monomers/ Dimers). 
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3.3.4 C opper (II) Binding to αS yn can be Observed by E S I-IMS -MS  
To investigate the conformational changes observed upon metal binding, αsyn 
was exposed to copper, iron, zinc, manganese and magnesium.    As shown in 
figure 3.10, only the binding of copper is observable by E S I-IMS -MS , despite the 
other metals being known to both affect the aggregation rate of the protein 
(Uversky et al., 2001) and having been demonstrated to bind to the protein by 
other techniques such as NMR  spectroscopy, tyrosine fluorescence quenching, 
and E S I-MS  (Golts et al., 2002; Binolfi et al., 2006; Peng et al., 2010; Liu and 
F ranz, 2007).  A range of buffers and concentrations were used in an effort to 
further investigate metal binding, including 5, 10, 25, 50 and 100mM ammonium 
acetate, 50mM ammonium bicarbonate, 10mM 4-methylmorpholine, 
water:MeOH and water:ACN:MeOH, however none of these facilitated the 
observation of metal binding.  Metals with different counter ions were also 
investigated, and a range of mass spectrometry machine parameters were 
attempted, including increased and decreased cone voltages, increased and 
decreased trap and transfer settings, and altered backing pressures. 
Multiple similar experiments were performed with the S 87D and S 129D αsyn, 
without metal binding being observed.  This suggests that E S I-IMS -MS  may be 
unsuitable for observations of metal binding.  It is also possible that the metal 
ions are complexing with a component of the buffer solution, such as the acetate 
in the ammonium acetate buffers making the ion unavailable for binding.   
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F igure 3.10:  E xpanded +14 and +7 CS Is of WT αS yn Demonstrating the Binding 
of Metal Ions. 
E xpanded mass spectra peaks of the +14 and +7 CS Is of 10µM WT αsyn in 
50mM ammonium acetate buffer, with or without addition of equimolar CuCl2, 
F eC l2, FeS , ZnS , MnCl2 and MgCl2, acquired by E S I-IMS -MS  in positive ion 
mode. 
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3.3.5 Addition of E quimolar Copper Increases the CS D of all αS yn Variants and 
Increases the Intensity of the E xtended Charge S tates 
As shown in figure 3.11A and 3.11B, upon immediate addition of equimolar C uCl2 
to 50mM ammonium acetate containing 10µM of either the proteins, another 
more extended CS I appears for all three variants, widening the CS D for WT and 
S 87D to +19 to +5, and S 129 to +18 to +5.  The CS D does not however further 
widen upon increasing the protein-copper ratio above 10µM. 
The dominant CS I within the extended conformational families of the WT protein 
also shifts towards the lower CS Is with increasing copper concentration, with a 
shift from +14 within the apo spectra, to +12 at a 100µM CuC L2 concentration, 
suggesting a shift in equilibria towards the more compact conformations.  
The dominant CS I of S 129D αsyn remains constant, with an almost equal share 
between the +14 and +13 CS Is under all conditions, suggesting only slight 
changes in the conformational states of the protein in the presence of increasing 
copper concentrations.  The dominant CS I of S 87D αsyn shifts towards the more 
extended +15 CS I at a 50µM CuC l2 concentration, suggesting a shift towards the 
more extended conformations. The dominant CS I within the compact 
conformations of all three αsyn variants remains constant at +7.   
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F igure 3.11A:  E ffect of Increasing CuC l2 Concentration on the CS D of WT, 
S 87D and S 129D αS yn. 
 CS Ds of WT, S 87D and S 129D αsyn in the presence of increasing 
concentrations of CuCl2. A) Untreated, B) 10µM C uC l2, C ) 20µM CuC l2. 
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F igure 3.11B:  E ffect of Increasing CuC l2 Concentration on the CS D of WT, 
S 87D and S 129D αS yn. 
 CS Ds of WT, S 87D and S 129D αsyn in the presence of increasing 
concentrations of CuCl2. D) 50µM CuCl2, E ) 100µM CuC l2. 
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3.3.6 Binding of Copper Causes and Increase in the Proportion of the Most 
Compact Conformations at E ach Charge S tate Ion, For All Three Protein Variants 
Investigated  
In section 3.3.5, the addition of copper ions to the WT αsyn solution shifted the 
expanded states CS D towards the lower C S Is, suggesting a shift towards the 
more compact states, despite the initial widening of the CS D observed upon 
addition of equimolar CuC l2. 
As previously described, each CS I of αsyn represents multiple conformations of 
the protein, of slightly altered degrees of compactness but with the same 
ionisation ability.  In this section, the conformational distribution of each CS I of 
the three protein variants, apo and in the presence of CuCl2, will be investigated 
via Gaussian fitting of the ATDs.   
F igure 3.12 shows the relative shifts in conformational equilibrium for the most 
dominant extended CS I, +14, of all three proteins, in the presence of increasing 
copper concentrations.  Very little alteration in conformational equilibrium is 
observed with either protein at this CS I, other than with WT αsyn after a CuCl2 
concentration of 50µM with 10µM αsyn is reached, where an increase in the more 
compact conformation C, is observed, from around 10% in the apo sample to 23 
and 32% in the presence of 50 and 100µM CuCl2, respectively.  However, little 
alteration can be observed overall within the extended states, indicating the 
conformations are not dramatically affected by the addition of this metal ion. 
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F igure 3.12:  E ffect of Increasing Copper Concentration on the Conformational 
E quilibrium at the +14 CS I of WT, S 87D and S 129D αS yn. 
The +14 CS I, representative of the extended conformations, of WT, S 87D and 
S 129D αsyn, at increasing CuCl2 concentrations.  C onformations A, B and C . 
 
F igure 3.13 shows the shows the relative shifts in conformational equilibrium for 
the +7 CS I, representative of the compact CS Is, of all three proteins.  A 
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substantial increase in the most compact of the three conformations present at 
this CS I, G, is observed upon addition of equimolar C uC l2 and above.  At an 
equimolar protein and copper concentration, an increase of 22.55%, from 31.29% 
apo to 53.84% of the total protein at this charge state is observed. This occurs 
via a reduction in the more extended conformations, F  and E .  Conformation E  is 
completely absent from the chromatogram of WT αsyn after addition of 100µM 
CuCl2.  Notably this state is completely lost for S 129D αsyn after addition of 20µM 
CuCl2.  This data indicates that the compact CS Is and conformations are affected 
by the addition of copper ions, where a shift in the equilibrium towards the more 
collapsed conformations is observed. 
For the remainder of this section, only the equimolar αsyn and C uC l2 results will 
be discussed, as representative of the action on copper of the different 
conformational states of αsyn and its variants.  Gaussian fitting of all CS Is may 
be viewed in appendices 3L to 3X .  As shown in appendices 3L-3P, at CS I’s +19 
to +15, S 87D αsyn undergoes little alterations to its conformational equilibrium 
upon the binding of copper.  WT and S 129D αsyn however show more notable 
changes, with a reduction in the more extended conformation A, in favour of the 
more compact conformation, B.  At the +14 and +13 CS Is, two of the more 
dominant peaks within the spectra, no significant alterations occur upon copper 
binding, as shown in appendices 3Q & 3R .  At CS I +12 in appendix 3S , a 
reduction in conformation C  is observed with the binding of copper, which was 
unexpected as it is the most compact conformation at this CS I. 
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F igure 3.13:  E ffect of Increasing Copper Concentration on the Conformational 
E quilibrium at the +7 CS I of WT, S 87D and S 129D αS yn. 
The +7 CS I, representative of the compact conformations, of WT, S 87D and 
S 129D αsyn, at increasing CuCl2 concentrations.  C onformations E , F  & G. 
 
At CS I +11, shown in appendix 3T, and through the lower CS Is, S 87D αsyn 
begins to respond more akin to the other variants, and new, compact 
conformations appear for all proteins as the equilibrium of extended conformers 
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further decreases in favour of more compact species.  For all three variants at the 
+11 CS I, a reduction in conformations B and C is observed in favour of, D.  
Unexpectedly, an increase in the most extended conformation, A, is also seen.  
At CS I +10 in appendix 3U, an increase in the increasingly compact 
conformations C , D, E  and F  is observed, along with a reduction in B.  A similar 
pattern is followed at CS I +9 in appendix 3V, where the extended C  and D reduce 
and an increase in E , F  and G is seen, and conformation B is no longer present.  
At CS I +8 shown in appendix 3W, C , D and E  reduce in favour of F  and G, and 
at CS I +7 in appendix 3X , C  and D are gone, and an increase in G via reduction 
in F  and E  is observed.   
Interestingly, no notable changes were observed at CS Is +6 and +5, as shown in 
appendices 3Y  & 3Z, despite being the most compact, and CS I +6 containing the 
only instance of the most compact conformation, conformation H.  This was true 
for all concentrations of CuCl2 investigated. 
This data together suggests that mimicking phosphorylation at serine residues 
does not result in large increases in the more compact, aggregation prone states 
of the protein overall, in comparison to the WT.  Copper ions however do have 
the ability to alter the conformational equilibrium of all three proteins investigated, 
and increase the population of the more aggregation prone conformations 
populated at CS Is +8 to +5. 
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3.3.7 Mimicking Phosphorylation at S erine129 but not S erine 87 Increases the 
Copper Binding Affinity of αsyn 
To determine their binding affinities for copper, the three protein variants were 
each dissolved in 50mM ammonium acetate at a protein concentration of 10µM, 
followed by addition of increasing concentrations of CuC l2, indicated on the 
figures as 1x, 2x, 5x, 10x, representing 10, 20, 50 and 100 µM CuCl2, 
respectively.  
As demonstrated in figure 3.14, extended states of the three protein variants, 
represented by the +14 CS I, readily bind just two copper ions at an equimolar 
(1x) and 20µM CuC l2 (2x) concentration.  Upon addition of 50µM C uC l2 (5x), the 
S 129D variant begins to bind three copper ions.  Also at this concentration, the 
majority of S 129D is bound to two copper ions, whereas WT and S 87D are mostly 
bound to one.  When the copper concentration is increased to 100µM (10x), all 
three proteins bind three copper ions, and a fourth copper peak appears.  At this 
concentration the dominant peak for both WT and S 87D is almost equally shared 
between αsyn bound to one or two coppers, whereas the majority of S 129D is 
bound to two ions. 
The compact conformations populated at CS Is +8 to +5, of all three protein 
variants, have a higher copper binding affinity than the extended CS Is.  As shown 
in figure 3.15, with the +7 CS I, all three proteins bind three copper ions when 
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exposed to 50µM (5x) CuC l2, as opposed to 100µM (10x) CuC l2 for the extended 
states.   
 
 
F igure 3.14: Copper Binding Affinities of the +14 CS I of WT, S 87D and S 129D α
S yn. 
Copper binding affinities at the +14 CS I of 10µM WT, S 87D and S 129D αsyn in 
50mM ammonium acetate buffer, at increasing CuCl2 concentrations, as 
determined by E S I-IMS -MS  in positive ion mode. (1x=10µM CuCl2, 2x=20µM 
CuCl2, 5x=50µM CuC l2, 10x=100µM CuCl2). 
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The same binding pattern is observed as with the extended CS Is, with WT and 
S 129D being almost equally bound to one or two copper ions, and S 129D being 
mostly bound to two ions, and a much smaller proportion being bound to three 
coppers.   At a 100µM (10x) CuCl2 concentration all three proteins bind four 
copper ions, with the majority of WT and S 87D binding two ions, whereas the 
dominant peak for S 129D is almost equally shared between protein bound to two 
or three copper ions.  Data presented here demonstrates that S 129D αsyn has a 
higher binding affinity for copper than WT or S 87D. 
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F igure 3.15: Copper Binding Affinities of the +7 CS I of WT, S 87D and S 129D α
S yn.   
C opper binding affinities at the +7 CS I of 10µM WT, S 87D and S 129D αsyn in 
50mM ammonium acetate buffer, at increasing CuCl2 concentrations, as 
determined by E S I-IMS -MS  in positive ion mode. (1x=10µM CuCl2, 2x=20µM 
C uCl2, 5x=50µM CuC l2, 10x=100µM CuCl2). 
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3.3.8  Mimicking Phosphorylation at S erine 87 S lows the Aggregation Rate of 
αsyn in vitro 
ThT assays were conducted in 50mM ammonium acetate buffer, with 70µM αsyn 
plus 70µM metal ions and 10µM ThT.  High protein concentrations were utilised 
to aid in the initiation of aggregation, which was monitored for 116 hours.  Data 
was normalized to the highest fluorescence reading to produce sigmoidal traces, 
as shown below.   
    
F igure 3.16:  E xample t1/2 and Le Calculation from Thioflavin-T Data. 
ThT data was normalized to the highest fluorescence value.  The time taken for 
each protein to reach half maximum fluorescence (t1/2) was determined using the 
method labelled A.  The lag end (Le) was determined via method B. 
 
As shown in figure 3.16, the data was fitted to determine the time taken for the 
protein to aggregate to half its highest value (t1/2) labelled in figure 3.16 as method 
A, and the end of the lag phase (Le) was determined by plotting a line of best fit 
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for the lag phase and the exponential growth phase, and calculating the intercept 
of the two, labelled method B in the figure (Mason et al., 2016). 
As shown in figure 3.17, the S 87D αsyn variant has a slower aggregation rate 
than WT or S 129D overall, whereas S 129D has an increased rate over WT.  The 
WT protein has an average t1/2 of 42.3± 14.8hrs, whereas the t1/2 of S 87D was 
increased to 54± 5.3hrs, and S 129D had the shortest t1/2 overall at 27.3± 2.1hrs. 
S ignificance was only determined between the S 87D and S 129D sample 
however, with S 129D showing a significantly increased rate of aggregation 
(p<0.05).   
The lag phase of WT αsyn aggregation lasts on average 25.7± 7.7hrs, whereas 
lag times for the phosphomimic mutants S 87D and S 129D are both reduced in 
comparison, to 23.6± 4.1 and 19.2± 1.2, respectively.  The lag end of S 87D was 
significantly slower than WT αsyn (p<0.05) and the end of the lag phase was 
significantly faster for S 129D than S 87D (p<0.05).  Again, no significance was 
determined between WT and S 129D αsyn, likely due to the variability in 
aggregation rates, particularly with the WT sample.  Hence the S 129D αsyn 
variant aggregates more rapidly than the WT or the S 87D proteins. 
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F igure 3.17: ThT Assay C omparing Aggregation R ates of WT, S 87D and S 129D 
αS yn. 
A) Average t1/2 values of WT, S 87D and S 129D αsyn observed from three 
separate ThT experiments. B) Average lag time end values of WT, S 87D and 
S 129D αsyn from three separate ThT experiments. (* p<0.05). 
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3.3.9  S 129D αS yn Aggregates Fastest of All Variants in the Presence of Metals 
As shown in figure 3.18, WT αsyn aggregation rates are increased in the 
presence of equimolar copper.  A significant reduction (p<0.05) in both t1/2, from 
an average 42.3± 14.8hrs to 18.3± 6.7hrs, and lag time (p<0.05) from an average 
25.7± 7.7 to 12.3± 5.6hrs can be observed, demonstrating copper can increase 
the aggregation rate of WT αsyn.  This data is in keeping with previously 
published findings (Mason et al., 2016; Uversky et al., 2001; Binolfi et al., 2006), 
and suggests the presence of copper ions aid in the pathogenesis of PD, by 
increasing the rate at which amyloid fibrils are formed through the increased 
population of the collapsed monomeric conformations. 
In the presence of equimolar iron however in ammonium acetate buffers, as 
shown in figure 3.18, the average lag time of the WT protein does not change in 
the presence of iron, at 24.6± 2.4hrs, compared with 25.7± 7.7 for the untreated 
sample, however the t1/2 value is decreased to just 34.3± 3.2hrs from 42.3± 14.8 
hrs, which suggests the elongation rate is faster than that of apo WT.  
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F igure 3.18: ThT Assay of WT αS yn With or Without CuC l2 or FeC l2. 
A) Averaged t½  values for WT αsyn apo, and in the presence of equimolar CuCl2, 
from three independent ThT experiments. B) Averaged lag time end values for 
WT αsyn apo, and in the presence of equimolar CuCl2, from three independent 
ThT experiments. (* p<0.05). 
 
t
1
/
2
 
(
h
r
s
)
 
L
e
 
(
h
r
s
)
 
B 
A 
118 
 
As shown in figure 3.19, S 87D reacts in a similar manner to WT in the presence 
of metals, but has a longer aggregation rate.  In the presence of equimolar 
copper, t1/2 is significantly reduced (p<0.05) from an average 54.0± 5.3hrs to 
32.0± 2.0hrs, and the lag phase is significantly reduced (p<0.05) from 
23.58± 4.1hrs to 20.3± 0.8hrs in comparison to the untreated protein.  As the 
aggregation rates overall are slowed in comparison to the WT protein, this would 
suggest that the protein is less amyloidogenic and potentially less pathogenic. 
However, like the WT protein this propensity to aggregate can be increased via 
the addition of copper.   
The S 87D mutant also acts in a similar manner to WT in the presence of 
equimolar iron.  With the S 87D αsyn variant however, an increase (p<0.01) in t1/2 
is observed of 54hrs to 78.8hrs, and the lag phase is also extended (p<0.01) to 
40hrs from 22hrs in buffer alone.  This was found to have greater statistical 
significance than the increase demonstrated upon incubation with copper, 
demonstrating the presence of iron slows the aggregation rate of this variant. 
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F igure 3.19: ThT Assay of S 87D αS yn With or Without CuCl2 or FeC l2. 
A) Averaged t½  values for S 87D αsyn apo, and in the presence of equimolar 
C uCl2, from three independent thioflavin-t experiments. B) Averaged lag time end 
values for S 87D αsyn apo, and in the presence of equimolar CuC l2, from three 
independent ThT experiments. (* p<0.05, ** p<0.01). 
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The S 129D mutant has the fastest aggregation rate overall in comparison to WT 
and S 87D, as shown in figure 3.20.  It also acts in a similar manner to WT in the 
presence of metals, with an increased aggregation rate in the presence of copper, 
and decreased rate in the presence of iron.   
As shown in figure 3.20, when diluted with equimolar copper, the protein has a 
significantly decreased (p<0.01) lag time from 13.7hrs to 7.8hrs, which is the most 
pronounced reduction observed for all proteins.  The t1/2 value is also significantly 
reduced (p<0.05) from 27.3hrs to 14.3hrs.   
In the presence of equimolar iron, lag time is statistically significantly increased 
(p<0.01) from 13.7hrs to 49.8hrs, and t1/2 was also significantly increased 
(p<0.01) from 27.3hrs to 60hrs.  Once again this was a more significant alteration 
than the increase in aggregation observed with copper. 
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F igure 3.20: ThT Assay of S 129D αS yn With or Without C uC l2 or FeC l2. 
 A) Averaged t½  values for S 129D αsyn apo, and in the presence of equimolar 
C uCl2 or FeCl2, from three independent ThT experiments. B) Averaged lag time 
end values for S 129D αsyn apo, and in the presence of equimolar CuCl2 or F eC l2, 
from three independent ThT experiments. (* p<0.05, ** p<0.01). 
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3.4  Discussion 
R esults presented in this chapter support the hypothesis that αsyn 
phosphorylation at S 129 has pathological significance for the development of PD, 
whereas S 87 phosphorylation appears to have a protective effect.   
When CS Ds of the three protein variants were examined from E S I-IMS -MS  
experiments, S 129D αsyn appeared to have a narrower CS D of +17 to +5 
compared with +18 to +5 for the WT and S 87D variants.  If this is a true result, it 
suggests that S 129D αsyn has a narrower conformational distribution overall.  
However, as discussed in chapter 1, questions are arising around the true 
reflection E S I-IMS -MS  and gas-phase conformations have on the conformations 
present within the solution.  Both unfolding and compaction of protein species 
and protein subunits of IDPs in the gas-phase have been previously reported 
(R uotolo et al., 2005; Zilch et al., 2007; Bohrer et al., 2008; Pagel et al., 2013; 
Borysik et al., 2015), and it appears that, rather than reflecting true solution 
conditions, E S I-IMS -MS  creates a broader conformational equilibrium containing 
both species present in solution, and those which are artefacts of the electrospray 
process.  Multiple repeats of the experiment were performed, with the same CS D 
observed each time.  We can be confident therefore, that the S 129D variant 
displays a CS D consistent with a more compact conformation.  However, it 
cannot be confirmed exactly which of these species observed, for all three 
proteins, are a true reflection of those present within the solution.  
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When the ATDs of each protein were compared, no significant alterations to the 
conformational distribution of the two phosphomimic proteins were noted in 
comparison to the WT.     
 E S I-IMS -MS  data shows that the addition of CuCl2 to the αsyn solution resulted 
in an increase in the proportion of the most compact conformations present within 
the compact CS Is +8 and +7 for all three protein variants. S 129D αsyn was 
determined to have a higher binding affinity for copper ions, and S 87D a lower 
affinity, relative to the WT protein.  S 129D was also shown via ThT assay to have 
an increased aggregation rate in comparison to WT, and S 87D had a slower 
aggregation rate than both other variants.  The aggregation rate of all three 
proteins was increased upon incubation with C uC l2, and decreased upon 
incubation with F eC l2.  Overall these results indicate that S 129 phosphorylation 
results in a protein that is more amyloidogenic than the WT protein, and has a 
higher affinity for copper ions.  
Changes in the spectral properties of what should be identical αsyn samples are 
seen within this chapter, and have been well documented previously.  These 
differences may be accounted for by several factors.  Variation between protein 
batches may be partially accounted for by the protein production method, by 
recombinant expression in E . coli.  S light alterations within the preparation can 
arise during sample handling, for example; the buffer composition, time spent in 
dialysis, time spent on the freeze drier, or whether the protein has been frozen 
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between growth in E . coli and its initial anion exchange chromatography 
purification step.  Despite care being taken to be consistent between 
preparations, the process has many manual steps, so there are opportunities for 
small variations to occur.  R esidual salts in the purification buffers can also alter 
the solution conditions and therefore the protein conformation and this could be 
an issue if there is variation in the dialysis or purification steps.   
Differences in conformational distribution between machine acquisitions months 
apart, particularly differences in drift times, can be also accounted for by several 
factors, including settings on the mass spectrometer, for example increased 
pressure in the ion mobility cell, atmospheric pressure changes around the E S I 
source and changes in the position of the E S I source, which is a particular issue 
if using a detachable auto-sampler such as the NanoMate. The mass 
spectrometer used in these experiments was also subject to mode changeover 
every few weeks between E S I and MALDI, which may cause other slight internal 
differences, for example with the Q-TOF pressure.  C alibration of the mass 
spectrometer should eliminate a number of issues with the internal settings, but 
atmospheric changes external to the machine are difficult to account for 
experimentally. 
There is a general issue within the ion mobility research community around 
differences in CCS s observed between research groups and their publications.  
This may be due to a lack of standardisation in machine settings, buffer 
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composition and molarity, and protein production methods between groups, as 
some research groups purchase pre-made proteins, whereas others produce 
them by recombinant expression.  Differences between identically made samples 
run using the same buffer and same machine settings have previously been 
reported in the literature, for example two experiments conducted on the same 
day with αsyn by the Bowers’ research group showed a CS D of +21 to + 5 for the 
initial sample, with the second sample from the same source run later in the day 
producing a CS D of +19 to + 5 (Beveridge et al., 2015).  These discrepancies 
between data sets observed within E S I-IMS -MS  experiments may also be a 
consequence of the production of artefact species during electrospray.   
E x vivo material from different patient and animal sources has also been found 
to give conflicting results in E S I-MS  experiments.  For example, when 
endogenous αsyn was isolated directly from mouse brain tissue, and subjected 
to mass spectrometric analysis for the first time, it was identified as an 
unstructured monomer containing significant post-translational modifications, 
including acetylation of the N-terminus, with a determined mass of 16,408 ± 894 
Da, rather than the predicted 14,485 Da (Burré et al., 2013), however the error 
observed within these experiments is extremely large at ± 894 Da, which does not 
lend much support to the findings.  Fauvet et al also demonstrated that αsyn 
isolated from human erythrocytes was predominantly an intrinsically disordered 
monomer, also using E S I-MS  to confirm the mass and demonstrated the 
existence of two protein species each with a different post-translational 
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modification; the main species with a mass of 14,504 Da, corresponding with a 
single acetylation on the protein, and a second at 14,519 Da, consistent with a 
single methionine addition.  CS D’s of the purified protein are not shown, however 
they did determine the CS D of recombinant αsyn as +19 to +12 CS Is, following 
both native and denaturing purification protocols (Fauvet et al., 2012).  Kang et 
al, also report that both N-terminal acetylated recombinant αsyn and non-
acetylated recombinant αsyn, under mild physiological conditions, present 
primarily as a disordered monomer by E S I-IMS -MS , with CS Ds of +14 to +7 and 
+13 to + 7 respectively (Kang et al., 2012) and this is in keeping with more 
recently reported data on WT vs acetylated forms (Mason et al., 2016).  The data 
presented in the literature on the conformational state of αsyn demonstrates that 
it is clearly influenced by the modes of preparation and the initial source of the 
material being analysed. 
Given these variations between both ex-vivo and recombinant proteins, results 
obtained in this chapter for WT αsyn are largely in keeping with those previously 
recorded. R ecently published data from this research group also showed there to 
be eight distinct conformations of WT αsyn when acquired in 50mM ammonium 
acetate at a concentration of 10µM using positive ion mode E DI-IMS -MS , using 
the same fitting methods as those reported here (Mason et al., 2016).  R elative 
proportions of the conformations at each charge state were very similar to results 
presented here, and the same pattern of extended conformer reduction in favour 
of more compact species can be seen.  However, there was a slight difference in 
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CCS  calculation at CS I +7 of ~60 Å2, though this small change is in keeping with 
differences in CCS  recorded in the literature (Phillips et al., 2015; Beveridge et 
al., 2015).  The wider CS D of WT αsyn observed in experiments presented in 
section 3.3.3 has also previously been reported by this research group, where 
acquiring WT αsyn in 50mM ammonium acetate showed a CS D of +18 to +6.  
This data was however, acquired using borosilicate glass capillaries rather than 
a NanoMate ion source (Illes-Toth et al., 2013).  A similar distribution of dimers 
was also noted in this study, with CS Is between +21 and +13 being observed 
(Illes-Toth et al., 2013).   
Other previously reported studies have observed fewer conformational species, 
despite observing a wider CS D.  For example, in positive ion mode WT αsyn was 
observed to populate four different conformations, again differentially 
characterised by their varying degrees of compactness (Beveridge et al., 2013).  
The most compact conformation spanned CS Is +5 to +10, the compact 
intermediate conformer spanned the +7 to +13 CS Is, the more disordered 
intermediate spanned the +10 to +17 CS Is, and the most expanded conformer 
spanned CS Is +14 to +24 (Beveridge et al., 2013).  This again can be put down 
to differences in mass spectrometry settings and the protein’s intrinsic disorder.  
Given the inherent variability observed with WT αsyn MS  data presented in the 
literature, the data presented in this chapter are consistent with our own and other 
research groups. 
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E S I-IMS -MS  spectra or conformational distributions for the S 87D and S 129D 
αsyn variants have not previously been reported.  The S 129D mutation has been 
investigated utilising C -terminal fragments of the protein, but no spectra for the 
whole proteins exist (Lu et al., 2011).  Data presented in this chapter suggests 
the S 129D mutant αsyn has a higher propensity to aggregate, and therefore may 
be the more pathogenic of the variants investigated, due to its slightly more 
compact conformational distribution, as demonstrated by its narrower CS D, and 
the increased CS D of the dimeric species.   
Metal binding studies showed that only copper binding to αsyn was observable 
under MS  compatible conditions.  The binding of magnesium and iron to WT αsyn 
has previously been demonstrated by NMR  spectroscopy, tyrosine fluorescence 
quenching, and E S I-MS  (Golts et al., 2002; Binolfi et al., 2006; Peng et al., 2010).  
The iron binding observed within E S I-MS  experiments however was achieved via 
addition of iron in the complex Fe(NH4)2(S O4)2, and performed on a linear ion trap 
mass spectrometer, and was also conducted in 50% methanol, which is not 
physiologically relevant and would be unsuitable for conformational studies 
conducted in this chapter.  Binding of metal ions such as C u(II) and Fe(II) to αsyn 
peptides has previously been observed using E S I-MS  using 50/50 v/v MeOH and 
H2O and by chemiluminescence (Liu and Franz, 2007; Lu et al., 2011).  Again, 
these buffers are not physiologically relevant, and attempts to reproduce this data 
here using the whole protein were unsuccessful. A range of different buffers and 
concentrations were investigated in this chapter, in an attempt to observe binding 
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of iron, zinc, magnesium and manganese, including 5, 10, 25, 50 and 100mM 
ammonium acetate, 50mM ammonium bicarbonate, 10mM 4-methylmorpholine, 
and water:ACN:MeOH.  Metals with other counter ions such as FeS , ZnS  and 
MnS  were also investigated, and a range of mass spectrometry machine 
parameters were applied.  One possible reason that metal binding is not observed 
is that the metal ions are complexing with a component of the buffer, such as the 
acetate in the ammonium acetate buffers.  E S I-IMS -MS  may also be unsuitable 
for observations of metal binding due to the addition of the drift tube and the low 
affinity of the interaction, and collisions with the buffer gas may dissociate ligand 
binding. It is possible this is what has occurred in experiments presented in this 
chapter, as the other metal ions investigated are known to have a much lower 
binding affinity for αsyn, and therefore may only be weakly associated and readily 
dissociated.  Despite the lack of binding observed in E S I-IMS -MS  experiments, 
Fe(II) was still found to slow the aggregation rate of WT, S 87D and S 129D αsyn 
in vitro.  It is likely that the binding was dissociated during the IMS  stages of the 
mass spectrometry experiments, due to its low binding affinity.    
The appearance of further CS Is and an increase in the intensity of extended 
conformations upon copper binding has however been reported in the literature, 
with a widening of CS D from +15 to +5 increased to +17 to +5 observed upon 
addition of equimolar CuCl2 (Mason et al., 2016).   The majority of other research 
investigating copper binding by E S I-IMS -MS  report the protein binding two 
copper ions, though some studies in the literature suggest the protein may be 
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able to bind as many as 16 copper ions (Ahmad et al., 2012).  A study using E S I-
IMS -MS  in negative ion mode, and utilising glycine to prevent the low affinity, 
non-specific binding of copper to αsyn, found the protein bound up to 2 copper 
ions at a 6:6.66 protein to copper ratio (12μM αsyn plus 80μM copper), however 
without glycine the protein bound 3 copper ions at this concentration, which is in 
keeping with the results presented here (Natalello et al., 2011).This study also 
demonstrated an increase in the number of copper ions binding with increasing 
copper concentration, with one copper ion binding at concentrations lower than 
the protein level, and increasing to two after the copper level was above that of 
the protein (Natalello et al., 2011).  Increased copper concentration and therefore 
increased copper binding is also known to increase the α-helical content of αsyn, 
as investigated by far-UV CD investigation (Ahmad et al., 2012).  S ome studies, 
as previously mentioned, suggest there may be up to 16 binding sites in total for 
metal ions to WT αsyn, suggesting there could be 14 non-specific binding motifs 
this binding is most likely brought about by non-specific electrostatic attraction 
(Ahmad et al., 2012). 
Currently three copper binding sites have been well established; one at the N-
terminus, one at H50, and a third in the C -terminal region (Binolfi et al., 2012).  
Initial studies suggested H50 to be the high affinity, initial binding site, and this is 
the case for copper binding to a large number of amyloid proteins (Ahmad et al., 
2012), though more recent studies suggest this is not the case, and the N-
terminal to be the highest affinity binding site with H50 and the C-terminal region 
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as lower affinity sites, as copper does not bind to histidine residues at pH levels 
below 6.0, but still readily binds copper ions at pH 2.5. α and β-synuclein however 
have the same E PR spectra when bound to copper, but the single histidine 
residue is in a different position; amino acid 65 instead of 50, therefore this also 
suggests this is not the high affinity or specific binding site otherwise the E PR 
spectra would be notably different (Ahmad et al., 2012).  A more recent study 
suggests H50 may be required for N-terminal copper binding to physiologically 
relevant N-terminal acetylated αsyn, as H50Q mutant αsyn missing the histidine 
residue, has a greatly impaired copper binding ability compared with N-terminally 
acetylated unmodified αsyn (Mason et al., 2016), though no differences were 
observed between unmodified H50Q and WT αsyn 
Previously published data analysing the CS D of αsyn in the presence of Cu2+ also 
reveals a decrease in disordered conformers and a shift towards the more highly 
compact conformations.  The binding of copper ions to αsyn is known to cause a 
stable turn like structure in the protein at the H50 binding site, and this folding 
offers favourable conditions for β-sheet nucleation as the protein is pulled round 
to become adjacent with itself.  Hydrogen bonds form between proximal amino 
acid side chains, anchoring and stabilizing the structure, and a β-sheet is formed.  
This serves as a template for further β-sheet formation and stacking of the protein 
(R ose et al., 2011).  It is still unclear where the primary copper-anchoring site is 
located on the protein, however data presented here would lend support to the 
primary site being H50, as the introduction of a stable turn into the αsyn sequence 
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upon Cu (II) binding (R ose et al., 2011), would cause a suitable compaction of 
the protein to produce the conformational changes observed in these 
experiments.  As no further compaction was observed upon the binding of 
multiple copper species within experiments presented here, it is likely that the 
binding of the first copper ion occurs at H50, introducing this turn into the protein 
and causing compaction, and the binding of further ions to the N or C -terminus 
has little effect on the conformation of the protein thereon. 
As no novel conformations appear to be produced upon copper binding, rather a 
shift between previously existing conformations, this suggests αsyn must readily 
sample this copper induced shape within its normal equilibrium, it is possible 
copper acts as the anchor for securing the entry to the amyloid aggregation 
pathway, rather than inducing the amyloid-forming conformations itself.  The 
ability of metal ions, particularly Cu2+ to promote oligomerisation and amyloid fibril 
formation of αsyn has been previously well established (Ahmad et al., 2012; 
Uversky et al., 2001), though very little data to date exists on the aggregation 
kinetics of the S 87D or S 129D phosphomimic mutants, or how metal ions affects 
this aggregation.  S tudies into the aggregation kinetics of S 129D vs WT αsyn 
have suggested there is no difference in the aggregation rate between the two 
proteins.  It must be considered that ThT experiments conducted here were 
performed in 50mM ammonium acetate rather than the commonly used tris 
buffer, in keeping with the mass spectrometry analysis performed here. These 
changes in conditions will have affected the aggreg
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3.5  Conclusions 
All experiments outlined in this chapter support the hypothesis that 
phosphorylation at serine129 promotes the pathogenesis of PD.  Data presented 
here shows faster aggregation times and increased interaction with metal ions as 
a result of mimicking phosphorylation. 
The S 129D protein aggregates faster than WT or S 87D αsyn, and this effect is 
increased in the presence of CuC l2.  Copper binding to all three protein variants 
investigated, induces a shift to more compact states but does not cause the 
formation of novel conformations.  It appears then that binding pushes the 
equilibrium towards the more amyloidogenic conformations which are already 
sampled by the protein within the equilibrium and may be acting to stabiles these 
compact states resulting in an increase in aggregation.   
A summary figure outlining the role of copper (II) binding and phosphorylation at 
S 129 in increasing the aggregation of αsyn can be observed in figure 3.21.  It 
appears copper binding causes a stable, turn-like structure on the αsyn protein, 
which causes a shift towards the more compact species within the protein 
equilibrium.  These compact species then further aggregate into oligomers, 
protofibrils and eventually the mature fibrils observed within LBs.  
Phosphorylation at S 129 also causes an increase in the aggregation rate of the 
protein, however the modification does not cause dramatic conformational 
changes to the protein, so it is still as yet unclear how this modification is causing 
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an increase in the formation of oligomeric species.  It could be that the charge on 
the protein causes it to more readily self-associate, or bind trace metals, but 
further investigation will be required to confirm this.  Given the increased affinity 
of S 129D to bind copper, this stabilisation of the aggregation prone compact 
states may be further enhanced by the presence of the phosphomimic, and 
interaction with the H50 binding site.  
The S 87D protein variant had the opposite effect, supporting previous 
suggestions that this modification could be protective.  The presence of Fe (II) in 
the samples, despite binding being unobservable during E S I-IMS -MS  analysis, 
also caused a delay in aggregation rates.  It is still unclear however how these 
pathways are functioning, but the site of phosphorylation does appear to be 
important in controlling the aggregation of the protein. 
Care must be taken in interpreting data from this chapter, due to the 
discrepancies with E S I-IMS -MS  and the use of phosphomimics, therefore data 
should now be acquired using the fully phosphorylated protein and using 
alternative methodologies in conjunction with E S I-IMS -MS , to fully elucidate the 
method of S 129 phosphorylation on the increased aggregation of the protein. 
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F igure 3.21: Proposed Mechanisms of Cu(II) and S 129D-Induced Increase in Aggregation 
The two proposed mechanisms by which Cu(II) and S 129 phosphorylation increase the aggregation rate of αsyn in vitro.  Top: The 
binding of Cu(II) causes a conformational change, shifting the equilibrium towards the more compact states, inducing increased 
aggregation.  Bottom: S 129 phosphorylation does not alter the conformation of the protein, or cause a shift towards the compact states, 
however aggregation is again accelerated, suggesting an alternative mechanism or pathway to that induced by the binding of C u(II). 
The two pathways are potentially linked, as indicated with the grey arrow, via the high affinity Cu(II) binding site at H50, as S 129D α
syn has a higher affinity for Cu(II) binding. 
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Chapter 4 – The E ffects of Curcumin and its Derivatives on 
α-S ynuclein Aggregation 
4.1  Introduction 
Curcumin is a polyphenolic compound found in the rhizomes, or underground 
stems, of the Curcuma longa plant and a variety of other Curcuma plant species.  
The yellowy-orange crystalline compound is most commonly encountered in the 
spice turmeric, and in its natural form it has been used for medicinal and culinary 
purposes in C hinese and Indian culture for thousands of years.  Due to its 
extensive use for a wide variety of ailments and in the preparation of numerous 
culinary dishes, curcumin has been dubbed “Indian gold”.  Its historic medicinal 
uses include the treatment of inflammation, dyspepsia, stress and mood 
disorders (Witkin and Li, 2013). 
R ecently curcumin has been proving its potential as a therapeutic for a range of 
diseases, including multiple types of cancers (Davatgaran-Taghipour et al., 2017; 
Allegra et al., 2017) and neurological disorders.  Publications citing curcumin on 
PubMed have risen steadily since 2003 (J i and S hen, 2014), with a search for 
“curcumin” yielding 9970 results at the time of writing compared to just 1014 in 
2003.  Curcumin has shown numerous pharmacological properties, including 
antioxidant, anti-inflammatory, anti-bacterial, anti-cancer, anti-spasmodic and 
anti-viral functions (J i and S hen, 2014; Modasiya and Patel, 2012; J ha et al., 
2016).  C urcumin has progressed into clinical trials for a number of diseases and 
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disorders, including colorectal neoplasia (Carroll et al., 2011), depression 
(Lopresti et al., 2015; S anmukhani et al., 2014) and AD (R ingman et al., 2005; 
Baum et al., 2008).   
Curcumin has been gaining interest as a potential treatment for Parkinson’s 
disease, due to its ability to reduce the aggregation of αsyn, along with several 
other amyloidogenic proteins, in vitro.  These include Aβ (Y ang et al., 2005), TTR  
(Ferreira et al., 2011) and PrP (Hafner-Bratkovič et al., 2008).  This suggests a 
possible common mode of action and it could therefore potentially be utilized as 
a therapeutic for a number of related amyloid diseases. 
 
4.1.1  Curcumin C hemistry 
The structure of curcumin was elucidated in 1910 and identified as 1,7-bis(4-
hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, also known as 
diferuloylmethane.  The molecular formula of curcumin is C 21H20O6, and it has a 
molecular weight of 368.38 Da.  Natural curcumin, when purified from plant 
sources, contains around 77% of the compound we term curcumin, plus two 
related compounds; demethoxycurcumin (18%) and bis-demethoxycurcumin 
(5%), the structures of which are shown in figure 4.1, and all three belong to a 
group of compounds known as diarylheptanoids.  Any future reference to 
curcumin in this chapter is referring to the first structure displayed in figure 4.1.  
Curcumin itself is insoluble in water at acidic and neutral pH, but soluble in polar 
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and non-polar organic solvents, and in alkali or organic solvents such as glacial 
acetic acid, DMS O or ethanol (Modasiya and Patel, 2012). 
 
 
 
 
F igure 4.1:  Natural Curcumin S tructures. 
The structures of A) curcumin, B) demethoxycurcumin and C) bis-
demethoxycurcumin.  Adapted from S andur et al., 2007. 
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4.1.2  Curcumin Bioavailability 
Despite curcumin’s promise as a therapeutic for a wide range of diseases, its 
clinical use has been hindered by the molecule’s poor bioavailability.  Curcumin 
is almost completely insoluble in water, is rapidly metabolised in the 
gastrointestinal tract and undergoes glucoronidation in the liver and because of 
this, it has demonstrated inadequate tissue absorption (R ingman et al., 2005; 
Kundu et al., 2016).  It has however been demonstrated to cross the blood brain 
barrier (BBB) in several mouse models of Alzheimer’s disease (Y ang et al., 2005; 
Kundu et al., 2016; R ingman et al., 2005; Garcia-Alloza et al., 2007; Mishra and 
Palanivelu, 2008).  S everal research groups have also used piperine as an 
adjuvant to improve curcumin’s oral bioavailability, with promising results in 
animal models (S ingh et al., 2015; Panahi et al., 2014; Ucisik et al., 2013; S hoba 
et al., 1998).  More recently, a study utilising piperine in combination with lipid 
nanoparticles greatly improved oral bioavailability in an in vivo mouse model, and 
demonstrated that the combination could still effectively cross the BBB (Kundu et 
al., 2016).  Piperine is known to inhibit hepatic glucoronidation, aiding the evasion 
of metabolism (R ingman et al., 2005).  Piperine alone has also been 
demonstrated to have neuroprotective effects, with anti-inflammatory, anti-
apoptotic and anti-oxidative stress functions being reported, making its pairing 
with curcumin even more exciting as a possible treatment for PD (S hrivastava et 
al., 2013; Al-Baghdadi et al., 2012). 
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4.1.3  Curcumin as an Inhibitor of Amyloid Aggregation 
The first reported success of curcumin as a potential anti-amyloid therapeutic was 
in 1998, when it was demonstrated that curcumin could block the activity of NFkB, 
a protein complex involved in DNA transcription, and prevent Aβ-induced 
apoptosis in human S K-N-MC cells, a neuroblastoma cell line (Kuner et al., 1998).  
A further study in 2001 also confirmed that curcumin, demethoxycurcumin and 
bis-demethoxycurcumin were all effective at  protecting both rat 
pheochromacytoma PC12 cells and human umbilical vein endothelial cells from 
Aβ(1-42) induced oxidative damage (Kim et al., 2001).   
S ince then, several in vitro and in vivo studies have proven curcumin’s 
effectiveness in reducing the amyloid formation of several different proteins.  The 
research was entirely focussed on Aβ and Alzheimer’s disease until 2008, when 
curcumin was shown by both western blot and in an S H-S Y 5Y  cell model, to 
inhibit the aggregation of αsyn (Pandey et al., 2008).  Curcumin has also been 
demonstrated to reduce the aggregation of the PrP protein in vitro, using ThT 
assays, where an increased lag time and 6-fold reduction in aggregate formation 
was observed.  In the same study it was also demonstrated that low doses of 
curcumin could effectively rescue cells from apoptosis induced by exposure to 
amyloid fibrils of PrP (Lin et al., 2013). 
Curcumin is also known to have antioxidant properties, which may be how it 
exerts its effects on amyloid aggregation.  It has been discussed in the literature 
that increased oxidative stress caused by overexpression of αsyn or relating to 
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increased levels of metals, such as iron, in the S NPC plays a key role in PD 
development and progression.  This is believed to occur through the production 
of ROS  (J enner and Olanow, 1996; Dexter et al., 1989).  It has also been shown 
that αsyn oxidised at methionine residues, aggregates more slowly than the 
unmodified protein via ThT studies.  This is suggested to be due to the production 
of stable, non-toxic oligomeric forms, which halt aggregation at this point, 
preventing the formation of mature amyloid fibrils (Glaser et al., 2005; Uversky et 
al., 2002; Zhou et al., 2010).  Oxidation at these residues has also been observed 
to alter the protein’s membrane binding properties, potentially shielding 
membranes from oxidative damage (S childknecht et al., 2013).  It has however 
been demonstrated that certain metals may induce fibrillation of the protein, 
despite methionine oxidation (Y amin et al., 2003).  This suggests there may be 
both beneficial and pathogenic roles for oxidised αsyn, and these roles may vary 
in different diseases (S childknecht et al., 2013).  It may be the effect of oxidative 
stress on the dopaminergic cells, as opposed to oxidation of αsyn, itself which is 
driving the protein aggregation and cell-death in PD.  
Phenolic antioxidants such as curcumin act as hydrogen donors, which inhibit the 
propagation of free radical chain reactions (Venkateswarlu et al., 2005), reducing 
the damaging effect.  Inhibition of free-radical species may therefore be a 
possible mechanism for curcumin’s prevention of αsyn aggregation.  It has also 
been suggested that curcumin exerts antioxidant effects through its inhibition of 
cyclooxygenase-2 (COX-2), lipoxygenase (LOX) and inducible nitric oxide 
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synthase (iNOS ), enzymes which are all important mediators of the inflammatory 
response (Menon and S udheer, 2007).  
Curcumin has promise in the treatment of a variety of diseases and by modifying 
the molecule, it should be possible to create a variety of bioavailable versions to 
solve several medical problems, from neurological diseases such as PD and AD, 
to a variety of cancers.  This chapter with focus on the use of E S I-IMS -MS  and 
ThT aggregation assays to investigate the effect of curcumin, and thirteen 
derivatives of the natural molecule, on the aggregation and conformation of αsyn, 
providing evidence for its potential use as an anti-amyloid drug for use in 
Parkinson’s disease. 
 
4.1.4  Potential Problems with C urcumin E xperiments 
It should be noted that experimentally, curcumin is known to interfere with ThT 
readings, due to the yellow colour and intrinsic fluorescence of the molecule 
(Hudson et al., 2009), but despite this the technique is still commonly used, as 
long as appropriate control measures are taken (Y anagisawa et al., 2015; Lin et 
al., 2013; J iang et al., 2012; Pal et al., 2016; Mirhashemi, 2012).  F luorescence 
of curcumin is also known to increase slightly upon protein binding, causing a red 
shift in λmax.  Care must be taken therefore to account for this intrinsic 
fluorescence, when studying the anti-amyloid properties of this molecule and its 
derivatives, when using ThT assays. 
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To control for the intrinsic fluorescence of the curcumin molecules, an initial 
baseline fluorescence reading was taken a few minutes after preparation, and 
these were subtracted from the end-point reading.  The initial fluorescence values 
of each derivative screened can be seen in appendix 4A. 
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4.2  Aims and Objectives 
In this chapter, E S I-IMS -MS  along with ThT assays will be utilised to investigate 
the anti-amyloid properties of natural curcumin and thirteen of its derivatives to 
screen for potential anti-amyloid drugs of the future. 
 
The main aims of the chapter were to: 
 Investigate the anti-amyloid properties of natural curcumin and thirteen 
in-house synthesised curcumin derivatives to determine whether the anti-
amyloid propensity of the molecule could be improved via modification 
 Investigate the mechanism of anti-amyloid action via E S I-IMS -MS  to 
determine which protein species, monomeric or oligomeric, are being 
bound and acted on by the curcumins 
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4.3  R esults 
4.3.1  Instrument S ettings and Considerations 
In order to observe the interaction of curcumin with αsyn, mass spectrometry 
conditions were optimised.  E arly experiments presented in section 4.3.2, used 
the following conditions; cone voltage 45V, source temperature 60 C˚ , Trap DC 
Bias 45, backing pressure 4.34mbar, trap 15V and transfer 20V.  Later 
experiments from section 4.3.3 onwards, were conducted using a lower trap and 
transfer settings of 10V and 15V respectively, and backing pressure of 3.47mbar.  
Higher trap and transfer energies can cause fragmentation of some proteins and 
dissociation of ligands during E S I-IMS -MS  experiments, and can also supress or 
dissociate oligomeric species within a sample (S chenauer and Leary, 2009; 
Y oung et al., 2014).  Later experiments with lower trap, transfer and backing 
pressure values allowed for curcumin binding to be observed, which was not 
visible in the earlier experiments, suggesting that for mass spectrometry 
experiments involving αsyn and curcumin, these settings should be reduced to 
avoid the apparent dissociation of the curcumin molecule from the protein. 
 
4.3.2 C urcumin and its Derivatives Inhibit the Aggregation of αS yn in vitro 
Natural curcumin was purchased from S igma Aldrich (CC1386).  A library of 
thirteen curcumin derivatives was kindly provided by Dr Akram Khan from the 
Biomolecular S ciences R esearch Centre at S heffield Hallam University, the 
structures and predicted molecular weights of which can be seen in table 4.1.   
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Curcumin  Predicted Molecular Weight S tructure 
Natural 
Curcumin 
368.38 
 
Derivative 1 336 
 
Derivative 2 364 
 
Derivative 3 392 
 
Derivative 4 420 
 
Derivative 5 408 
 
Derivative 6 390 
 
Derivative 7 398 
 
Derivative 8 396 
 
Derivative 9 284 
 
Derivative 10 312 
 
Derivative 11 376 
 
Derivative 12 432 
 
Derivative 13 316 
 
Table 4.1:  S tructures of Natural Curcumin and Curcumin Derivatives. 
S tructures and predicted molecular weight values of natural curcumin and 
thirteen in-house prepared derivatives, kindly provided by Dr Akram Khan of 
S heffield Hallam University. 
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To determine the effects of each of these derivatives on amyloid formation, ThT 
assays were conducted in 50mM ammonium acetate buffer, to mimic conditions 
utilised during mass spectrometry experiments, with WT αsyn at a high 
concentration of 70µM to induce aggregation.  Curcumin and derivatives were 
diluted appropriately so the final concentration of curcumin was equal to that of 
the protein, and the final DMS O volume was 1%.  As a control, the same 
concentration of DMS O was also added to the WT αsyn samples.  S amples were 
incubated for 4 days at 37ºC with continuous shaking, as described in section 
2.2.4.2, to induce the formation of amyloid fibrils, before an end-point 
fluorescence reading was obtained.  E xperiments were conducted in triplicate, 
and error bars generated from the standard deviation of the mean.  R esults are 
presented as a percentage value of the aggregation of the WT αsyn only sample 
fluorescence. 
R esults shown in figure 4.2 clearly show decreased fluorescence signals, 
indicative of a lack of amyloid formation, in the presence of natural curcumin, and 
several derivatives screened.  Natural curcumin reduced the amount of β-sheet 
containing aggregates to around 23± 0.05% of the total found in the WT αsyn 
alone sample, with a reduction in fluorescence signal of 76.9± 0.05% being 
observed, with significance of p<0.0001 as calculated by non-parametric Kruskal-
Wallis and post-hoc C onover-Inman test.  S ignificance of all derivatives screened 
in comparison to the WT αsyn sample and the natural curcumin sample can be 
seen in table 4.2.  
148 
 
           
F igure 4.2:  Curcumin Derivative S creen for αS yn Aggregation Inhibition.  
E nd point fluorescence readings from a ThT assay investigating the effects of 
70µM natural curcumin or curcumin derivatives (Dvt) on the aggregation of 
equimolar WT αsyn, after subtraction of the initial t=0 fluorescent reading.  
R esults are shown as a percentage of the αsyn only sample (****= p<0.0001).  
Only the significance of derivatives 5 and 7 are shown on the graph. 
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Derivatives 1, 2, 3, 5, 7, 8, 9, 10, 11, 12 and 13 all also significantly reduced the 
fluorescence signal of the samples compared to the protein alone (p<0.05 – 
p<0.0001), whereas derivative 4 caused a significant increase in fluorescence 
signal (p<0.05) with an increase of 41.1± 0.19% being observed.  Derivative 6 
caused no significant alterations to fluorescence either way.  This demonstrates 
that not all derivatives of curcumin would be suitable in either preventing or 
treating amyloid aggregation, and there is structural specificity to the prevention 
of aggregation.  Hence, specific functional groups on the molecule are key to this 
interaction, and will be discussed in greater detail later in the chapter. 
Three of the derivatives screened, numbers 5, 7 and 9, were significantly more 
effective at reducing protein aggregation than natural curcumin, with a reduction 
in fluorescence signal of 97.4± 0.005% (p<0.0001), 98.7± 0.003% (p<0.0001) and 
88.5± 0.02% (p<0.0001) respectively being observed.  In contrast, derivatives 1, 
2, 3, 4, 6, 10, 11 and 12 were all significantly less effective than the natural 
molecule, with an increase in fluorescence observed in comparison.  Derivatives 
8 and 13 showed no significant change, suggesting they are equally as effective 
as natural curcumin. 
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Curcumin S ignificance Over αS yn Only S ignificance Over Natural 
Curcumin 
Natural Curcumin P<0.0001 (Increased) P<0.0001 
Derivative 1 P=0.003 (Increased) P<0.0001 
Derivative 2 P=0.0115 (Increased) P<0.0001 
Derivative 3 P<0.0001 (Increased) P<0.0001 
Derivative 4 (Increased) P=0.0266 (Increased) P<0.0001 
Derivative 5 P<0.0001 P<0.0001 
Derivative 6 - (Increased) P<0.0001 
Derivative 7 P<0.0001 P<0.0001 
Derivative 8 P<0.0001 - 
Derivative 9 P<0.0001 P=0.0048 
Derivative 10 P<0.0001 (Increased) P=0.0012 
Derivative 11 P<0.0001 (Increased) P<0.0001 
Derivative 12 P<0.0001 (Increased) P<0.0001 
Derivative 13 P<0.0001 - 
Table 4.2:  S ignificance of Curcumin Derivatives Anti-Amyloid Aggregation 
Propensity Over αS yn Alone or Natural Curcumin. 
P values were determined using Kruskall-Wallis and post-hoc Conover-Inman 
statistical analysis.  Table cells without stated P values (-) were not significant. 
 
To assess whether the enhanced effect of the derivatives was exclusive to αsyn, 
a second amyloidogenic protein was also investigated.  Lysozyme was chosen 
as it assembles at pH 2.0 and 65 C˚  (Cao et al., 2004) and hence the ability of the 
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derivatives to bind to amyloid proteins could be investigated under alternative 
assembly conditions.  Aggregation studies were conducted as described in 
section 2.2.4.3, and an initial fluorescence reading was again taken and 
subtracted from the end-point results to account for the intrinsic fluorescence of 
the curcumins.  
 
         
F igure 4.3:  Curcumin Derivative S creen for Lysozyme Aggregation Inhibition. 
E nd-point fluorescence readings from a ThT assay investigating the effects of 
70µM natural curcumin or derivatives (Dvt)on the aggregation of equimolar 
lysozyme, after subtraction of the initial t=0 fluorescent reading.  R esults are 
shown as a percentage of the lysozyme only sample (*** = p<0.001, **** = 
p<0.0001). 
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As shown in figure 4.3, the action of curcumin and its derivatives on lysozyme 
aggregation followed a slightly different pattern to that seen with WT αsyn in figure 
4.2.  Natural curcumin was again highly effective at reducing the total aggregates, 
in comparison to lysozyme alone, with a reduction in fluorescence signal of 67.6
± 0.29% being observed in comparison to the lysozyme alone sample.  Only two 
successful repeats of the natural curcumin samples were obtained for this 
experiment, so statistics could not be performed to compare the natural molecule 
with the untreated, or derivative containing samples.  Derivatives 5, 7 and 9 were 
again highly effective at reducing the aggregation observed in the untreated 
sample, with a reduction in fluorescence of 63.8± 0.08% (p<0.001), 73.2± 0.06% 
(p<0.0001) and 69.1± 0.14% (p<0.001) observed respectively.  Derivatives 8 and 
12 were also determined to cause a significant decrease in lysozyme aggregation 
(p<0.05 and p<0.05, respectively) and interestingly derivative 4, which 
significantly increased the aggregation of αsyn (p<0.05), had the opposite effect 
on lysozyme, causing a significant (p<0.05) decrease in the aggregation of this 
amyloid protein.  The significance of all curcumin’s effectiveness at inhibiting 
lysozyme aggregation can be seen comparatively in table 4.3.   
Given that both αsyn and lysozyme aggregation can be inhibited by curcumin, 
but there are differences in the anti-amyloid properties of the derivatives between 
the proteins, this would suggest that different curcumin derivatives will have 
differing efficacies dependent on the protein of interest, and these would need to 
be carefully designed and optimised for each individual amyloidogenic protein. 
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Curcumin S ignificance Over 
Lysozyme Only 
S ignificance Over Natural 
Curcumin 
Natural Curcumin Not available (N/A) N/A 
Derivative 1 - N/A 
Derivative 2 - N/A 
Derivative 3 - N/A 
Derivative 4 P=0.0202 N/A 
Derivative 5 P=0.0049 N/A 
Derivative 6 - N/A 
Derivative 7 P=0.0008 N/A 
Derivative 8 P=0.0492 N/A 
Derivative 9 P=0.0013 N/A 
Derivative 10 - N/A 
Derivative 11 - N/A 
Derivative 12 P=0.0155 N/A 
Derivative 13 - N/A 
Table 4.3:  S ignificance of Curcumin Derivatives Anti-Amyloid Aggregation 
Propensity Over Lysozyme Alone or Natural Curcumin. 
P values were determined using Kruskall-Wallis and post-hoc Conover-Inman 
statistical analysis.  Table cells without stated P values (-) were not significant. 
N/A is stated where statistical analysis could not be performed due to low n 
numbers. 
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4.3.3  Curcumin S lows the Time-Induced Autoproteolytic Fragmentation of 
Monomeric αS yn 
To investigate the mode of action of curcumin and its derivatives in reducing αsyn 
aggregation, a range of mass spectrometry experiments were performed.  WT 
αsyn was dissolved in 50mM ammonium acetate with equimolar natural curcumin 
or one of the 13 derivatives, dissolved in DMS O with a final concentration of 1%, 
and subjected to positive ion mode E S I-IMS -MS .  Mass spectrometry in this 
section was performed with a cone voltage of 45V, source temperature 60 C˚ , 
Trap DC Bias 45, backing pressure 4.34e0, trap 15.0 and transfer 20.0. 
As shown in figure 4.4, after immediate addition of curcumin or derivatives 5 or 
7, no immediate mass shift was observed and no new ions corresponding to the 
protein bound to one or more curcumin molecules were detected.  The same lack 
of binding was observed for all 13 derivatives tested, as shown in appendix 4B.  
This would indicate that these curcumin molecules do not readily bind to either 
the extended or compact monomeric αsyn conformations within these samples.  
1
5
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Figure 4.4.  E S I-IMS -MS  S pectra of WT αsyn with Natural Curcumin, Derivative 5 and Derivative 7.  
Positive ion mode E S I-IMS -MS  of 70µM WT αsyn in 50mM ammonium acetate with 1% DMS O, with or without the presence of equimolar 
curcumins. A) WT αsyn, B) WT αsyn + natural curcumin, C) WT αsyn + derivative 5, D) WT αsyn + derivative 7. 
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Ion mobility data was examined to investigate if any conformational changes had 
occurred to the protein, despite the apparent lack of binding.  Individual peaks 
were selected from the drift scope plot and exported to mass lynx separately to 
avoid any overlapping drift times from other CS Is.  No alterations to the extended 
conformations of the protein, within the higher CS Is, were observed, determined 
by alterations to the protein’s ATDs upon immediate addition of either natural 
curcumin or derivatives 5 and 7, as shown in appendix 4C .  However, when the 
compact states were examined, a decrease in the most compact states present 
within these CS Is was observed, as shown in figure 4.5, via Gaussian fitting to 
the +6 CS I.   
This decrease in the compact state suggests curcumin, despite not extensively 
binding to the monomeric protein, may be influencing the equilibrium of the 
conformations observed within the more compact CS Is.  The observed reduction 
in percentage of the most compact species from 16.88% of the total protein at 
CS I +6, in the presence of DMS O alone, is most pronounced with derivative 
number 5, where a reduction to just 2.78% is observed, in comparison to 13.90% 
with natural curcumin.   
To investigate any potential delayed changes to binding or the oxidation state of 
the protein, repeat spectra were acquired over time.  S amples were left at room 
temperature for 48h, for further investigation by E S I-IMS -MS .  Ion mobility data 
was again examined, and no notable differences in conformational equilibrium 
were observed for the extended CS Is +14 to +10 (appendix 4D), equivalent to 
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that observed at time zero.  There were also little differences observed at the 
compact CS Is in comparison to the time zero findings.  As shown in figure 4.6, 
and table 4.4, at the +6 CS I, the proportion of the most compact conformation, H, 
had increased in the apo sample, and again samples containing curcumin or 
derivatives had a decreased proportion of the protein present in this 
conformation.  
At this time point, derivative 7 appeared to be the most efficient at reducing the 
compact states.  An increase in the most compact conformation, H, is observed 
in the curcumin free samples with a percentage of 48.83% of the total protein, in 
comparison to just 16.88 at t=0, whereas in the presence of natural curcumin this 
conformation is reduced to just 17.49%, and with derivatives 5 and 7 to 17.16% 
and 10.28% respectively.  This suggests that, despite a lack of binding to the 
protein, the altered solution conditions brought about by the curcumin is reducing 
the proportion of the more amyloidogenic conformations within the sample, and 
shifting the equilibrium in favour of the more extended, less amyloidogenic states. 
No additional adduct peaks were observed at any time point and, as shown in 
figure 4.7, after 48hrs of incubation peaks corresponding to bound protein were 
still absent from the spectra.  No other mass shifts were identified on any CS Is. 
The conformational alterations to the +6 CS I, at both time points, have been 
tabulated for comparison in table 4.4 after the figures. 
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F igure 4.5: ATDs of the +6 CS I of αS yn upon Immediate Addition of Curcumins. 
Gaussian fitting was performed on the +6 charge state ion of WT αsyn after 
immediate addition of A) 1% DMS O, B) 1% DMS O + equimolar natural curcumin, 
C ) 1% DMS O + equimolar derivative 5, and D) 1% DMS O + equimolar derivative 
7.  Conformations F , G, H. 
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F igure 4.6: ATDs of the +6 CS I of αS yn after 48hrs Incubation with C urcumins. 
Gaussian fitting was performed on the +6 charge state ion of WT αsyn after 48hrs 
incubation with A) 1% DMS O, B) 1% DMS O + equimolar natural curcumin, C ) 1% 
DMS O + equimolar derivative 5, and D) 1% DMS O + equimolar derivative 7.  
C onformations F , G, H. 
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 t=0hrs t=48hrs 
 F  G H F  G H 
Untreated 26.28% 56.83% 16.88%    9.17% 41.99% 48.83% 
Curcumin 22.06% 64.04% 13.90% 26.93% 55.58% 17.49% 
Derivative 5 34.14% 63.08% 2.78% 16.47% 66.38% 17.16% 
Derivative 7 27.43% 67.42% 5.16% 9.86% 79.86% 10.28% 
Table 4.4:  ATD alterations to +6 CS I of WT αS yn in the Presence of Curcumins. 
ATDs are shown as a percentage of each conformation present within the +6 CS I 
of WT αsyn, after immediate addition and following 48hrs incubation with 
curcumin, or derivatives 5 or 7. Conformations F , G & H. 
 
It was also observed during these experiments that the addition of curcumin and 
its derivatives appear to prevent the autoproteolytic fragmentation of the protein 
observed after 48hrs in the absence of curcumin, also shown in figure 4.7. 
In the sample containing 1% DMS O, fragment ions can be observed between the 
usual monomeric and dimeric protein CS Is observed, at m/z 1011.35 and 
1348.13.  These two fragment ions are of a higher intensity than any of the 
monomeric peaks in the protein only spectra at this time point, and these have 
been highlighted in grey boxes on figure 4.7, on the following page.   
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F igure 4.7:  E S I-IMS -MS  S pectra of WT αS yn after 48hr Incubation with Curcumins. 
E S I-IMS -MS  of 70µM WT αsyn in 50mM ammonium acetate with 1% DMS O, with or without the presence of equimolar curcumin after 48hrs 
incubation at room temperature. A) WT αsyn, B) WT αsyn + natural curcumin, C) WT αsyn + derivative 5, D) WT αsyn + derivative 7.  Novel 
fragment ions, highlighted in grey boxes, can be observed. 
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The most intense of the fragment peaks, with a predicted m/z of 1011.39 
represents the +4 CS I of a fragment comprised of amino acid residues 1-39, and 
the second, with a predicted m/z of 1348.19 represents the +3 CS I of the same 
protein fragment.  This region of the protein includes the N-terminus, its 
acetylation site, and one of the protein’s copper binding sites.   
In the sample containing natural curcumin, the intensity of this peak relative to 
the +11 CS I of αsyn is greatly reduced.  The intensity of the fragment ion peaks 
is then further reduced in the samples containing derivatives 5 and 7, relative to 
the +11 CS I, with derivative 5 appearing to reduce the intensity of the fragment 
ions more than derivative 7.  This suggests that the curcumin molecules may be 
protecting the αsyn monomer from autoproteolytic fragmentation.  
Other alternative fragment ions are also observed within the spectra and are of 
lower intensity than any of the intact protein peaks, these are listed in table 4.5.  
Despite a peptide fragment of aa1-18 being observed, no corresponding 
fragment of aa19-140 was detected.  This may be due to further proteolysis of 
the 19-140 fragment into smaller sections, which are below the limit of detection, 
or further aggregation of this fragment.  
Lower intensity fragment ions, are still reduced relative to the full-length protein 
in the presence of natural curcumin, or derivative numbers 5 and 7, akin to the 1-
39 fragment ions, with derivative 5 appearing to show a greater reduction.  No 
binding of any of the curcumin derivatives was observed to any of the fragment 
ions detected.   
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Observed Mass 
R ange (m/z) 
Predicted Mass 
(m/z) 
Charge S tate Ion Amino Acid 
R esidues 
941.55-941.56 941.56 +2 1-18 
1011.35-1011.61 1011.39 +4 1-39 
1305.46-1305.59 1305.54 +8 40-140 
1348.13-1348.15 1348.19 +3 1-39 
1491.94-1492.11 1491.9 +7 40-139 
1740.45-1740.83 1740.38 +6 40-139 
2088.11-2088.37 2088.26 +5 40-139 
Table 4.5: Fragment ions of WT αsyn observed by E S I-IMS -MS  after 48hrs 
Incubation with Curcumins. 
F ragment ions of 70µM WT αsyn observed by E S I-IMS -MS  after 48hrs incubation 
with or without natural curcumin or derivative 5 or 7, at room temperature.  
 
 
4.3.4  Curcumin S electively Binds to Oligomeric S pecies of αsyn 
Increasing evidence from in vitro and in vivo studies, suggest that it is in fact the 
oligomeric species causing neurotoxicity in PD rather than the mature amyloid 
fibrils themselves (Glabe and Kayed, 2006; Karpinar et al., 2009; Winner et al., 
2011; Martin et al., 2012; Danzer et al., 2009; Danzer et al., 2007), therefore 
curcumin and the derivatives acting upon these species, rather than the 
monomeric protein, could be advantageous for its potential role as a curative or 
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preventative treatment.  As curcumin and its derivatives cannot be observed to 
bind to the monomeric protein under mass spectrometry conditions, it was 
hypothesised that it may be exerting its effect on the oligomeric species, as has 
been suggested in previous studies (S ingh et al., 2013).        
WT αsyn was dissolved in 50mM ammonium acetate to a final concentration of 
70µM, and curcumin was added in ethanol to a final concentration of 70µM with 
10% E tOH.  As shown in appendix 4E , there is no visible difference between drift 
scope mobilograms or mass spectra of WT αsyn alone or WT αsyn with the 
addition of E tOH, indicating there are no gross effects on CS D or conformation 
brought about by the solvent, and no alterations to CS D were observed. 
At this relatively high protein concentration, and under E S I-IMS -MS  conditions 
described earlier in the chapter, WT αsyn monomers display a CS D of +18 to +4 
CS Is.  Low order oligomeric species including dimers, with a CS D of +7 to +23, 
trimers with a distribution of +10 to +17 and a single tetramer of CS I +15 can also 
be observed in the higher m/z ranges.  The appearance of lower order oligomeric 
species is likely due to the higher protein concentrations utilised in these 
experiments, which were chosen because they can induce aggregation and the 
formation of oligomers.  The m/z range of the drift scope mobilogram containing 
the most distinguishable oligomeric species, m/z 1800-5000, has been expanded 
in figure 4.8, where monomeric and oligomeric species have been labelled with 
numbers corresponding to the number of monomers in the protein complex.    
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F igure 4.8: Drift S cope Plot of 70µM αS yn S howing Oligomeric S pecies Present. 
E S I-IMS -MS  of 70µM αS yn in 50mM ammonium acetate shows species ranging 
from monomers to tetramers within the drift scope mobilogram, labelled by the 
number corresponding to the number of monomers within the protein complex. 
 
Upon immediate addition of equimolar curcumin, novel peaks could be detected 
within the drift scope plot, next to the dimer peaks represented by CS Is +9 to +12, 
as shown in figure 4.9, where they have been highlighted in white boxes.  These 
peaks also include the monomer peaks corresponding to the +5 and +6 CS Is, as 
they co-populate both monomers and dimers.  Dimers, trimers and tetramers 
were also reduced in intensity within the drift scope mobilogram in the presence 
of equimolar curcumin, as shown in figure 4.10, which suggests that those 
present in the sample prior to addition of curcumin may have been dissociated. 
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F igure 4.9:   Drift S cope of 70µM WT αS yn and 10% E TOH, With and Without 
C urcumin. 
A) 70µM WT αsyn + 10% E TOH, B) 70µM WT αsyn + 10% E TOH + 70µM natural 
curcumin.  Upon addition of equimolar curcumin, novel peaks (indicated by white 
arrows) can be detected next to the monomer/dimer peaks of CS Is +5/+10 and 
+6/+12, and the dimer peaks of CS Is +9, which have been highlighted in white 
rectangles, and a reduction in intensity of oligomeric species was observed.  
A 
B 
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Mass spectra were extracted from the drift scope mobilogram, and peaks 
corresponding to bound curcumin were visible at the dimer CS Is of +9 and +11, 
and the monomer/dimer peaks of +5/+10 and +6/+12, as shown in figure 4.11.    
 
F igure 4.10: E xtracted monomer and dimer spectra peaks of 70µM WT αS yn in 
50mM Ammonium Acetate, with and without Curcumin. 
E xtracted spectra peaks of the +8 monomer/+15 dimer CS I and the +5 
monomer/+9 dimer CS I, demonstrating a reduction in peak intensity of the 
dimeric species, highlighted with arrows, over the untreated protein (A), after, B) 
immediate addition of equimolar curcumin and C ) after 8hrs incubation with 
equimolar curcumin. Dotted lines highlight dimer peak intensity. 
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F igure 4.11: E xtracted E S I-IMS -MS  peaks of 70µM WT αS yn in 50mM ammonium acetate + 10% E tOH, with or without addition 
of 70µM curcumin.  
E xtracted E S I-IMS -MS  spectra peaks demonstrating the binding of curcumin to dimeric species of WT αS yn, at CS Is; A) +6/+12 
monomer/dimer, B) +11 dimer, C) +5/+10 monomer/dimer, D) +9 dimer, E ) +6/+12 + curcumin, F ) +11 + curcumin, G) +5/+10 + 
curcumin, H) +9 + curcumin. 
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The isotopic distribution of the bound protein in close proximity to the 
monomer/dimer peaks containing the +5/+10 and +6/+12 CS Is were calculated, 
with a spacing of 0.1 Da and 0.08 Da respectively.  These were determined to 
correspond to +10 and +12 CS Is, confirming that curcumin was bound exclusively 
to the dimeric species within the sample as opposed to the monomers at these 
CS Is.   
 
 
Monomer/Dimer 
Peak (m/z) 
Predicted 
Mass 
Mono + 1 
Curcumin 
Predicted 
Mass 
Mono + 2 
Curcumin 
Predicted 
Mass 
Dimer + 1 
Curcumin 
Predicted 
Mass 
Dimer + 2 
Curcumin 
Observed 
Mass 
2411.57 2472.40 2533.79 2441.70 2472.40 2472.78 
2630.72   2663.58 2697.69 2664.13 
2983.83 2966.68 2965.88 2929.84 2966.68 2930.68 
3215.12   3255.26 3296.20 3256.22 
Table 4.6:  Predicted and Observed Masses of αS yn Monomers and Dimers. 
Predicted and observed masses of monomers and dimers at CS Is +6/+12, +11, 
+5/+10 and +9, in the m/z range 2400-3400 bound to one or two molecules of 
natural curcumin. Predicted masses which have been identified within the spectra 
are highlighted in green. 
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As highlighted in table 4.6, the majority of the dimers bound one curcumin 
molecule, whereas the dimer under the +6/+12 monomer/dimer peak appeared 
to bind two molecules of curcumin. The predicted mass of the dimeric +12 CS I 
bound to one curcumin is 2441.70 and two curcumins is 2472.40, and this 
compares to 2472.78 in the observed data, indicating this dimeric species had 
bound two curcumin molecules, and this oligomeric species may have a higher 
binding affinity for curcumin.   The predicted mass for the +10 dimeric species 
bound to one curcumin is 2929.84 and to two curcumins is 2966.68, and this 
compares to an observed mass of 2930.68, suggesting this dimeric species has 
only bound the one molecule.  This data indicates that the dimeric species are 
able to bind curcumin, and that the different dimers may have different binding 
affinities.  
Ion mobility data was also examined for conformational changes occurring to the 
dimers in the presence of bound curcumin, but no notable alterations to 
conformational equilibria or CCS  were detected in these experiments. 
To investigate whether any further reduction in oligomer peak intensities, or 
increase in curcumin binding to the oligomers could be observed over time, 
samples were incubated at 37 C˚  for 8 hours, before further examination by E S I-
IMS -MS , and the drift scope plot is shown in figure 4.12.  The extended incubation 
resulted in further reduction in the peaks associated with the oligomeric species 
observed between m/z 2000 and 4300.  This demonstrates a time dependent 
effect of the curcumin on the oligomers. 
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F igure 4.12:  Drift S cope of 70μM αsyn in 50mM Ammonium Acetate with 
E quimolar Curcumin, Demonstrating a Reduction in Oligomeric S pecies.  
After 8hrs incubation of 70μM αsyn with equimolar natural curcumin, E S I-IMS -
MS  revealed a further reduction in oligomeric species, indicated by white arrows, 
as observed from the drift scope mobilogram.  A) 70µM WT αsyn + 10% E TOH, 
B) 70µM WT αsyn + 10% E TOH + 70µM natural curcumin. 
 
A 
B 
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Ion mobility data was examined to investigate the conformational changes to the 
oligomers upon curcumin binding after 8h.  The peaks corresponding to the +11 
and +9 dimers were selected individually from the drift scope plots, as they 
contain only bound dimeric species and there is no co population with monomers, 
along with those of their curcumin bound counterparts.  As with the t=0 samples, 
no altered peak shapes were detected in these experiments at t=8hours, 
suggesting no alterations to the dimer conformations had occurred after 8hrs. 
In order to determine if there is dose dependence to the action of curcumin, the 
experiment was repeated using a lower curcumin concentration of 10µM, with 
70µM αsyn.  As shown in appendix 4F , the same reductions in oligomer 
intensities within the drift scope were observed after immediate addition of 
curcumin, and in appendix 4G after 8hrs incubation, demonstrating curcumin is 
effective even when the molarity is 7-fold lower than that of the protein, and there 
were no alterations to the binding pattern of curcumin observed.   
 
 
4.3.5 Curcumin Derivatives Displaying Anti-Amyloid Aggregation Properties Also 
Demonstrate Dissociation of Oligomers 
Curcumin in the previous sections has been shown to disaggregate preformed 
oligomers. To investigate if this mechanism of action was exclusive to natural 
curcumin, a similar experiment was conducted using the two most successful hits 
from the derivative screen, derivatives 5 and 7.  As a control, derivative 11 was 
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also examined to ensure that this loss of signal was not due to changes in 
ionisation brought about by the presence of a small molecule within the sample.  
This compound displayed moderate anti-amyloid activity in vitro, as 
demonstrated by ThT, but it was significantly less effective than natural curcumin    
For the successful derivatives, similar results were obtained as with the native 
curcumin molecule, as shown in figures 4.13 and 4.14.  Upon immediate addition 
of equimolar concentrations of derivative number 5 and 7, shown in figures 4.13 
and 4.14 respectively, dimeric species within the original αsyn sample reduced in 
intensity or disappeared entirely from the drift scope plot, indicating these 
derivatives also have the ability to dissociate pre-formed αsyn oligomeric species. 
When the less successful derivative, number 11, was examined, as shown in 
figure 4.15, upon immediate addition to the αsyn sample, very little difference in 
the signal of the monomeric or dimeric species in the sample was observed.  This 
data would indicate that the loss of the oligomers with natural curcumin and 
derivatives 5 and 7 is due to binding or interaction with the dimers as opposed to 
any ion suppression brought about by the presence of a small molecule in the 
solution. 
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F igure 4.13:  Drift scope plots of WT αsyn and WT αsyn + Derivative 5. 
Drift scope plots of A) WT αsyn + 10% E tOH and B) WT αsyn + 10% E tOH + 
derivative 5, showing a reduction in dimeric species, indicated by white arrows, 
after immediate addition of the derivative.  
 
A 
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F igure 4.14:  Drift scope plots of WT αsyn and WT αsyn + Derivative 7. 
Drift scope plots of A) WT αsyn + 10% E tOH and B) WT αsyn + 10% E tOH + 
derivative 7, showing a reduction in dimeric species, indicated by white arrows, 
after immediate addition of the derivative.  
A 
A 
B 
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F igure 4.15:  Drift scope plots of WT αsyn and WT αsyn + Derivative 11. 
Drift scope plots of A) WT αsyn + 10% E tOH and B) WT αsyn + 10% E tOH + 
derivative 11, showing no reduction in dimeric species, indicated by white arrows, 
after immediate addition of the derivative.  
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4.3.6  Curcumin binds to the NAC R egion of αS yn 
As an accompanying experiment, an αsyn mutant with the NAC  region of aa61 to 
95 removed, was also analysed by E S I-IMS -MS  with and without the presence of 
natural curcumin and derivatives, numbers 5, 7 and 11.  Previous studies have 
suggested that curcumin initially binds to the aliphatic residues found within the 
hydrophobic NAC  region of the protein (Ahmad and Lapidus, 2012; S pinelli et al., 
2015; Gautam et al., 2017).  After the initial interaction, it has been suggested 
that the aromatic ring structures within the curcumin molecule further bind to 
nearby hydrophobic residues (Ahmad and Lapidus, 2012; Gautam et al., 2017).  
This may lead to a decreased hydrophobic surface area on the protein, which has 
previously been suggested as a mechanism for curcumin’s anti-amyloid action 
on oligomeric structures in a previous study into αsyn toxicity (S ingh et al., 2013). 
70µM curcumin or derivative 5 and 7 were added to 70µM αsyn with the NAC  
region deleted.  No binding was observed to any of the peaks in the spectrum, as 
shown in figure 4.16, where the most abundant peak and a more compact peak 
from higher in the spectra, and shown in appendix 4H, where the spectra as a 
whole can be seen. 
This lends further support to previous reports that curcumin specifically binds to 
αsyn within the NAC  region.  This region is known to be essential for the 
aggregation of the protein.  It also demonstrates that there is no non-specific 
interaction between αsyn and the curcumin molecules, as they are not readily 
binding to the monomer or protein with a region essential for aggregation 
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removed.  This suggests that the NAC  region is required for curcumin binding, 
and this interaction only occurs with the dimeric species. 
   
F igure 4.16:  Compact and E xtended CS Is of NAC  αS yn With or Without 
C urcumins. 
E xpanded view of the most abundant and a more compact CS I of NAC deleted 
αsyn in the presence of curcumin, A) αsyn only, B) + equimolar natural curcumin, 
C ) + equimolar derivative 5 and D) + equimolar derivative 7, showing no mass 
shift and no novel peaks. 
A 
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4.4  Discussion 
R esults presented in this chapter demonstrate that curcumin and several 
curcumin derivatives can prevent the aggregation of WT αsyn in vitro, seemingly 
through prevention of autoproteolytic fragmentation and oligomer formation. This 
appears to occur via dissociation of preformed, low-order, early oligomeric 
species such as dimers, and prevention of further aggregation, as described in 
sections 4.2.4 and 4.2.5. 
ThT assays were performed to determine the anti-amyloid propensity of natural 
curcumin and 13 derivatives, on both WT αsyn and a second amyloidogenic 
protein, lysozyme.  The proposed mechanism of action of ThT is to bind to the β-
sheet structures in amyloid aggregates, resulting in a red shift in λmax, and an 
increase in fluorescence signal intensity.  Curcumin and its derivatives are known 
to exhibit intrinsic fluorescence, therefore their use in ThT assays has been 
questioned (Hudson et al., 2009), however the technique is still commonly used 
and reliable, provided appropriate control measures have been taken 
(Y anagisawa et al., 2015; Lin et al., 2013; J iang et al., 2012; Pall et al., 2016; 
Mirhashemi, 2012).  Due to the nature of the experiments reported here, any 
increase in signal resulting from the curcumin or its derivatives binding to amyloid 
fibrils would result in aberrantly high signals.  This would mean a false negative, 
as opposed to false low readings or false positives.  High fluorescence readings 
would still indicate that amyloid material had been formed and the curcumin 
derivative was non-functional in its ability to prevent aggregation.  S o, while some 
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potential hits may have been missed via this method, due to their intrinsic 
fluorescence, those which are producing lower readings can still be considered 
successful inhibitors of aggregation.  Initial fluorescence readings were also 
taken at t=0 and subtracted from the end point readings, to control for the 
curcumin’s intrinsic fluorescence.   
These aggregation studies, initially suggested that natural curcumin and several 
derivatives of the natural molecule, can inhibit the aggregation of both WT αsyn 
and, lysozyme, in vitro, with varying degrees of success, dependent on their 
structure.  Not all curcumin derivatives were successful inhibitors however, and 
derivative 4 in particular caused a significant increase in signal when compared 
to WT αsyn alone.  The derivatives had different patterns of inhibition for the two 
proteins investigated, suggesting that different curcumin derivatives will have 
different efficacies depending on the amyloidogenic protein of interest.  In the 
case of αsyn, most derivatives significantly reduced the aggregate formation as 
detected by fluorescence readings in comparison to the protein alone sample, 
whereas derivative 4 significantly increased the formation of aggregates, and 
derivative 6 caused no significant alterations either way.  Derivatives 5, 7 and 9 
significantly reduced aggregate formation in comparison to natural curcumin 
(p<0.0001, p<0.0001, and p<0.005 respectively), indicating these may be more 
effective anti-aggregation drugs for αsyn than the natural molecule.   
S tructurally it has been suggested that two aromatic groups separated by a planar 
backbone are essential for inhibition of aggregation of Aβ (J ha et al., 2016), and 
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hydrogenation at conjugated double bonds of the central 7 carbon atoms in the 
backbone has been demonstrated to be important for curcumin’s antioxidant 
properties.  The natural molecule contains a phenolic group (-OH) at position-4 
on the aromatic ring structures, and a methoxyl group (-OCH3) at position-5.  
Both derivatives 5 and 7 also contain the phenolic group at position-3 on the 
aromatic rings, whereas the less successful modulators of aggregation do not, 
indicating that this must be a key feature for more successful aggregation 
inhibition.  Derivative number 5 also contains an extra aromatic group in the form 
of a benzene ring at position-4 and position-5 of the natively occurring aromatic 
group, whereas derivative 7 contains a nitro group (-NO2) at position-4, both 
these modifications also appear to increase the molecule’s anti-aggregation 
propensity.  Derivative number 9 however does not contain the usual benzene 
ring group, but instead contains a furan ring, or pentene ring containing an oxygen 
atom at position-4, with a methyl group at position-3.   
Interestingly, derivatives 1, 2 and 3 all also significantly reduced the aggregation 
of αsyn in comparison to the protein alone sample.  These derivatives all have an 
oxygen atom bound to position-5 of the aromatic group, attached to a 
hydrocarbon chain of 1 to 3 carbon atoms, increasing with derivative number.  
Derivatives 1 and 2 have a similar effect, whereas derivative 3 demonstrated the 
largest reduction in aggregation.  Derivative 4 however, which showed a 
significant increase in aggregation, has the same general structure as derivatives 
1-3, but the oxygen is on a hydrocarbon chain of 4 carbon atoms, suggesting that 
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the length of this chain may also be important for anti-amyloid propensity, and 
when the length is increased over 3 carbon atoms the chain may be too long for 
the interactions with the protein to take place.  It is possible the molecule no 
longer fits into the space between the β-sheets formed during aggregation.  This 
does not appear to be the case with lysozyme however, as derivative 4 caused a 
decrease in aggregation of this protein. 
In terms of lysozyme, no derivatives appeared more successful at inhibiting 
aggregation than natural curcumin, and significance could not be determined due 
to low experimental repeats, however derivatives 5, 7 and 9 again were the most 
effective inhibitors, significantly reducing the fluorescence signal in comparison 
to the protein alone sample (p<0.001, p<0.005 and p<0.001, respectively), which 
again indicates that some modifications of the natural molecule are more 
successful at inhibiting amyloid aggregation than others.  The different actions of 
the derivatives presented here suggests that careful redesign of curcumin 
derivatives should allow for more successful inhibition of aggregation of several 
different amyloid proteins, and different derivatives will have varied degrees of 
success dependent on the protein of interest.   
Natural curcumin has previously been demonstrated to slow the aggregation of 
αsyn in vitro using the ThT assay in a number of studies, at varying 
concentrations including 2:1 curcumin to protein ratio (Wang et al., 2010), 1.5:1 
curcumin to protein ratio (Ahmad and Lapidus, 2012) and equimolar 
concentrations (Herva et al., 2014; Ahsan et al., 2015), where a curcumin 
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derivative, N-(3-nitrophenylpyrazole), was also found to have a similar effect  on 
aggregation (Ahsan et al., 2015).  N-(3-nitrophenylpyrazole) has two nitrogen 
atoms in place of the oxygens on the planar backbone, one of which is also 
bonded to a benzene ring with a nitro group at position-4.  A range of curcumin 
analogues have also been investigated by another group, however this study 
determined the rate of aggregation to increase in the presence of curcumins (J ha 
et al., 2016).  This was concluded by the authors to be due to differing buffer 
conditions used between different research groups, as αsyn aggregation is highly 
affected by its solution conditions as previously noted, and all studies have been 
completed under different assay conditions, though all at physiologically relevant 
pH.  ThT was also absent from the samples containing curcumin in the J ha et al. 
study, so this may have had some effect on the results, as they were relying on 
the fluorescence of the curcumin molecule alone as an indicator of aggregation, 
as opposed to the β-sheet detection of ThT.  S imilar findings from another group 
have also suggested curcumin does not inhibit the aggregation of the Aβ protein, 
but increases the formation of “off-pathway” soluble, non-toxic oligomeric species 
(Y ang et al., 2005), and this has also been demonstrated with IAPP (Nedumpully-
Govindan et al., 2016).  The mechanism of the effect of curcumins on the 
conformation of IAPP may again have been affected by solution conditions, which 
is an ongoing problem in research into intrinsically disordered proteins as they 
are highly sensitive to solution conditions, as previously discussed.  Results 
presented in this chapter however, lend support to findings from the previously 
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mentioned work (Wang et al., 2010; Ahmad and Lapidus, 2012; Ahsan et al., 
2015; Herva et al., 2014) determining that curcumin slows the aggregation of 
αsyn in vitro.   
Aggregation of lysozyme has also previously been observed to slow in the 
presence of natural curcumin using the ThT assay, where curcumin to protein 
ratios ranging from 0.5:1 to 5:1 demonstrated increasing effectiveness with an 
increase in curcumin concentration (Borana et al., 2014).  Natural curcumin has 
also been demonstrated to reduce the aggregation of the prion protein PrP in vitro 
using ThT assays, where in the presence of curcumin, a 6-fold reduction in 
fluorescence was observed (Hafner-Bratkovič et al., 2008).  Curcumin has also 
been observed to slow the aggregation of the Aβ protein in vitro in a number of 
studies (Y ang et al., 2005; Ono et al., 2004), suggesting that curcumin has anti-
aggregation properties against a variety of amyloid forming proteins.  As there 
are conflicting results from research groups however, care must be taken in 
interpreting results, and careful experimental design should be applied to keep 
solution conditions as close to physiologically relevant conditions as possible 
when investigating novel drug candidates. 
R esults presented in this chapter demonstrate that curcumin and derivatives 5 
and 7 appear to slow the autoproteolytic fragmentation of WT αsyn observed by 
E S I-IMS -MS  after 48hours, which may be one mechanism by which it is exerting 
its anti-amyloidogenic properties.  The most prolific fragments observed in the 
sample without curcumin were N-terminal truncations consisting of the first 39 
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amino acids.  This fragment does not form part of the NAC  region, and is therefore 
unlikely to be able to aggregate itself.  It is also conserved in β-synuclein, which 
is known not to aggregate (Tsigelny et al., 2007). 
The counterpart fragment of aa40-140 however does contain the NAC region, 
along with the highly disordered C-terminal region containing the phosphorylation 
and some metal binding sites, and is susceptible to aggregation.  The cleavage 
of this region of the protein may be essential for further aggregation, suggested 
by the much lower intensity of this fragment within the sample, which indicates 
that this region may have aggregated into higher order species.  The prominent 
aa1-39 fragments observed within these experiments would also not be expected 
to aggregate, as they also do not contain the NAC  region.  The cleavage of this 
N-terminal region may however be essential for the remaining region containing 
the important NAC component to begin the nucleation step necessary for 
aggregation to progress.   
Autoproteolysis of αsyn has been suggested to be a key part of the 
oligomerisation process, and several fragments formed during the aggregation 
process have previously been identified using techniques such as gel 
electrophoresis, E S I-IMS -MS  and MALDI-MS  (Vlad et al., 2011).  F ragment aa40-
140 has previously been observed using E S I-IMS -MS  (Vlad et al., 2011), though 
it was not determined to be of importance to aggregation in this study and was 
not examined further than identification via electrophoresis.  The same 
investigations did however deem fragment aa72-140 to be of particular 
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importance, demonstrating increased aggregation when examined via IMS -MS  
(Vlad et al., 2011).   F ragments of αsyn have also been demonstrated previously 
to be intrinsically amyloidogenic.  Data presented here indicates that curcumin 
and its derivatives have the ability to prevent autolytic cleavage of αsyn and 
appears to correlate with their ability to prevent amyloid formation, as both 
derivatives 5 and 7 were also demonstrated to prevent fragmentation, reduce the 
formation of amyloid material as demonstrated by ThT assay data, and dissociate 
oligomers as shown by E S I-IMS -MS . 
These initial E S I-IMS -MS  experiments, presented in section 4.3.3, and the ThT 
assay data presented in section 4.3.2, were performed with curcumin dissolved 
in DMS O.  DMS O is generally considered an unsuitable solvent for proteins, as 
it can affect the protein’s conformational distribution, and increased 
concentrations have been shown to denature and unfold proteins, such as 
lysozyme and myoglobin, though this has been documented to occur in higher 
DMS O concentrations than used here (Arakawa et al., 2007; J ackson and 
Mantsch, 1991).  It was observed that the presence of DMS O in the E S I-IMS -MS  
samples was supressing the most extended CS Is of the protein, as shown in 
figure 4.17.  S pecifically, CS Is +15 to +17 are absent from the spectra entirely, 
and CS Is +14 and +13 are at a much lower intensity than in the DMS O free 
sample, with a shift of the dominant extended CS I from +13 to +11, and a shift of 
the dominant compact CS I from +7 to +6 in the presence of a final concentration 
of 1% DMS O.   
1
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F igure 4.17:  S pectra showing suppression of extended CS Is by DMS O. 
E S I-IMS -MS  spectra of A) 70μM αsyn in 50mM ammonium acetate + 1% 
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Due to this suppression, all future E S I-IMS -MS  spectra were acquired using 
curcumin dissolved in a final concentration of 10% E tOH.  The presence of 20% 
E tOH is known to increase the rate of amyloid formation, and is utilised in 
protocols when synthesising pathogenic oligomers from monomeric αsyn (Illes-
Toth et al., 2015; Danzer et al., 2007; R oberts and Brown, 2015).  Therefore, any 
interference from E tOH would be expected to enhance oligomeric species as 
opposed to repress them. 
These later E S I-IMS -MS  experiments concluded that curcumin and the 
derivatives were not binding to the monomeric protein, rather they were exerting 
their effect on the oligomeric species present within the sample.   
Binding of one or more curcumins could be observed to dimeric species within 
the sample, and this led to a decrease in dimer and trimer intensities as observed 
within the drift scope mobilograms.   
There is a possibility that the oligomeric species disappear in the presence of 
curcumin as they are aggregating into higher order oligomers and fibrils as a 
protective mechanism, which has been previously suggested as a mechanism for 
dealing with the presence of misfolded amyloid proteins, however this does not 
correlate with the results obtained by ThT assay, where a decrease in signal, 
indicative of a lack of higher order amyloid material, was observed.  It has been 
previously reported that curcumins may cause aggregation into soluble, less 
toxic, off-pathway oligomeric species as protective mechanism (Y ang et al. 2005; 
Nedumpully-Govindan et al., 2016; J ha et al., 2016).  However, no higher order 
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oligomeric species were observed by E S I-IMS -MS  in these experiments, 
suggesting the most likely mechanism of action observed here to be dissociation 
of oligomers and prevention of further assembly, through processes such as 
halting autoproteolytic fragmentation. 
It must also be considered that both the generation and disappearance of these 
oligomeric species could be a product of the electrospray process and transition 
into the gas phase.  As previously discussed in chapters 1 and 3, the 
conformation of IDPs such as αsyn can be affected in the gas phase, causing the 
generation of protein species not present in solution conditions (Borysik et al., 
2015; Pagel et al., 2013; S aikusa et al., 2013).  However, the more folded and 
globular a protein, the more stable it is in the gas-phase (S carff et al., 2008; 
S aikusa et al., 2013), therefore these structures would be less likely to be affected 
than monomeric species.  E xperiments were also repeated a number of times 
with the same result observed, lending support to the data presented here.  It is 
possible however that the binding of monomeric αsyn and curcumin did not 
survive transition into the gas-phase, and this could be why binding to the 
monomeric form was not observed in these experiments. 
Previous studies from other research groups have also suggested that curcumin 
only binds to oligomeric forms of αsyn, in keeping with results presented in this 
chapter.  S ingh et al. used hydrogen-deuterium exchange to demonstrate a weak 
association of LMW (50-100kDa) αsyn oligomers with curcumin, where no 
association with monomeric 14kDa protein was observed.  The authors did not 
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observe any binding to the monomer by AFM, S E C Chromatography or S DS -
PAGE  analysis, but did again observe binding to oligomers and mature fibrils 
(S ingh et al., 2013).  This study did not however report any dissociation of the 
preformed species into monomeric protein.  Data recently presented by Ahmad 
and Lapidus however, reported that curcumin strongly bound to the monomeric 
protein, detected by a variety of optical absorbance and fluorescence methods 
(Ahmad and Lapidus, 2012).  The altered morphology of the oligomeric species 
observed within these studies, corresponds with results from E S I-IMS -MS  
experiments reported in section 4.3.3, where a decrease in the more aggregation 
prone compact CS Is was observed.  Curcumin has also previously been 
observed to bind to oligomeric and fibrillar species of the Aβ protein (Y anagisawa 
et al., 2011).  Due to the nature of these previously explored techniques, and the 
high specificity of mass spectrometry in comparison, data presented in this 
chapter indicates that curcumin has a disaggregating mechanism of action 
towards lower order oligomeric species. 
F inally, it was also deduced that curcumin cannot bind to αsyn when the NAC  
region is deleted, indicating this is the binding region for the molecule.  This was 
unsurprising as the molecules do not appear to bind to the monomeric protein, 
but lends support to previous reports suggesting that this region is important for 
the binding of curcumin, and essential for the aggregation of the protein (Giasson 
et al., 2001; Ahmad and Lapidus, 2012). 
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4.5  Conclusions 
Collective evidence presented in this chapter demonstrates that the anti-fibrillary 
properties of curcumins can operate with multiple amyloid proteins, and suggests 
the polyphenolic compound could therefore hold potential as a therapeutic for a 
number of different but related amyloid diseases.  Data presented in this section 
demonstrates that some curcumin derivatives, in particular numbers 5 and 7, 
have increased anti-fibrillary effects in comparison to the native compound, as 
observed by the ThT assay screen. These derivatives have also been 
demonstrated to influence amyloid formation by both αsyn and lysozyme.  They 
follow a similar but not identical pattern in their inhibition, indicating that different 
curcumin derivatives have similar effects on aggregate formation, but differ in 
their effectiveness between different proteins.  Activity of the derivatives is related 
to their structures and, within these experiments, the most successful candidates 
against αsyn all contain an –OH group attached to the benzene ring at position-
3, suggesting this to be important for its anti-fibrillary properties against αsyn at 
least.  The development of curcumin derivatives as viable drug candidates is also 
greatly hindered by their poor bioavailability.  S ynthesising novel curcumin 
compounds with increased activity and increased bioavailability is therefore a 
potential viable method for future amyloid targeting therapeutics. 
The proposed mechanisms of interaction between curcumins and αsyn, and how 
this affects the amyloid aggregation of the protein can be seen in figure 4.17.  
Overall data presented here demonstrates curcumin and its derivatives slow and 
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prevent the aggregation of αsyn in vitro, and it appears this mechanism is related 
to both reducing the fragmentation of the protein, and binding to pre-formed 
oligomeric species such as dimers, dissociating the protein complexes and thus 
preventing their further aggregation into amyloid material. 
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F igure 4.17:  Proposed Mechanism of Curcumin Action. 
Proposed mechanism of curcumin’s interaction with the amyloid aggregation 
pathway of WT αsyn.  Compact conformations aggregate into lower-order 
oligomeric species including dimers.   Curcumin is proposed to bind to dimeric α
syn within the region highlighted in a dashed blue oval, leading to the dissociation 
of these dimeric species back into monomeric protein, thus preventing the usual 
further aggregation into higher order oligomers, protofibrils, then mature amyloid 
fibrils. 
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Chapter 5 - Cellular R esponses to Cu(II) and Curcumin 
Treatment 
5.1  Introduction 
Understanding how αsyn interacts with ligands, such as metal ions and curcumin 
in solution, provides a wealth of useful information on both the structure of the 
complexes and alterations to the protein's aggregation propensity.  However, to 
understand these interactions fully, and how they may impact on the pathology 
of diseases such as PD, it is essential to investigate these interactions at the 
cellular level.   
It has been established that the addition of metal ions, such as copper, to the 
media of growing S HS Y 5Y  cells results in the formation of intracellular 
aggregates of αsyn (Wang et al., 2010).  It has however yet to be established 
whether these aggregates are phosphorylated at the potentially pathogenic 
residue of S 129, as is the case for αsyn found in mature LBs of PD patients.   
 
5.1.1  Metal Homeostasis  
Transition metals such as copper, iron, zinc, manganese and cobalt are essential 
for a multitude of regulatory and catalytic roles in the growth of all organisms from 
the micro to the macro scale.  However, excesses of these metals can be toxic, 
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therefore it is essential for organisms to regulate the intracellular levels of these 
metals (J aishankar et al., 2014).   
Metal ions play a vital role in a number of cellular processes, including cell 
structure maintenance, regulation of gene expression, and neurotransmitter 
release (Chen et al., 2016), and transition metals such as copper and iron have 
been shown to be essential co-factors for almost half of known proteins (Waldron 
et al., 2009).  Copper and iron are both intrinsically expressed throughout the 
brain in varied concentrations dependent on the brain region, with high levels 
being observed within the S NPC (Wright et al., 2009). 
Copper is a known cofactor for several cellular proteins, such as cytochrome c 
oxidase, which is involved in the mitochondrial production of ATP, and C u/Zn-
superoxide dismutase (S OD1), which is an antioxidant, with a role in free-radical 
scavenging (S athasiviam and S haw, 2005).  The immune system is known to 
utilise copper as an antimicrobial, with activated macrophages showing a high 
level of copper within the phagosomes used to capture and disable invading 
microbes (Festa and Thiele, 2011).  Cellular levels of copper are mainly regulated 
by copper pumps, the failure of which leads to intracellular accumulation of the 
metal and eventually toxicity and cell death (Arciello et al., 2005). 
Almost all cells require iron for activities such as oxygen transport, energy 
metabolism and DNA synthesis.  Iron is essential biochemically due to its redox 
activity however this activity can be prone to the production of oxidative radicals. 
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During Fenton reactions iron cycles between its Fe2+ and Fe3+ states generating 
R OS  such as hydroxyl radicals (Wang and Pantopoulos, 2011).  E levated levels 
of ROS  lead to oxidative stress within the cells, which disrupts cellular processes 
and results in toxicity, therefore cellular iron must also be tightly regulated.  
Ferritin and haem transporters are predominantly used to regulate cellular iron 
levels, and in particular iron bound to ferritin can be transported throughout the 
body for use in a variety of cellular processes (Keel et al., 2008; Wang and 
Pantopoulos, 2011). 
 
5.1.2  αS yn Phosphorylation 
 αS yn has five known phosphorylation sites, S 87, Y 125, S 129, Y 133 and Y 136, 
with these modifications suggested to play roles in processes such as membrane 
binding (Y 125), autophagy (S 129) and proteolytic degradation (S 129) (Tenreiro 
et al. 2014; Machiya et al. 2010; Chau et al. 2009).   Around 90% of αsyn found 
within the LBs of PD patients is found to be phosphorylated at S 129, whereas in 
healthy individuals, only around 4% of the protein has undergone this modification 
at any possible residue, strongly suggesting a pathological role for this particular 
modification (Anderson et al., 2006; Fujiwara et al., 2002).  S tudies aimed at 
determining this pathological role have so far yielded conflicting results, with both 
protective and pathogenic roles for S 129 phosphorylation reported, and it is 
therefore unclear what the role of this modification is, in PD pathogenesis. 
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Four of the five phosphorylation sites are found within the highly disordered C -
terminal region of the protein (Oueslati, 2016), which is also the location of the 
majority of metal binding sites, as shown in figure 1.2 in chapter 1.  It is yet to be 
determined what the effect of phosphorylation, in particular at S 129, and the 
binding of metals to αsyn is on cell viability and protein aggregation in the cellular 
environment, and whether the two events have a synergistic influence on the 
pathogenesis of PD. 
 
5.1.3  S HS Y -5Y  Neuroblastoma Cells as a Model for Neurodegeneration 
The cell line S HS Y -5Y  has been used extensively in PD research due to its 
dopaminergic properties. This neuroblastoma cell line is a subclone of the cell 
line S K-N-S H, which was isolated in the 1970s from a bone marrow biopsy of a 
four year old female with metastatic neuroblastoma, and has undergone three 
rounds of clonal selection to achieve its phenotype (Biedler et al., 1978; X icoy et 
al., 2017).  The cells are known to have dopamine-β-hydroxylase and tyrosine 
hydroxylase activity, and have been demonstrated to convert dopamine to 
norepinephrine in vitro, (Biedler et al., 1978; R oss and Biedler, 1985; X icoy et al., 
2017; S chlachetzki et al., 2013).  Because of their phenotype, these cells have 
been utilised for many years in studies of PD, for example in investigations into 
αsyn aggregation and candidate drug screens, and studies of the role of αsyn in 
DA toxicity (Hasegawa et al., 2004; C olapinto et al., 2006; Wang et al., 2010; 
X icoy et al., 2017).    
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5.2  Aims and Objectives 
E xperiments conducted in this chapter were designed to investigate the links 
between phosphorylation and copper-induced aggregation of αsyn within a 
cellular model.  The main objectives were as follows: 
 To monitor the induced aggregation and cytotoxicity of αsyn following 
metal treatment. 
 To determine if αsyn is phosphorylated within the S H-S Y 5Y  cellular model 
following treatment with copper.  
 To investigate the possible inhibitory effects of natural curcumin on the 
formation of metal induced aggregates.  
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5.3  R esults 
S HS Y 5Y  neuroblastoma cells were exposed to a range of copper concentrations, 
100, 300 and 500μM, for 48 hours.  Immunocytochemistry utilising the antibody 
specific to αsyn residues 121-125 (S yn211), and the antibody specific to αsyn 
phosphorylated at S 129 (phos129) was performed, to determine the effect of 
copper on the intracellular aggregation of αsyn, and the phosphorylation state of 
the protein in these conditions.  Apoptosis and viability of the cells was also 
assessed using DAPI staining and trypan blue dye.   
 
5.3.1  Incubation of S HS Y 5Y  cells with CuC l2 Causes an Increase in the 
Formation of Intracellular Aggregates  
The number of cells containing aggregates was determined by blinding the 
images and counting 200 cells per experimental condition. Three repeat 
experiments were compared for statistical analysis as described in chapter 2.  
Aggregate numbers were averaged and are presented as a percentage of the 
total cell count in figure 5.5.   
E xamples of positively and negatively assigned cells can be observed in figure 
5.1, and an example of a scored dataset can be seen in figure 5.2, both of which 
have been included without the DAPI staining overlay for clarity.   
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F igure 5.1:  E xample of Positively and Negatively Assigned Aggregate S taining 
in S HS Y 5Y  Cells. 
S HS Y 5Y  cells stained with the syn211 antibody to WT αsyn, observed with a 
100x objective. A) Negative cell showing only cytoplasmic staining and B) 
Positive cell showing the presence of intracellular inclusions. 1000x magnification.  
                  
F igure 5.2:  E xample of a S cored S H-S Y 5Y  Dataset. 
Blue dots represent cells marked as negative for aggregates.  Green dots 
represent cells marked as positive for aggregates. Over-exposed cells or those 
not in focus were not scored, as shown, and removed from the dataset. 
A  
"  
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As shown in figure 5.3, when cells were exposed to increasing levels of CuCl2, 
aggregated forms of αsyn, as highlighted on each image with white arrows, can 
be observed within the cells.  These can be seen more clearly in the 100x 
objective example image in figure 5.4.   
  
  
F igure 5.3:  E ffect of Increasing CuCl2 C oncentration on Aggregate Counts in S H-
S Y 5Y  Cells S tained with the S yn211 Antibody. 
S H-S Y 5Y  cells incubated with increasing levels of CuCl2 for 48hrs and stained 
with the syn211 antibody specific to αsyn aa121-125.  A) Untreated, B) 100µM 
C uCl2, C) 300µM CuCl2, D) 500µM CuCl2. White arrows point directly to 
aggregates within select cells in each image.  
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F igure 5.4:  E xample of Aggregate Formation using 100x Objective. 
S H-S Y 5Y  Cells treated with 300µM C uCl2 for 48hrs show formation of punctate 
αsyn aggregates. White arrows point directly to aggregates within the cells. 
1000x magnification. 
 
Positive staining for αsyn within the cytoplasm was observed in all cells, due to 
its intrinsic expression, with the highest intensity being observed ringed around 
the nucleus, as shown in figure 5.1A, in the untreated samples.   
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F igure 5.5: Percentage of S H-S Y 5Y  Cells Containing αS yn Aggregates S tained 
for S yn211, upon Increasing CuC l2 Concentration. 
Percentage of cells containing distinct intracellular aggregates of αsyn after 
exposure to different concentrations of CuC l2 (**=p<0.01, **** = p<0.0001). n=3. 
 
As shown in figure 5.5, an average 26.5± 6.7% of cells in the untreated sample 
contained distinct punctate aggregates of αsyn.  Upon incubation with 100µM 
CuCl2 for 48hrs, a significant (p<0.01) increase in cells containing identifiable 
aggregates to 55.8± 3.8% was observed.  Upon incubation with 300µM CuC l2 a 
significant (p>0.0001) increase in aggregates to 72.3± 8.1% of cells is observed, 
and upon incubation with 500µM CuC l2, a further increase to 86.6 ± 3.1% 
(p<0.0001) was seen.  This suggests that increasing CuC l2 levels in the media, 
increases the aggregate load within the cells. 
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When examining the statistical significance between the different CuCl2 
concentrations, also shown in figure 5.5, a significant increase in the percentage 
of cells containing distinct aggregates is observed between cells incubated with 
100µM CuCl2 and cells incubated with 300µM CuCl2 (p<0.01).  Aggregate 
numbers also significantly increase (p<0.01) in between cells incubated with 
300µM CuC l2 and 500µM CuC l2. This data would also indicate that the extent of 
the aggregation is dose dependent on the amount of copper used to treat the 
cells. 
The intensity of the αsyn fluorescence was quantified using ImageJ  image 
analysis software, as described in section 2.2.5.6, as a means of monitoring the 
expression levels.  As displayed in figure 5.6, a significant increase in corrected 
total cell fluorescence (CTCF ) was observed between the untreated cells and 
those incubated with 300µM CuC l2 (p<0.05), and untreated and cells incubated 
with 500µM CuC l2 (p<0.05).  No significance increase in fluorescence was 
determined between untreated cells and those treated with 100µM CuCl2.  This 
suggests that incubation with 300µM or 500µM CuC l2 causes an increase in the 
expression of αsyn, as determined by increases in the level of fluorescence.  
Image analysis also indicates that at concentrations greater than 300µM CuCl2 
there is no further increase in αsyn expression levels, yet the number of 
identifiable aggregates does increase. Further examples of stained cells utilised 
to determine these aggregation counts and fluorescence intensities can be 
observed in appendix 5A-5D.   
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F igure 5.6:  Image J  Analysis of the F luorescence Intensity of S H-S Y 5Y  Cells 
S tained with the S yn211 Antibody, at Increasing CuC l2 Concentration. 
F luorescence intensity of S H-S Y 5Y  cells incubated with different concentrations 
of CuC l2, stained with the S yn211 αsyn antibody, as determined by quantification 
on ImageJ  image analysis software (*=p<0.05). n=3. 
 
Data presented here suggests that incubation of S H-S Y 5Y  neuroblastoma cells 
with increasing concentrations of CuC l2 results in the formation of intracellular 
aggregates of αsyn, and the percentage of cells containing aggregates increases 
with increased copper concentration.  Data also suggests that the total αsyn level 
expressed within the cells increases after incubation with 300 and 500µM CuC l2, 
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determined by an increase in overall fluorescence, indicating that increased 
aggregate formation is, in part, due to an increase in expression of αsyn.   
 
5.3.2  Incubation of S HS Y 5Y  cells with CuCl2 Causes an Increase in Apoptosis  
To determine whether incubation with copper causes cytotoxicity, cells were also 
examined for signs of apoptosis upon incubation with CuC l2.  Counting measures 
utilised in section 5.3.1 were followed, counting 200 cells per condition and 
examining for signs of apoptosis.  Apoptotic cells were identified, as shown in 
figure 5.7, by expression of one or more of three predetermined signals of 
apoptosis, visible via DAPI staining; chromatin condensation, nuclear elongation 
and nuclear fragmentation.  C ells containing one or more of these signs were 
marked as positive.  Apoptotic cell counts are presented in figure 5.8 as a 
percentage of the total cell count.  
               
F igure 5.7:  S igns of apoptosis in S HS Y 5Y  Cells, V isible With DAPI S taining.  
A) Nuclear condensation, B) Nuclear elongation and C) Nuclear fragmentation. 
Taken using a 100x objective. 1000x times magnification. 
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As shown in figure 5.8, an average 17.7± 2.8% of untreated cells showed signs 
of apoptosis.  The percentage of apoptotic cells increased significantly (p<0.05) 
to 58± 2.7% upon 48hrs incubation with 100µM C uC l2.  Upon incubation with 
300µM CuCl2, a significant (p<0.001) increase to 78.5± 4.3% was observed.  No 
further increase in apoptotic cell numbers was observed when cells were 
incubated with 500µM CuCl2, with 75.7± 4.0 cells showing one or more signs of 
apoptosis.   
  
F igure 5.8:  Percentage of Cells S howing S igns of Apoptosis after Treatment with 
C uCl2. 
Percentage of cells showing at least one distinct sign of apoptosis after exposure 
to increasing concentrations of CuCl2 (* = p<0.05, ** = p<0.01, *** = p<0.001). 
n=3. 
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As shown in figure 5.8, there is a significant (p<0.01) increase in number of 
apoptotic cells between cells incubated with 100µM CuC l2 and 300µM CuC l2, 
whereas no significant alterations were observed between cells treated with 
300µM CuCl2 and 500µM C uC l2. 
R esults here demonstrate that exposure to CuCl2 induces apoptosis in S HS Y 5Y  
cells after 48hrs incubation, alongside the formation of intracellular aggregates.  
Not all apoptotic cells showed signs of aggregate formation, and not all aggregate 
containing cells showed signs of apoptosis, which may suggest the two 
mechanisms are independent responses to the presence of the metal ions.   
 
5.3.3  Incubation of S H-S Y 5Y  cells with CuCl2 Causes a R eduction in Cell Viability  
Trypan blue dye was used to quantify the level of cell viability following copper 
treatment for 48 hours.  Untreated cells had an average viability of 86.1± 3.9%, 
which was reduced to 57.1± 3.9% (p<0.01) upon incubation with 100µM CuC l2, 
as shown in figure 5.9.  Incubation with 300µM CuC l2 also resulted in a statistically 
significant (p<0.0001) reduction in viability to 48.5± 3.4%, and incubation with 
500µM CuCl2 resulted in a further decrease to just 40.9± 2.3% (p<0.0001). 
When statistical analysis was performed between each different CuCl2 
concentration, as shown in figure 5.9, a significant (p<0.01) decrease in viability 
was observed between both cells incubated with 100 and 300µM CuCl2, and 
between 300 and 500µM CuC l2, suggesting cell viability decreases with exposure 
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to increased CuCl2 concentrations.  This data correlates well with the image 
analysis data and indicates that increasing concentrations of copper result in cell 
death through an apoptotic pathway. 
            
 
 
F igure 5.9: Cell V iability of S H-S Y 5Y  Cells After Incubation with C uCl2. 
C ell viability of S H-S Y 5Y  cells incubated with increasing concentrations of CuCl2 
for 48hrs, shown as percentage of total cells within the sample (** = p<0.01, **** 
= p<0.0001). n=3. 
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5.3.4  Incubation of S HS Y 5Y  cells with CuC l2 Induces Aggregates of αsyn 
Phosphorylated at S erine-129 
To investigate the phosphorylation state of both the intrinsic αsyn, alongside the 
aggregates formed in the presence of CuCl2, S HS Y 5Y  cells were treated with 
copper and stained utilising antibody specific to αsyn phosphorylated at S 129.  
As shown in figure 5.10, there is positive staining for phosphorylated αsyn in all 
experimental conditions, including the cells incubated without copper.  F igure 
5.10A, showing untreated cells, demonstrates a similar pattern of cytoplasmic 
staining to that observed with the cells stained for syn211 in section 5.3.2.  It has 
been reported previously that around 4% of cytosolic αsyn is phosphorylated at 
S 129 in the healthy human brain (Kim et al., 2014), so a small percentage of 
phosphorylated cells would be expected.  However, the untreated cells analysed 
here showed a considerable increase over what was expected. 
Following treatment with copper, mean numbers were again calculated via the 
same counting system employed in section 5.3.1, as shown in figure 5.11 and 
representative images are given in appendices 5E  to 5H. 
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F igure 5.10:  E ffect of Increasing C uCl2 Concentration on Aggregate Counts in 
S H-S Y 5Y  Cells S tained with the Phos129 Antibody. 
S H-S Y 5Y  cells incubated with different concentrations of CuCl2 for 48hrs and 
stained with the phos129 antibody specific to αsyn phosphorylated at serine 129.  
A) Untreated, B) 100µM CuC l2, C ) 300µM CuCl2, D) 500µM CuCl2.  White arrows 
point directly to aggregates within select cells in each image. 
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F igure 5.11:  Percentage of S H-S Y 5Y  Cells Containing αS yn Aggregates S tained 
for Phos129, upon Increasing CuCl2 Concentration. 
Percentage of cells containing distinct intracellular aggregates of phosphorylated 
αsyn after exposure to different concentrations of CuCl2 (* = p<0.05, ** = p<0.01). 
n=3. 
 
As shown in figure 5.11, an average 23± 4.6% of untreated cells contained distinct 
aggregates stained with the phos129 antibody.  Upon incubation with 100µM 
CuCl2, a statistically significant increase (p<0.01) to an average 95.8± 1.6% of 
cells displayed phosphorylated aggregates of αsyn.  Addition of 300µM or 500µM 
CuCl2 resulted in mean cell counts of 93.5± 3.1% (p<0.01) and 95.2 ± 3.5% 
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(p<0.0001) respectively.  A significant increase in cells containing aggregates 
upon increased copper concentration was also noted (p<0.01). 
When the average fluorescence intensities of the cells were calculated using 
Image J  image analysis software, as shown in figure 5.12, a statistically 
significant (p<0.05) increase in fluorescence was observed with all three CuCl2 
concentrations, but no significance was observed between the three 
concentrations.  This again suggests that there is an increase in αsyn expression 
within the cells, measured via an increase in fluorescence intensity, alongside the 
increase in aggregate formation. 
     
 
 
 
 
 
F igure 5.12:  Image J  Analysis of the F luorescence Intensity of S H-S Y 5Y  Cells 
S tained with the Phos129 Antibody, at Increasing CuC l2 Concentrations. 
F luorescence intensity of S H-S Y 5Y  cells incubated with different concentrations 
of CuC l2, stained with the phos129 αsyn antibody, as determined by 
quantification on ImageJ  software (* = p<0.05). n=3. 
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When the aggregate counts between the syn211 and Phos129 
immunocytochemistry experiments are directly compared, as shown in figure 
5.13, there is a significant increase in the percentage of cells containing 
phosphorylated inclusions compared with those stained for unmodified αsyn.   
 
   
F igure 5.13:  Comparison of Cell Percentage C ontaining Inclusions of S yn211 
and Phos129 S tained Aggregates. 
Direct comparison of the number of S H-S Y 5Y  cells containing inclusions 
following incubation with different concentrations of CuCl2. S taining was 
performed with the anti-syn211 or anti-phos129 αsyn antibodies. Percentage of 
cells containing distinct aggregates of αsyn (**=p<0.01, ***=p<0.001, 
****=p<0.0001). n=3. 
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Following incubation with 100µM CuCl2, 55.8± % of 3.6cells stained positive for 
aggregates with the syn211 antibody, however with the phos129 antibody this 
was significantly (p<0.0001) increased to 95.8 ± 1.6%.  After incubation with 
300µM CuC l2, 72.3% of cells stained positive for aggregates with syn211, and a 
significantly (p<0.001) higher percentage of 93.5 ± 3.1% stained positive with 
phos129.  After incubation with 500µM CuC l2, the percentage of cells staining 
positive for aggregates with the phos129 antibody was again significantly (p<0.01) 
higher than those stained with the syn211 antibody, with counts of 95.2± 3.5% 
and 86.6± 3.1%, respectively.   
.   
5.3.5  Incubation of S HS Y 5Y  with Curcumin Appears to have No E ffect on 
Formation of CuC l2 Induced Aggregates of αS yn 
To determine if the copper-induced aggregation of αsyn could be prevented, 
300µM CuCl2 was added to the cell media, to induce aggregation, along with 
three different concentrations of natural curcumin, 4, 7 and 10 µM.  As shown in 
figure 5.14, distinct aggregates can still be observed under all experimental 
conditions. 
Cells containing aggregates were counted, employing the system utilised in 
previous sections.  Representative images used to obtain cell counts are shown 
in appendices 5I to 5L.  
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F igure 5.14:  E ffect of Increasing Curcumin Concentration on Aggregate Counts 
in S H-S Y 5Y  Cells Treated with 300µM CuC l2 and S tained with the S yn211 
Antibody. 
S H-S Y 5Y  cells co-incubated with to 300 µM CuCl2 for 48hrs and stained with the 
syn211 antibody specific to αsyn aa121-125.  A) 300 µM CuCl2 only, B) 300 µM 
C uCl2 + 4µM Curcumin, C ) 300µM CuCl2 + 7µM Curcumin, D) 300 µM CuCl2 + 
10µM Curcumin.  White arrows point directly to aggregates within select cells in 
each image. 
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F igure 5.15:  Percentage of S H-S Y 5Y  Cells Containing Distinct αS yn Aggregates 
S tained with S yn211, after Co-Incubation with Copper and Curcumin. 
Percentage of cells containing distinct intracellular aggregates of αsyn after 
incubation with 300µM C uCl2 and different concentrations of natural curcumin.  
No significant alterations were noted between those treated with copper alone or 
copper and curcumin. 
 
As shown in figure 5.15, and akin to results presented in section 5.4.1, the 
presence of 300µM CuCl2 caused a significant increase (p<0.0001) in the number 
of cells containing distinct aggregates of αsyn after 48hrs incubation.  Untreated 
cells demonstrated an average 26.5 ± 6.7% of cells containing aggregates, 
whereas cells treated with 300µM CuC l2 contained aggregates in an average 72.3
± 8.1% of cells. 
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Upon addition of 4µM natural curcumin alongside 300µM CuC l2, an average 70.2
± 0.8% of cells were still found to contain aggregates, suggesting the addition of 
curcumin at this concentration had no effect on the formation of αsyn aggregates 
induced by addition of CuC l2 and no statistically significance was seen.  The same 
was true for co-incubation with 300µM C uC l2 and either 7µM or 10µM curcumin, 
with positive cell counts of 70.5± 3.3% and 75.8± 5.7%, respectively.  This data 
demonstrates that, in this cell model of PD, addition of natural curcumin alongside 
incubation with CuC l2 for 48hrs did not prevent the formation of CuCl2 induced 
aggregates of αsyn.    
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5.4  Discussion 
R esults presented in this chapter demonstrate that the incubation of S H-S Y 5Y  
cells in the presence of copper for 48hrs results in the formation of intracellular 
aggregates of αsyn. These aggregates were identifiable via immunocytochemical 
staining with the syn211 antibody with the addition of 100, 300 or 500µM CuCl2 
to the media resulting in a significant increase (p<0.01, p<0.0001 and p<0.0001, 
respectively) in the percentage of cells containing these aggregates.  S ignificant 
increases (p<0.01) in aggregate positive cells were also noted with increased 
copper concentration, indicating a dose dependence to the response.  This 
increase in aggregate formation also resulted in an increase in the average 
fluorescence intensity of the cells, as quantified with the use of Image J .  
Incubation with 300 or 500µM CuCl2 both resulted in a significant (p<0.05) 
increase in fluorescence intensity.  This suggests that the presence of copper 
may also be inducing an increase in αsyn expression within the cells, alongside 
an increase in the formation of intracellular inclusions. 
Incubation with CuCl2 also resulted in a concurrent increase in apoptosis, as 
determined via DAPI staining and trypan blue.  Incubation with 100µM C uCl2 
caused a significant (p<0.05) increase in the percentage of cells demonstrating 
one or more signs of apoptosis compared with the untreated cells, and a 
significant increase (p<0.01) was again observed in comparison to 100 µM CuC l2, 
when cells were incubated with 300µM C uC l2.  No significant increase was seen 
when CuC l2 concentration was increased further.  Interestingly not all cells 
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containing aggregates showed signs of apoptosis, which would suggest that it is 
not the aggregate load itself inducing an apoptotic response in the cells, but 
another action of the copper ions.  Possible causes include an increase in the 
presence of R OS  (Cardaci et al., 2008; Davies et al., 2011).  As previously 
discussed in chapter 3, αsyn is known to possess ferrireductase activity, utilising 
copper bound to the protein in the process (Davies et al., 2011).  This iron cycling 
results in the production of R OS  species, which are known to induce oxidative 
stress and apoptotic responses in S HS Y 5Y  cells (Cardaci et al., 2008), therefore 
this is a plausible theory as to how copper ions induce apoptosis in this model.  It 
has also been previously established that R OS  and oxidative stress are key 
factors in iron-induced αsyn aggregation in S H-S Y 5Y  cells, so this may be the 
case for copper.  ROS  have also been linked with the S 129 phosphorylation of 
αsyn in an S H-S Y 5Y  model, suggesting the addition of copper may induce an 
increase in αsyn phosphorylation (Perfeito et al., 2014).  This increase in S 129 
phosphorylation was also demonstrated by results in this chapter, and it is also 
plausible that this phosphorylation could be the cause of the apoptotic effects.   
This increase in apoptosis was also coupled with a decrease in cell viability, as 
determined via trypan blue staining.  Mean cell viability was significantly (p<0.01) 
reduced upon incubation with 100 µM CuCl2 and was significantly (p<0.01) 
decreased further upon increased copper concentrations of 300µM CuC l2 or 
500µM CuC l2, indicating there is a dose response.  Copper has also been 
previously demonstrated to reduce cell viability to just 50% after treatment with 
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150µM for 24 hours (Arciello et al,. 2005) and in another study reduction to 50% 
viability was seen with 200µM after 48h (Wang et al., 2010).  E xperiments in this 
chapter were performed with 100, 300 and 500µM CuCl2, in order to include 
experiments with both lower and higher copper concentrations than those 
previously reported, and a similar reduction in viability, to 57.1± 3.9%, 48.5± 3.4% 
and 40.9± 2.3% respectively was observed. 
Previously published data suggests that the extracellular toxicity of αsyn requires 
the interaction of copper ions, which results in the formation of a unique type of 
oligomer, suggested to potentially be the toxic, disease causing state (Wright et 
al., 2009).  Due to the increased cell toxicity observed in these experiments, it is 
also plausible that these are the aggregates observed within experiments, and 
these aggregates themselves are causative of the increased apoptosis and 
decreased cell viability observed.  
It has previously been reported that copper ions may be essential for aggregate 
formation, as decreasing intrinsic copper levels via the use of a chelex compound 
caused a reduction in the percentage of cells containing αsyn aggregates, from 
12.7% of untreated cells, to just 3.8% in the presence of the compound.  
Incubation with the chelex and 10µM copper was able to restore the aggregate 
counts to those of the untreated cells, and addition of 100µM copper resulted in 
an increase in cells containing aggregates to 37.7% (Wang et al., 2010).  Within 
the Wang study, αsyn within the untreated and cells treated only with the chelex 
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compound was predominantly found ringed around the nucleus, comparable to 
the results presented in this chapter.  The study also investigated truncated 
versions of αsyn and H50A mutants, to demonstrate that the N-terminal region of 
the protein is essential for its aggregation in the presence of copper (Wang et al., 
2010).  A separate study also determined copper to be essential for the formation 
of toxic αsyn aggregates in an S H-S Y 5Y  model, producing a unique, toxic form 
of protein complex, and deduced that iron did not induce the formation of toxic 
oligomers.  C opper was also shown to increase the load and toxicity of 
aggregated forms of the protein (Wright et al., 2009), similar to the results 
presented here. 
R esults in this chapter also demonstrate that both copper induced and intrinsic 
aggregates formed within S H-S Y 5Y  cells, are phosphorylated at the potentially 
pathogenic amino acid residue S 129, with 23± 4.6% of untreated cells staining 
positive.  This intrinsic phosphorylation has been reported before, where 10% of 
cells positively stained for WT αsyn also stained positive for the S 129 modification 
(Perfeito et al., 2014).  This modification is known to be involved in the clearance 
of the protein from the cytosol and may mark these aggregates for degradation.  
When cells were incubated for 48h with the addition of 100, 300 or 500µM CuCl2 
to the media, a significant increase to over 90% (p<0.01, p<0.0001 and p<0.0001, 
respectively) in the number of cells staining positive for phosphorylated 
cytoplasmic inclusions of αsyn was observed for all treatments, though no 
difference was noted between the concentrations.  When these values were 
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compared to those obtained with the syn211 antibody for unmodified αsyn, a 
significantly higher percentage of cells stained positive for phosphorylated 
inclusions.  No difference in inclusion formation was observed between the 
untreated samples.  This suggests that treatment with CuC l2 results in a 
significantly higher number of cells containing phosphorylated aggregates.     
In these experiments, it could not be determined whether all aggregates stained 
for syn211 were also phosphorylated, however if that was the case then there 
should be little difference in counts between the experimental data sets, using the 
different antibodies.  It was demonstrated in chapter 2 that the phos129 antibody 
utilised in these experiments does not have the capacity to bind to WT αsyn.  It 
would generally be expected that the syn211 antibody would bind all αsyn 
aggregates, despite post-translational modification, but these results suggest that 
is not the case.  It is possible that the phosphorylation at S 129 is causing a 
conformational change which no longer allows the syn211 antibody to bind to the 
aggregate. This may result as the binding epitope for the syn211 is within the C-
terminal very close to this phosphorylation position, at residues 121-125 and 
could become masked on phosphorylation and subsequent aggregation.  The 
environment of the C -terminal domain of αsyn is also known to change as fibril 
assembly takes place with the access to this region by nanobodies decreasing 
on fibril maturation, so it is possible as the protein is phosphorylated it aggregates 
further, shielding the syn211 binding epitope (Guilliams et al., 2013; E l-Turk et al., 
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2016).  What is clear however is that treatment with copper induces the formation 
of phosphorylated intracellular inclusions.   
It is unknown from these results if the copper ions are causing the 
phosphorylation of the protein, which in turn is driving its aggregation or if 
aggregation of the protein occurred due to binding of pre-existing phosphorylated 
protein.  It has been shown that overexpression of αsyn within S H-S Y 5Y  cells is 
sufficient to induce aggregation of the protein, and these aggregates were not 
found to be phosphorylated at S 129 (Kondo et al., 2011). Hence phosphorylation 
is not a prerequisite for intracellular aggregation.   
Given that αsyn is intrinsically phosphorylated in the cytoplasm as seen in the 
control cells, the presence of copper could induce this version of protein to readily 
aggregate into the observed inclusions.  It is also that the increased copper 
binding affinity of S 129 phosphorylated αsyn has an influence on intracellular 
aggregation.  If the S 129 phosphorylated αsyn is binding the copper more readily 
than WT within the cells, this could be why a higher number of phosphorylated 
aggregates are observed.  If the copper binds more readily, triggering 
aggregation into phosphorylated aggregates, lower levels of copper may be 
available for the unmodified αsyn to bind, therefore it would form less aggregates. 
Further investigation will however be required to fully determine the role of 
phosphorylation in metal-induced aggregation, and whether the two are 
dependent on one another.  S uch experiments could include the prevention of 
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phosphorylation by knockdown of key kinases or removal of the phosphorylation 
site by CR IS PR.  R esults presented here however do suggest that 
phosphorylated αsyn is more likely to be associated with aggregates upon 
exposure to copper ions, and aggregated αsyn appears more likely to be 
phosphorylated than the non-aggregated forms. 
In order to investigate whether the copper induced aggregation of αsyn could be 
prevented in this cellular model, cells were co-incubated with 300µM CuC l2, which 
was demonstrated to induce a significantly high number of aggregates, along with 
a selection of increasing curcumin concentrations.  No difference however in the 
percentage of cells containing distinct aggregates in the presence or absence of 
curcumin was observed, suggesting that, in this cellular model, curcumin is 
unable to prevent the copper-induced aggregation of the protein.  
Previous studies utilizing S H-S Y 5Y  models demonstrated the ability of curcumin 
to reduce the toxicity of pre-formed oligomers which were added to the cells, in 
line with the MS  data in chapter 4.  Treatment with oligomers alone resulted in a 
reduction in cell viability to just 60%, whereas co-incubation with oligomers and 
curcumin increased the viability to 80% (S ingh et al., 2013).  Another study 
showed incubation with curcumin reduced the toxic effects of R OS  damage, 
induced by addition of extracellular αsyn and increased cell viability (Wang et al., 
2010), and a third similar study showed novel curcumin analogues could increase 
cell viability compared to cells treated with αsyn alone (J ha et al., 2016).   
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It is possible that the aggregation enhancing effects of copper are overriding the 
inhibitory effect of curcumin on the oligomers by causing a shift to the aggregation 
prone compact state and increasing the rate of assembly.  If the aggregates 
produced are the unique copper induced oligomers previously described (Wright 
et al., 2009), this suggests they are too intrinsically stable to be dissociated.  
Copper is also known to have at least three binding sites on the αsyn protein, and 
it is possible that this binding of copper masks the binding site for curcumin on 
these oligomers, either through conformational change, or by covering the 
binding epitope.  Data in this thesis suggests dissociation of the lower order 
species is possible, but this may not be the case for the larger oligomers formed 
in the presence of copper.  It is also plausible that the cell is breaking down the 
curcumin molecules, or they are not entering the cell in the first place. It is also 
feasible that the concentrations utilised in this study are not sufficient to influence 
aggregates formed within cells.  Overall, data presented here indicates that 
curcumin cannot prevent the copper-induced aggregation of αsyn. 
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5.5  Conclusions 
As summarised in figure 5.16, results presented in this chapter demonstrate that 
exposure of S HS Y 5Y  cells naturally expressing αsyn to increasing concentrations 
of CuC l2 induces intracellular aggregates of αsyn, akin to the increase in in vitro 
aggregation observed in earlier ThT assays.  The percentage of cells containing 
αsyn aggregates is increased significantly upon exposure to increased copper 
concentrations, indicating there is a dose response to copper-induced 
aggregation. 
αS yn phosphorylated at S 129 has been shown to aggregate faster in vitro, and 
results presented here indicate that the aggregates formed within S HS Y 5Y  cells 
upon exposure to C u(II) are also phosphorylated at this residue, and an increased 
number of phosphorylated aggregates were detected in comparison to 
phosphorylated.  It is likely that these aggregates formed in the presence of 
copper are the copper-specific oligomers which have been suggested to be the 
toxic, disease-causing conformations (Wright et al., 2009).  Cell viability is also 
found to be decreased, and apoptosis increased with increasing concentrations 
of CuCl2, indicating these higher concentrations have an increased apoptotic 
effect.  
Despite being effective at preventing αsyn aggregation in an in vitro assay, co-
incubation of S HS Y 5Y  cells with natural curcumin and 300µM CuCl2 does not 
appear to have any protective effect on either cell viability, or against the 
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formation of C u(II)-induced aggregates, indicating that, in this model, curcumin is 
unable to prevent the copper-induced aggregation of αsyn. 
 
F igure 5.16:  S ummary of Chapter 5 F indings on the Interaction of Copper, S erine 
Phosphorylation and Curcumin in an S HS Y 5Y  PD Model. 
Both copper and S 129 phosphorylation increase the aggregation rate of αsyn in 
vitro.  Upon addition of copper to S HS Y 5Y  cell media, an increase in αsyn 
aggregation and phosphorylation was observed.  Curcumin has the ability to 
prevent the aggregation of αsyn in vitro. However, in this cell model, the addition 
of curcumin to S HS Y 5Y  cells was unable to prevent the aggregation induced by 
the addition of cu(II).  
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Chapter 6 – F inal Discussion and Conclusions 
The overall hypothesis of this thesis was that αsyn aggregation can be modulated 
by altering the population of the compact, aggregation prone conformational 
states present within its normal equilibrium, via processes such as post-
translational modification or ligand binding.  The aims were to determine the 
effects of post-translational modification on the metal binding characteristics of 
αsyn, to determine if aggregation could be inhibited via the use of small molecule 
inhibitors, specifically curcumin and its derivatives, and to examine the 
relationship between metal ions and the proteins phosphorylation state in a 
cellular model of PD.   
E S I-IMS -MS  was employed to investigate the changes in conformational 
distribution of αsyn.  C hapter 3 presents data acquired relating to the alterations 
in conformation brought about by mutations mimicking serine phosphorylation, 
namely S 87D and S 129D αsyn, and changes in conformation of the three proteins 
in the presence of copper.  In this case, the binding of copper increased the 
relative proportions of the compact state, and was correlated with an increase in 
aggregation as monitored by ThT assays.  The key findings from this chapter can 
be viewed in figure 6.1, and will be discussed in sections 6.1 and 6.2.  Chapter 4 
presents data showing that curcumin derivatives bind to dimeric oligomers of 
αsyn, but not the monomeric protein.  ThT assays were again utilised to 
demonstrate a reduction in aggregation propensity in the presence of curcumin 
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and a range of curcumin derivatives.  The main findings of this chapter can be 
viewed in figure 6.3, and will be discussed in sections 6.4.   F inally, chapter 5 
demonstrated that exposure of a neuronal cell line to copper results in punctate 
aggregates of both unmodified and phosphorylated αsyn, but the formation of 
these aggregates could not be prevented by the presence of curcumin.  The main 
findings will be discussed in sections 6.3 and 6.5, and a summary schematic can 
be viewed in figure 6.2. 
IDPs such as αsyn are highly heterogeneous, and can have altered CS Ds and 
conformational distributions between mass spectrometry acquisitions, which has 
been discussed in the literature (Beveridge et al., 2015), and is evident from the 
wide range of CS Ds and conformational distributions reported (Beveridge et al., 
2015; Mason et al., 2016; Illes-Toth et al., 2013; Kang et al. 2012).  This variation 
in the data was addressed here by acquiring data sets within as short a time 
frame as possible to limit the environmental effects on the electrospray process, 
and utilising freshly made recombinant proteins.  For the majority of experiments 
presented in this document, WT αsyn had a CS D of +18 to +5, well within the 
range of previously published data (Beveridge et al., 2015; Mason et al., 2016; 
Illes-Toth et al., 2013; Kang et al. 2012), and had two distinct conformational 
groups evident from the spectra as a whole.  The first an extended family 
spanning conformations +18 to +9 dominated by the +14 CS I, and a second, 
more compact family spanning conformations +8 to +5, dominated by the +7 CS I.  
This latter, more compact family is linked with aggregation, in keeping with other 
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published data (Beveridge et al., 2015; Kang et al., 2012; Illes-Toth et al., 2013; 
Mason et al., 2016). 
 
6.1 Insights into the E ffect of Phosphorylation on the Conformational 
Distribution and Aggregation of αS yn  
R esults presented in chapter 3 demonstrated that WT αsyn occupies eight 
distinct sub-conformations present within the expanded and collapsed 
conformations, ranging in size from 1303.7 Å2 to 3185.5 Å2, and these 
conformations are present in varying proportions throughout multiple CS Is.  The 
Gaussian fitting technique was used, in keeping with recently reported publication 
(Mason et al., 2016), to investigate the conformational changes brought about by 
mimicking serine phosphorylation.  S ubstitution of serine residues for aspartic 
acid, creating protein variants, S 87D and S 129D, and the subsequent analysis 
reveals these variants occupy the same eight conformational families as the WT 
protein, in a similar conformational equilibrium.  S 129D αsyn appeared to have a 
wider CS D overall, though this is possibly an artefact of acquisition.  E S I-IMS -MS  
has recently been discovered to over-exaggerate the conformational dynamics of 
true solution proteins, causing compaction of IDPs or their subunits (Borysik et 
al., 2015; Pagel et al., 2013), and altered CS Ds have been observed between 
protein solutions acquired at different times on the same day (Beveridge et al., 
2015), therefore care must be taken to not over interpret this data.  No significant 
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alterations to the CCS  of the eight conformations are observed between protein 
variants however, suggesting they have the same conformational distribution 
overall, and mimicking phosphorylation did not alter the protein significantly.  
This data suggests the three proteins should have the same aggregation 
propensity, as they contained almost identical proportions of the most compact 
and amyloidogenic states.  This was however, not the case.  ThT studies 
determined that S 87D αsyn has a slower aggregation rate overall than WT αsyn 
with an increase in t1/2 of aggregation, and an increase in lag time was observed.  
In contrast, S 129D αsyn had a decreased t1/2 in comparison to WT αsyn, and a 
reduction in lag phase was observed.  This is in keeping with previously reported 
findings utilising C-terminal fragments of αsyn phosphorylated at S 129, and a 
phosphomimic S 129E , which also showed an increased aggregation propensity 
(Lu et al., 2011; Nübling et al., 2014).  It is important to note however, that 
phosphomimics may behave differently to truly phosphorylated αsyn (Oueslati, 
2016), and there is a large body of contradictory data already available utilising 
both phosphomimics and phosphorylated αsyn (Oueslati et al., 2012; Paleologou 
et al., 2008), therefore it is recommended these experiments are repeated with 
phosphorylated protein before any definitive conclusions are drawn on the 
implications of serine phosphorylation on αsyn aggregation in PD.    
Data presented in this thesis however suggests that S 129D αsyn is more 
amyloidogenic than WT αsyn, and its S 87D counterpart.  This lends support to 
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the hypothesis that αsyn phosphorylated at S 129 is pathologically relevant in PD, 
whereas S 87 phosphorylation is not, and could possibly be protective (Oueslati 
et al., 2012).  As the conformational distribution and CCS ’s of the two 
phosphomimic proteins were relatively unchanged in comparison to WT αsyn, 
this indicates there is another reason mimicking phosphorylation is increasing 
aggregation rates, other than by increasing the population of the more compact 
conformational species.  This limited change in the relative proportion of the 
compact state could indicate that this increase in aggregation is determined by 
the assembly of higher order oligomers, rather than the conformational state of 
the monomer. 
 
6.2  Insights into the E ffect of Phosphorylation on the Interaction of αS yn 
with Metal Ions 
Metals are known to be involved in PD, and have been shown to increase the 
rate of αsyn aggregation in vitro.  In chapter 3, E S I-IMS -MS  was used to 
determine the effect of metal binding on the conformation of αsyn.  Only the 
binding of copper to WT αsyn and its phosphomimic variants could be observed 
with E S I-IMS -MS  and the binding of other metals investigated was not seen under 
the experimental conditions attempted.  This is potentially due to dissociation of 
the metal ligands, due to their low binding affinity, either during the electrospray 
process or in the interior of the mass spectrometer.  It is also possible that 
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interference from buffer components has prevented binding of the other metals 
being observed. 
Nevertheless, the effect of copper binding on αsyn was determined.  Upon 
addition of equimolar copper to the samples of all three αsyn variants, peaks 
corresponding to the bound proteins were easily observable.  This accompanied 
the appearance of a novel, more extended CS I within the mass spectra for all 
three proteins, widening the CS D of WT and S 87D αsyn from +18 to +5, to +19 
to +5, and the CS D of S 129D αsyn from +17 to +5 to +18 to +5.   
This widening of the CS D is also accompanied by alterations to the proteins 
conformational distribution.  At CS Is +11 to +5, for all three αsyn variants 
investigated, an increase in the more compact conformations at each CS I is 
observed upon the binding of one or two copper ions, with increases in 
conformations D, E , F , G and H observed.  This is in agreement with previously 
published findings for the WT protein (Mason et al., 2016), and demonstrates that 
the binding of copper ions to the lower CS Is representing more compact protein 
structures, causes an increase in the more compact, amyloidogenic 
conformations.  As these conformations are more compact, they would be 
expected to have a higher propensity for aggregation, increasing the risk of PD 
(Bernstein et al., 2004; Illes-Toth et al., 2015; Mason et al., 2016).  As this is true 
for all protein variants, and there is little notable difference between the 
conformational distributions of the three, it suggests that mimicking 
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phosphorylation at S 87 or S 129 has little effect on the individual conformational 
states observed upon copper binding, and suggests copper binding to the 
variants occurs in the same manner as for the WT protein.  
Aggregation rates of the three αsyn variants in the presence of copper and iron 
were investigated using ThT assays, which demonstrated that the incubation of 
equimolar CuC l2 with all three protein variants, resulted in a statistically significant 
(p<0.05) increase in the rate of aggregation, determined via t1/2 and Le values.  
This indicates that the conformational changes in favour of more compact species 
observed upon copper binding, is causing an increase in the aggregation rates of 
all three proteins.   
All three variants display a shift towards the more compact states upon copper 
binding, resulting in increased aggregation rates over the apo values.  The 
variants did however show differences in their affinities for copper binding.  S 87D 
αsyn had the lowest binding affinity overall, binding just two copper ions to the 
compact CS Is at a 10 and 20µM copper concentration whereas WT and S 129D 
readily bound three.  At higher concentrations of 50µM CuCl2, S 129D was able 
to bind up to 4 copper ions, with the majority of the protein within the sample now 
being bound to two copper ions.  WT and S 87D bound three copper ions at this 
concentration, with most of the proteins bound to one.  At a 100µM concentration, 
all four proteins bound four copper ions, but the majority of S 129D within the 
sample was now bound to three ions.  S 87D and WT predominantly bound to two 
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ions at this concentration.  This indicates that mimicking phosphorylation at S 129 
results in a higher binding affinity over WT and S 87D.  S ome studies have 
concluded that phosphorylation overall resulted in a lower binding affinity for 
copper (Oueslati et al., 2012), whilst others indicated an increased binding affinity 
(Lu et al., 2011), though these studies utilised C -terminal fragments rather than 
the whole protein.  The data demonstrates that S 129D αsyn has a higher affinity 
for copper ions than the WT version of the protein.  This may help to explain why 
in intracellular inclusions and ex vivo LB material, the protein is both 
phosphorylated and rich in metal ions. 
It was also noted in these investigations that only the binding of the first copper 
ion, to either protein variant, caused a significant alteration to the proteins 
conformation, as assessed by Gaussian fitting.  It has been previously suggested 
that the H50 copper binding site is the initial, high affinity site, and it has also been 
demonstrated that Cu(II) binding to this domain causes a significant alteration to 
the conformation, via the introduction of a β-hairpin turn at this residue (R ose et 
al., 2011). 
Due to the significant alteration observed upon the binding of the first copper ion, 
but not subsequent ions, this supports the hypothesis that this is the residue is 
where the copper ions are initially binding, and it is this modification that results 
in the conformational changes required to alter the equilibrium and trigger 
increased aggregation, rather than the binding to other residues. 
2
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F igure  6.1: E ffect of Cu(II)-binding and Phosphorylation on αS yn Aggregation. 
The two proposed mechanisms by which Cu(II) and S 129 phosphorylation increase the aggregation rate of αsyn in vitro.  Top: 
The binding of Cu(II) causes a conformational change, shifting the equilibrium towards the more compact states, inducing 
increased aggregation.  Bottom: S 129 phosphorylation does not alter the conformation of the protein, or cause a shift towards the 
compact states, however aggregation is again accelerated, suggesting an alternative mechanism or pathway to that induced by 
the binding of Cu(II). The two pathways are potentially linked, as indicated with the grey arrow, via the high affinity Cu(II) binding 
site at H50, as S 129D αsyn has a higher affinity for Cu(II) binding. 
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6.3  Insights into the E ffect of Metal Ions on Intracellular Aggregation and 
Phosphorylation of αS yn 
Data presented within chapter 5 demonstrates that incubation of S H-S Y 5Y  cells 
with copper for 48 hours causes a significant (p<0.01-0.0001) increase in the 
number of cells containing intracellular aggregates of WT αsyn.  This number also 
further increases (p<0.01) with increasing copper concentration, indicating a dose 
response to treatment with this metal.  This increase in aggregates also coincided 
with an increase in fluorescence intensity within the cells (p<0.05), suggesting an 
increase in overall αsyn expression levels, upon incubation with either 300 or 
500µM CuCl2.  It has previously been suggested that copper is a requirement for 
intracellular aggregation.  When intrinsic levels of the metal are reduced via use 
of a chelex compound, intracellular aggregation was greatly reduced.  This loss 
of aggregation propensity could be both recovered, and increased in untreated 
cells via further copper addition (Wang et al., 2010). 
Incubation with copper also resulted in an increase (p<0.01) in the percentage of 
cells containing one or more signs of apoptosis, as determined by DAPI staining, 
and a decrease in cell viability as determined by trypan blue staining, which again 
increased significantly with increased copper concentration (p<0.01).  This is in 
keeping with previously published reports that incubation with copper reduces 
viability to 50% (Arciello et al., 2005; Wang et al., 2010). 
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Interestingly, not all cells containing high numbers of aggregates were apoptotic, 
which suggests it is not the aggregate load causing an increase in toxicity within 
these cells, but potentially another action of copper.  One possibility could be 
increased oxidative pressure, or increased production of R OS , and αsyn is known 
to hold some ferrireductase activity, utilising copper bound to the protein in the 
process, which would lead to an increased formation of R OS  such as hydroxyl 
free radicals, and is a potential mechanism of action here. 
Data presented in chapter 5 also demonstrated that the majority cells in the 
presence of copper contain aggregates which are phosphorylated at S 129.  This 
suggests addition of copper appears to promote the formation of phosphorylated 
aggregates, and this may well be linked to the higher affinity for copper of 
phosphorylated αsyn.  A low level of S 129 phosphorylated αsyn is present within 
the cells intrinsically, and this pool of protein may preferentially bind the copper 
due to its higher binding affinity, resulted in the observed aggregates, and it is 
known once bound to copper the protein has a higher propensity for aggregation.  
It is still unclear as to whether the addition of copper is causing an increase 
phosphorylated αsyn within the cells, and whether this aids in driving the 
increased formation of aggregates observed. 
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F igure 6.2:  S ummary of the Interaction Between C u(II), S erine Phosphorylation 
and Curcumin in an S HS Y 5Y  Model of PD. 
C hapter 1 demonstrates that both copper and S 129 phosphorylation increase the 
aggregation rate of αsyn in vitro.  In chapter 5, upon addition of copper to 
S HS Y 5Y  cell media, an increase in both αsyn aggregation and phosphorylation 
was observed.  Curcumin was shown in chapter 4 to prevent the aggregation of 
αsyn in vitro. However, in chapter 5, in this S HS Y 5Y  cell model, the addition of 
curcumin to S HS Y 5Y  cells was unable to prevent the aggregation induced by the 
addition of C u(II). 
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6.4  Insights into the Interaction of WT αS yn Monomers and Oligomers with 
the Polyphenolic Compound Curcumin and a Variety of Curcumin 
Analogues 
One potential therapeutic strategy for the treatment of PD is the prevention of 
aggregation of αsyn via the use of small molecule inhibitors.  The polyphenolic 
compound, curcumin, has previously been demonstrated to reduce the 
aggregation of WT αsyn in vitro (Pandey et al., 2008; S ingh et al., 2013; 
Y anagisawa et al., 2015).  To determine whether the compound, which has poor 
bioavailability in its natural form, could be improved upon in terms of its anti-
amyloid propensity, E S I-IMS -MS  experiments and ThT assays were performed, 
utilising a selection of curcumin derivatives. 
ThT assays demonstrated that natural curcumin significantly (p<0.0001) reduced 
the formation of amyloid aggregates to around 23% of the total found in the WT 
αsyn alone sample, in keeping with previous studies (Wang et al., 2010; J ha et 
al., 2016; Ahsan et al., 2015; Pandey et al., 2008; S ingh et al., 2013; Y anagisawa 
et al., 2015).  The majority of derivatives significantly reduced the fluorescence 
signal of the samples compared to the protein alone (p<0.05 – p<0.0001), with 
derivatives 5 and 7 almost inhibiting aggregation entirely, whereas derivative 4 
caused a significant increase in fluorescence signal (p<0.05), and derivative 6 
caused no significant alterations to fluorescence either way.  Derivatives 5 and 7 
were both found to be significantly (p<0.0001) more effective than natural 
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curcumin.  Both these derivatives share a phenolic group at position-3 on the 
native aromatic ring, that appears to be of importance, indicating that 
modifications of the molecule could provide a good candidate for novel therapies 
for PD. 
The derivatives were also investigated for their anti-amyloid properties against 
another amyloidogenic protein, lysozyme, whose aggregation can also be 
reduced by the presence of natural curcumin.  The derivatives followed a similar 
but not identical pattern of inhibition to with αsyn, however derivatives 5 and 7 
were again the most effective (p<0.001 and p<0.0001, respectively).  This 
indicates that not all derivatives of curcumin will be suitable in either preventing 
or treating amyloid aggregation, so specific functional groups on the molecule 
must be key to this interaction with the different amyloid proteins, therefore careful 
design of the molecules is needed to create successful potential drugs for 
different amyloidosis.  
To investigate the anti-amyloid mechanism of curcumin and derivatives 5 and 7, 
a number of E S I-IMS -MS  experiments were performed.  Neither the natural 
molecule nor the two derivatives were observed to bind the monomeric protein, 
even after extended incubation times.  After this extended incubation however, it 
was observed that the presence of natural curcumin or derivative 5 or 7 prevented 
the autoproteolytic fragmentation observed in the untreated sample after 
48hours.  F ragmentation of αsyn has previously been identified as an important 
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step in aggregation (Vlad et al., 2011), therefore the prevention of this auto 
fragmentation could be one of the mechanisms by which curcumins exert their 
anti-aggregation properties on αsyn.   
Currently published literature is contradictory, and reports have been published 
claiming both curcumin binds to the monomeric species of αsyn (Ahmad and 
Lapidus, 2012), and stating it only binds to oligomeric forms of the protein (S ingh 
et al., 2013).  E S I-IMS -MS  data presented here strongly suggests that curcumins 
could not bind the monomer, whereas binding was observed only to low order 
oligomeric forms, such as dimeric species, supporting the work of S ingh and 
colleagues.   
E S I-IMS -MS  also indicated that curcumin and derivatives 5 and 7 could not only 
bind to these dimers, but dissociate dimers pre-formed within the sample, as 
observed via a reduction in intensity within drift scope mobilograms.  This 
dissociation was not observed with another curcumin derivative, number 11, 
which had a lower anti-aggregation propensity.  The control demonstrates that 
the loss in signal intensity is not a result of the presence of the small molecule 
effecting the ionisation process, and is specific to the interactions between αsyn 
and the curcumin molecules.  
It was also demonstrated via E S I-IMS -MS  that curcumin could not bind to αsyn 
with the NAC  region deleted, however this is most likely due to the inability of this 
αsyn variant to dimerise.  It also supports previous reports of this region encoding 
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being curcumins binding motif (Ahmad and Lapidus, 2012).  It has been 
suggested that curcumin binds to the NAC region and increases the 
reconfiguration rate of αsyn as a mechanism.  It is possible the NAC  region 
becomes more exposed upon oligomer formation, allowing the binding of 
curcumin, where this region may be more shielded in monomeric forms of the 
protein (Wong and Krainc, 2017).  It is therefore possible that oligomer formation 
exposes the NAC region, allowing the curcumins to bind to the protein, leading to 
dissociation of the oligomers into monomeric species, which have a reduced 
fragmentation rate and therefore a reduced rate of aggregation. 
 
6.5  Insights into the E ffect of C urcumin on Metal Ion-Induced Intracellular 
Aggregation of αS yn 
When S H-S Y 5Y  cells were co-incubated with CuCl2 and natural curcumin, no 
reduction in aggregate formation in comparison to cells incubated with CuCl2 
alone was observed, suggesting curcumin had no effect on copper-induced 
aggregate formation.  Previous studies have demonstrated an increase in cellular 
viability upon incubation with curcumins (S ingh et al., 2013; J ha et al., 2016), but 
there is no previous data available on the incubation of cells with metals and 
curcumins.  It is likely that the effect of copper binding is too stable to be 
overridden by curcumin, especially as it has a much weaker binding affinity for 
αsyn than copper ions, as previously demonstrated here.  It is also possible that 
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the oligomeric species formed within the cells upon copper exposure are too 
highly ordered for the curcumin to interact with and dissociate, as the proposed 
binding site within the NAC region may be shielded.  It appears that the 
intracellular aggregation brought about by the presence of copper cannot be 
inhibited by curcumin or its derivatives.   
 
6.6  F inal Conclusions 
In summary, this thesis has demonstrated that the conformational state of αsyn 
can be modulated by small molecule interactions.  Molecules that increase the 
population of the compact states, such as copper ions, increase the rate of 
aggregation, and molecules such as curcumin which disrupt oligomeric 
assembly, prevent this aggregation.  Modification of the protein by 
phosphorylation, mimicked here with the exchange of serine for aspartic acid, 
resulted in increased rates of aggregation in vitro, an effect which was further 
enhanced by the presence of copper.  In cell culture, copper induces the 
formation of phosphorylated, intracellular aggregates, but this could not be 
prevented by curcumin.  These observations support the idea that 
phosphorylation of αsyn at S 129 has a direct role to play in PD, and that this role 
can be modulated by exposure to copper.  An overall summary figure of the thesis 
findings can be seen in figure 6.3. 
246 
 
 
F igure 6.3:  Overall S ummary of Main Thesis F indings. 
C opper binding, particularly at the H50 binding domain, pushes the 
conformational equilibrium of α syn towards the compact conformations, 
increasing its aggregation. Phosphorylation at S 129 also increases α syn 
aggregation, through an unknown pathway.  Copper induces formation of αsyn 
aggregates within an S HS Y 5Y  PD cell model, which are also phosphorylated at 
S 129.  Curcumin is proposed to bind to dimeric αsyn, within the NAC region, and 
prevent this aggregation.  However, curcumin is unsuccessful at preventing 
copper-induced aggregate formation within the S HS Y 5Y  cell model. 
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Chapter 7 – Future Work 
7.1  Phosphorylation and Metal Interactions 
7.1.1  Phosphorylation of αS yn 
As phosphorylation of WT αsyn was not successfully completed within this project, 
it is now important to conduct the same experiments utilising protein which has 
been successfully phosphorylated, to both determine differences between actual 
phosphorylated protein and the phosphomimics, which are still regularly utilised 
in research due to their ease of production in comparison. 
 
7.1.2  Phosphorylation and Metal Interactions of E x Vivo αS yn 
It would be also very interesting to examine ex vivo αsyn from PD patients via 
E S I-IMS -MS  and investigate both the phosphorylation state of the protein and its 
conformational distribution.  For example, αsyn from the cerebrospinal fluid of PD 
patients could be purified via affinity precipitation, and LC -MS  before investigation 
via E S I-IMS -MS  to determine any metal binding, conformational changes upon 
metal binding, or in comparison to recombinant proteins, or to investigate whether 
ex vivo material has any further propensity to bind metals or aggregate in vitro. 
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7.2  Interactions of αS yn and Curcumin 
7.2.1  Confirmation of Anti-Aggregation Propensity 
As the ThT assay is susceptible to interference from other fluorescent sources, 
such as the curcumin molecules investigated, it is important to investigate their 
effect on aggregation of αsyn via another, non-fluorescent technique before this 
data is ready for publication.  Incubation with the curcumin derivatives followed 
by imaging via electron microscopy to visualise the aggregates formed is a viable 
alternative to investigate their effects, without the potential for bias caused by 
their intrinsic fluorescence. 
 
7.2.2 Increased Bioavailability of Curcumin Molecules 
Though curcumin appears to be a viable candidate for PD therapy, due to results 
presented in this investigation and elsewhere, the problem with its bioavailability 
must be overcome before curcumin can progress to clinical trials in humans. 
S ynthesising alternative curcumin derivatives based on insights from this study 
and others will provide a good basis to begin designing novel curcumin molecules 
with increased bioavailability and increase anti-aggregation propensities, for PD 
and other amyloid diseases. 
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7.2.3 F urther Investigations into the Prevention of Copper-Induced Aggregation 
by Curcumins 
 
The relationship between copper-induced aggregation and whether curcumin 
could be utilised to prevent this aggregation also warrants further investigation.  
A ThT assay containing both copper and curcumins would give further insight into 
whether copper-induced aggregation could be prevented by this molecule or one 
of its derivatives.  E S I-IMS -MS  was attempted utilising both copper and curcumin, 
and early experiments indicated that curcumin did not prevent the copper-
induced conformational changes observed with the compact conformations of the 
protein.  This was not repeated enough or with a large enough variety of copper 
and curcumin concentrations to draw definitive conclusions, therefore should be 
further examined. 
 
7.3  Cellular R esponses to Metal Ions and Curcumin 
7.3.1  Confirmation of Phosphorylation S tate 
 
Due to the unexpected results obtained when using the antibody specific to αsyn 
which has undergone phosphorylation at serine-129, an alternative method of 
investigation should be employed.  It is possible the antibody was binding to 
another protein within the cells, which could be why there was an increase in 
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inclusions, for example stress bodies look extremely similar, as do aggregates of 
the transcription protein E IF2β, so this exclusivity cannot be fully confirmed. 
 
 
7.3.2  Further Investigation into Curcumins E ffect on Metal Induced Aggregates 
In vitro E S I-IMS -MS  results and aggregation studies suggested curcumin should 
be protective against the formation of intracellular aggregates.  This however was 
not the case in cellular investigations conducted here.  It is possible the curcumin 
was not taken up by the cells in the first place, so this requires further optimisation 
and investigation before definitive conclusions can be drawn.  It would also be 
interesting to examine the effects of copper and curcumin on cells stained with 
the phos129 antibody, to determine if there are any effects on the phosphorylated 
aggregates. 
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Appendices 
Appendix 2A: 
 
Appendix 2A: Anion exchange chromatograph of αS yn.  Fractions were collected 
for S DS -PAGE  within the region marked by the red dashes. 
Appendix 2B: 
 
Appendix 2B: S ize exclusion chromatograph of αS yn.  Fractions were collected 
for S DS -PAGE  within the marked region.  
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Appendix 3A: 
 
Appendix 3A: Drift scope plot of WT αsyn acquired in 50mM ammonium acetate 
using E S I-IMS -MS  in positive ion mode.   
 
Appendix 3B: 
 
Appendix 3B: Drift scope plot of S 87D mutant αsyn acquired in 50mM ammonium 
acetate using E S I-IMS -MS  in positive ion mode.   
030216 50A A WT  A PO 5.raw  : 1
030216 50A A S 87D A PO.raw  : 1
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Appendix 3C : 
 
Appendix 3C : Drift scope plot of S 129D mutant αsyn acquired in 50mM 
ammonium acetate using E S I-IMS -MS  in positive ion mode.   
 
 
 
 
 
 
 
 
030216 50A A S 129D A PO 1.raw  : 1
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Appendix 3D: 
  
Appendix 3D: ATD of each charge state ion of S 87D mutant αsyn acquired by 
E S I-IMS -MS  in 50mM ammonium acetate under previously described conditions.   
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Appendix 3E : 
 
 
Appendix 3E : Conformational arrangement of S 87D mutant αsyn acquired in 
50mM ammonium acetate using E S I-IMS -MS  in positive ion mode.  S 87D αsyn 
occupies the same 7 distinct conformational families as WT αsyn. 
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Appendix 3F : 
  
Appendix 3F : ATD of each charge state ion of S 129D mutant αsyn acquired by 
E S I-IMS -MS  in 50mM ammonium acetate under previously described conditions.   
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Appendix 3G: 
 
 
Appendix 3G: Conformational arrangement of S 129D mutant αsyn acquired in 
50mM ammonium acetate using E S I-IMS -MS  in positive ion mode.  S 129D αsyn 
occupies the same 7 distinct conformational families as WT and S 87D αsyn. 
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Appendix 3H:  
 
 
 
Appendix 3H: Normalised thioflavin-t fluorescence data with WT αsyn with 
repeats shown in grey and mean fluorescence from three separate experiments 
in black, S 87D repeats in light pink and mean fluorescence from three separate 
experiments in dark pink, and S 129D repeats in light purple and mean 
fluorescence from three separate experiments in dark purple.   
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Appendix 3I:  
 
Appendix 3I: Normalised thioflavin-t fluorescence data with WT αsyn repeats 
shown in grey and mean fluorescence from three separate experiments 
normalized in black. WT αsyn + equimolar CuCl2 repeats in light blue, mean from 
three independent experiments in darker blue. WT αsyn + equimolar FeCl2 
repeats in yellow, mean from three independent experiments in orange. 
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Appendix 3J : 
Appendix 3J : Normalised thioflavin-t fluorescence data with S 87D αsyn repeats 
shown in pink and mean fluorescence from three separate experiments 
normalized in darker pink. S 87D αsyn + equimolar CuCl2 repeats in light blue, 
mean from the three independent experiments in darker blue. S 87D αsyn + 
equimolar FeCl2 repeats in yellow, mean from the three independent experiments 
in orange. 
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Appendix 3K: 
 
Appendix 3K: Normalised thioflavin-t fluorescence data with S 128D αsyn repeats 
shown in purple and mean fluorescence from three separate experiments 
normalized in darker purple. S 129D αsyn + equimolar CuC l2 repeats in light blue, 
mean from the three independent experiments in darker blue. S 129D αsyn + 
equimolar FeCl2 repeats in yellow, mean from the three independent experiments 
in orange. 
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Appendix 3L: 
 
Appendix 3L: +18 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
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Appendix 3M: 
 
Appendix 3M: +17 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of 
conformations A, B & C . 
 
Key F indings: 
No notable changes observed with S 87D αsyn.  WT and S 129D both demonstrate 
an increase in conformation B via a decrease in the most extended conformation, 
A.  S 129D had the highest proportion of conformation B of all the apo proteins. 
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Appendix 3N: 
 
Appendix 3N: +16 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
 
Key F indings: 
No notable differences in apo samples.  No notable changes observed with S 87D 
upon addition of CuC l2.  WT & S 129D again show an increase in B via reduction 
in A.  S 129D when bound to two C uCl2 ions also shows notable increase in the 
most compact conformation, conformation A. 
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Appendix 3O: 
 
Appendix 3O: +15 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
 
Key F indings: 
S 87D has the highest proportion of conformation C  of the apo samples.  All 
protein variants show an increase in conformation B via a reduction in A.  The 
most pronounced difference is seen with WT αsyn bound to two copper ions. 
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Appendix 3P: 
 
Appendix 3P: +14 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
 
Key F indings: 
No real alterations.  WT and S 129D αsyn both have an increased proportion of 
conformation C  in the apo samples. 
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Appendix 3Q: 
 
Appendix 3Q: +13 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
 
Key F indings: 
No notable alterations to WT or S 129D.  S 87D shows slight increase in 
conformation B via a reduction in C . 
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Appendix 3R : 
 
Appendix 3R : +12 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations A, B & C . 
 
Key F indings: 
No Notable alterations to S 87D αsyn.   WT & S 129D show slight decrease in most 
compact conformation, conformation C.  
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Appendix 3S : 
 
Appendix 3S : +11 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of 
conformations A, B, C , D & E . 
 
Key F indings: 
All protein variants show an increase in conformations A & D via a reduction in 
conformations B & C. 
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Appendix 3T: 
 
Appendix 3T: +10 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations B, C , D, E  & F . 
 
Key F indings: 
All protein variants show an increase in conformations C , D, E , & F , via a 
reduction in conformation B.  
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Appendix 3U: 
 
Appendix 3U: +9 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of 
conformations C , D, E , F  & G. 
 
Key F indings: 
All protein variants show an increase in conformations E , F  & G via a reduction 
in C  and/or D. 
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Appendix 3V: 
 
Appendix 3V: +8 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of 
conformations C , D, E , F  & G. 
 
Key F indings: 
All protein variants demonstrate an increase in conformations F  & G via a 
reduction in conformations C , D & E . 
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Appendix 3W: 
 
Appendix 3W: +7 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations E , F  & G. 
 
Key F indings: 
All proteins show an increase in conformation G via a reduction in conformations 
F  & E . 
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Appendix 3X: 
 
Appendix 3X : +6 charge state ion of WT, S 87D and S 129D in the presence of 
equimolar CuCl2 with Gaussian fitting applied to show relative proportions of  
conformations F , G & H. 
 
Key F indings: 
No notable changes observed with any protein variants. 
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Appendix 4A: 
 
Appendix 4A:  Initial ThT fluorescence readings of 70µM natural curcumin and 
the thirteen derivatives, upon immediate addition to equimolar WT αsyn in 50mM 
ammonium acetate containing 10µM thioflavin-T. n=3 
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Appendix 4B: 
 
Appendix 4B:  No binding was observed during E S I-IMS -MS  experiments with 
any of the curcumin derivatives after immediate addition to equimolar αsyn. 
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Appendix 4C  
 
Appendix 4C:  Gaussian fitting was performed on the +11 charge state ion of WT 
αsyn after immediate addition of A) 1% DMS O, B) 1% DMS O + equimolar natural 
curcumin, C ) 1% DMS O + equimolar derivative 5, and D) 1% DMS O + equimolar 
derivative 7.  No alterations to the protein conformations were observed. 
 
 
 
A 
C  D 
B 
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Appendix 4D: 
 
Appendix 4D:  Gaussian fitting was performed on the +11 charge state ion of WT 
αsyn after 48hours incubation with of A) 1% DMS O, B) 1% DMS O + equimolar 
natural curcumin, C ) 1% DMS O + equimolar derivative 5, and D) 1% DMS O + 
equimolar derivative 7.  Curcumin and the derivatives appear to reduce the 
proportion of the most compact conformation observed within this charge state 
ion. 
 
 
 
A B 
C  D 
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Appendix 4E : 
     
 
 
 
 
 
        
     
 
 
 
 
    
Appendix 4E : A) Drift scope plot of 70µM αsyn in 50mM ammonium acetate 
acquired by E S I-IMS -MS , B) 70µM αsyn + 10% E tOH, and C) Corresponding 
mass spectra of 70µM αsyn +/- 10% E tOH. 
240816 A PO T0.raw  : 1
240816 ETOH T 0.raw  : 1
A 
C 
B 
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Appendix 4F : 
 
 
 
- 10% E tOH/37Deg 10uM Curc – drift scope and spectra  
 
 
 
Appendix 4F : Upon immediate addition of 10µM curcumin to 70µM αsyn, a 
reduction in oligomeric species is observed, akin to that seen with addition of 
equimolar curcumin. 
 
 
 
 
 
240816 A PO T0.raw  : 1
240816 C URC 10 T0.raw  : 1
312 
 
Appendix 4G: 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4G: After 8hrs incubation of 10µM curcumin with 70µM αsyn, a further 
reduction in oligomeric species is observed, akin to that seen with addition of 
equimolar curcumin. 
 
 
240816 ETOH T 8.raw  : 1
240816 C URC 10 T 8.raw  : 1
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Appendix 4H: 
 
Appendix 4H: None of the curcumin derivatives investigated were observed to 
bind to αsyn with the NAC region removed. 
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Appendix 5A: 
 
Appendix 5A:  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Untreated cells stained for S yn211. 
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Appendix 5B: 
 
Appendix 5B:  E xample ICC  image utilised for grading of aggregate counts in 
chapter 5.  100µM CuCl2 treatment of S HS Y 5Y  cells stained for S yn211. 
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Appendix 5C: 
 
Appendix 5C :  E xample ICC  image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Treatment with 300µM CuC l2 and stained for 
S yn211. 
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Appendix 5D: 
 
Appendix 5D:  E xample ICC imageof S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Cells treated with 500µM C uC l2 and stained for 
S yn211. 
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Appendix 5E : 
 
Appendix 5E :  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Untreated cells stained for Phos129. 
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Appendix 5F : 
 
Appendix 5F:  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  C ells treated with 100µM CuC l2 stained for 
Phos129. 
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Appendix 5G: 
 
Appendix 5G:  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  C ells were treated with 300µM C uC l2 and stained 
for Phos129. 
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Appendix 5H: 
 
Appendix 5H:  E xample ICC  image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  C ells were treated with 500µM C uC l2 and stained 
for Phos129. 
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Appendix 5I: 
 
Appendix 5I:  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Cells were treated with 300µM CuC l2 and stained 
for S yn211. 
323 
 
Appendix 5J : 
 
Appendix 5J :  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Cells were treated with 300µM CuC l2 + 4µM 
curcumin and then stained for S yn211. 
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Appendix 5K: 
 
Appendix 5K:  E xample ICC image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Cells were treated with 300µM CuC l2 + 7µM 
curcumin and stained for S yn211. 
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Appendix 5L: 
 
Appendix 5L:  E xample ICC  image of S HS Y 5Y  cells utilised for grading of 
aggregate counts in chapter 5.  Cells were treated with 300µM CuCl2 + 10µM 
curcumin and stained for S yn211. 
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Appendix 6:  
 
Publications 
 
Mason R J , Paskins AR , Dalton CF & S mith DP (2016) "C opper binding and 
subsequent aggregation of alpha-synuclein is modulated by N-terminal 
acetylation and is ablated by the H50Q missense mutation." Biochemistry. 
55(34):4737-41. doi: 10.1021/acs.biochem.6b00708 
 
Publication is included at the end of the appendices. 
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Appendix 7: 
Conference Dissemination 
13-15/09/2016:  BMS S  Annual Meeting (E astbourne, UK) - Oral  
17/12/2015:  BMR C/ME RI Christmas Poster E vent (S heffield, UK) - Poster  
22/09/2015:  S heffield Glia S ymposium (S heffield, UK) 
7-8/07/2015:  BMS S  IM-MS  S IG Annual Meeting (Liverpool, UK)  
27-30/06/2015: 27th International S ymposium on Cerebral Blood F low, 
Metabolism and Function / 12th International Conference on Quantification of 
Brain Function with PE T (Vancouver, C anada) - Poster  
Paskins et al., (2016) ‘Investigating metal binding and the resulting 
conformational changes and aggregation of monomeric wild-type alpha-synuclein 
and a phosphorylation mimic’ J ournal of Cerebral Blood F low and Metabolism. 
36:594-595 
11/12/2014:  BMR C/ME RI Christmas Poster E vent (S heffield, UK) - Poster  
24-29/08/2014:  IMS C (Geneva, S witzerland) - Poster  
01-02/07/2014:  BMS S  IM-MS  S IG Annual Meeting (Manchester, UK)  
31/03/2014 - 02/04/2014:  BMS S  Annual Meeting (Manchester, UK) - Poster  
17/12/2013:  BMRC/ME RI Christmas Poster E vent (S heffield, UK) - Poster  
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Appendix 8: 
Teaching and Public E ngagement 
 
Undergraduate Laboratory Demonstrating – Oct 2014 – April 2017 (S heffield 
Hallam University) 
Work experience S upervision - J uly 2013, 2014 & 2015 (S heffield Hallam 
University)  
S cience and E ngineering Week E vent - March 2014, 2015 & 2016 (S heffield 
Hallam University) 
FameLab – February 2017 (S heffield) 
PubHD  – March 2017 (S heffield) 
The Big Bang Y orkshire - J une 2016 (Doncaster) 
230th Gleadless S couts S cience Fair - April 2016 (S heffield)  
Biotechnology Y E S  Competition - October 2015 (GS K, S tevenage) 
3 Minute Thesis Competition - J une 2015 (S heffield Hallam University) 
Multidisciplinary R esearch Café – March 2015 (S heffield Hallam University) 
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Appendix 9: 
 
Training C ourses 
 
09/07/2016:  Mass S pectrometry Imaging S ymposium (S heffield, UK) 
18/04/2016:  Royal S ociety of Biology S cience Communication Workshop 
(London, UK) 
28/04/2015 - 01/05/2015:  Common Purpose Leadership Award (S heffield, UK) 
01-02/07/2014:  BMS S  Ion Mobility-Mass S pectrometry S pecial Interest Group 
Training Course (Manchester, UK)  
31/03/2014 - 02/04/2014:  BMS S  Introduction to Mass S pectrometry Course 
(Manchester, UK) 
 
 
 
 
